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Summary
The prognosis for seizure control is an important consideration for patients diagnosed 
with epilepsy. Reversing the social restrictions imposed by seizures and returning to a 
productive life requires complete and sustained seizure control. The epilepsies are a 
heterogeneous group of disorders and clinicians discussing the prognosis of epilepsy need 
to be aware of the natural history of each epilepsy syndrome. Longitudinal follow up 
studies in newly diagnosed patient populations are required to delineate the natural 
history of the various syndromes. Previous studies have suggested that the early course of 
epilepsy is predictive of its longer-term behaviour in the majority of cases. If response to 
individual antiepileptic drugs (AEDs) in specific epilepsy syndromes can be predicted, 
prognosis can be assessed more accurately. Genetic influences on response to treatment 
are probably important in this regard. The completion of the Human Genome Project has 
opened up the possibility of correlating variations in the human genome with the 
variability of response to drugs. The discipline of pharmacogenomics, which seeks to 
study the genetic influence on response to drugs, has the potential to allow drug therapy 
to be optimised for each patient, maximising the chances of success. Identification of 
single nucleotide polymorphisms (SNPs) in candidate genes correlating with response to 
AED treatment can help identify patients at risk of developing drug resistant epilepsy.
Epilepsy is associated with an increased mortality risk. The excess risk varies depending 
on the population studied, and is influenced by patients’ clinical and demographic 
characteristics. Clinicians discussing mortality issues with patients need to be aware of 
the potential risk in each individual. This is best deduced from studies in representative 
patient groups. Risks need to be studied separately in patients with newly diagnosed and
20
chronic epilepsy, as the prognoses in these two groups are likely to be different, in terms 
of both seizure control and survival.
Treatment outcomes were analysed in patients newly diagnosed with epilepsy at the 
Epilepsy Unit, Western Infirmary, Glasgow over a 20-year period by retrospective review 
of research case notes. Response to treatment was defined as a 12-month seizure free 
period and those who remained seizure free till the end of follow up were considered to 
be in remission. A total of 890 patients had been diagnosed with epilepsy. Treatment 
outcomes were known for 780 who were included in the analysis of treatment outcomes. 
Four major categories of response to treatment were observed: those who responded 
rapidly and completely to treatment with the first AED (immediate responders), those 
who responded with further changes to therapy including combination treatment (delayed 
responders), those who had an initial period of good control before experiencing seizure 
recurrence and being subsequently uncontrolled (relapse), and those who never achieved 
12 month seizure free period (uncontrolled). Over 90% of those responding to treatment 
achieved remission. Of those responding to treatment 83% had completed 12 seizure free 
months by 3 years from starting AEDs. Those failing the first AED had significantly 
lower likelihood of responding to further pharmacotherapy if the reason for failure was 
lack of efficacy rather than adverse effects. For patients failing 2 well tolerated 
antiepileptic drug regimes, the chances of seizure freedom with pharmacotherapy was 
less than 10% and for those failing 3 such regimes, this figure was only 3%. Alcohol 
abuse, history of head injury and febrile seizures, psychiatric co-morbidity and family 
history of epilepsy showed significant univariate association with uncontrolled epilepsy. 
Voltage gated sodium channels are important in the generation action potentials in the 
brain and also serve as molecular targets for a range of AEDs. SNPs resulting in altered
21
amino acid sequence in the sodium channel a subunit have the potential to influence the 
response to AED treatment. Nav1.2, encoded on SCN2A, is the most widely expressed 
sodium channel a subunit in seizure-prone areas of the human brain. A case control 
association study was conducted to examine the prevalence of a specific SNP (R19K), in 
the SCN2A gene among responders and non-responders to AED treatment, identified 
from 400 epilepsy clinic attendees. The R19K polymorphism was significantly more 
prevalent in non-responders in this population (OR 2.07, 95% Cl 1.08-3.97, p=0.024), 
but the predictive value of the polymorphism in identifying non-responders was low (test 
efficiency 48%).
Mortality was studied separately in the newly diagnosed patients (n=890) and in patients 
chronic epilepsy, referred after unsuccessful treatment elsewhere (n=2689). Comparison 
was made to an age and sex matched Scottish control cohort. Significantly more deaths 
were observed in both cohorts of patients than could be expected based on the mortality 
in the control population. Standardised mortality ratios (SMR) were 1.41 (95% Cl 1.15 -  
1.74) for the newly diagnosed patients and 2.04 (95% Cl 1.82-2.27) for patients with 
chronic epilepsy. In the newly diagnosed patients, more deaths than expected were 
observed for patients with symptomatic and unclassified epilepsy, but not for those with 
idiopathic or cryptogenic epilepsy. In the chronic epilepsy cohort, excess mortality was 
seen for all types of epilepsy other than idiopathic generalised. Highest mortality was 
seen in younger patients, especially in those with symptomatic epilepsy. The incidence of 
Sudden Unexpected Death in Epilepsy (SUDEP) was 1.08 per 1000 patient years in 
newly diagnosed epilepsy, and 2.4 per 1000 patient years in chronic epilepsy in this 
analysis.
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In conclusion, the prognosis of newly diagnosed epilepsy is obvious within the first 3 
years of starting treatment. Patients who do not respond to the first 2 well tolerated AED 
regimes have les than 10% chance of achieving remission with further pharmacotherapy 
and should be evaluated in a specialist epilepsy centre. The approach of analysing single 
SNPs on candidate genes lacks the power to usefully predict response to AED treatment. 
Identifying a number of genetic markers that correlate with treatment and using more 
sophisticated analyses paradigms such as haplotype-based approaches can improve the 
predictive value. Mortality risks are higher in patients with chronic epilepsy compared to 
those with newly diagnosed epilepsy. This excess is most marked for younger patients, 
especially those with symptomatic epilepsy. SUDEP remains a rare event for patients 
with epilepsy, but is significantly more likely in patients with chronic epilepsy.
23
Part I 
General Introduction
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1. Determining pharmacological intractability in epilepsy
1.1. Introduction
1.1.1. Historical considerations
Mankind has known epilepsy since the earliest civilisations. There are descriptions of 
epileptic phenomena in the Babylonian tablets dating back to 2nd millennium BC (Arts 
and Vree, 2001). Descriptions that are suggestive of epilepsy can also be found in Persian 
Egyptian and Mesopotamian texts. The word epilepsy is derived from Greek 
epilambanien, which means to seize or attack. This terminology may have roots in the 
ancient belief that all diseases were caused by attacks of gods or demons. Ancient Greeks 
considered epilepsy the scared disease although Hippocrates ascribes its supposed divine 
origin to “men’s inexperience and their wonder at its peculiar character” (Hippocrates, 
c.400 BC). The impressive nature of generalised seizures also probably led to the term 
‘the great disease’ which finds its way into medieval French as grand mal, a term in use 
until recently. Robert Bentley Todd first proposed the electrical basis of nervous 
functioning. His successor John Huglings Jackson is generally credited with developing 
the electrical theory epilepsy, paving the way for modem epileptology (Reynolds, 2004).
1.1.2. Natural history of treated epilepsy
The term epilepsy covers a wide range of disorders with the common symptom of 
recurrent unprovoked seizures. The natural history and prognosis vary depending on the 
underlying aetiology and the specific epilepsy syndrome. Our understanding of the 
natural history of the different seizure disorders is imperfect. Some syndromes have a 
genetic aetiology, yet incomplete penetrance and phenotypic variability in most 
genetically mediated epilepsy syndromes suggest a strong environmental influence 
(Johnson and Sander, 2001). The majority of patients with acquired epilepsy are likely to
25
have an underlying genetic predisposition modified by environmental factors (Figure 1). 
The dynamics of the causative and modifying factors determine the outcome of each 
epilepsy syndrome, including response to treatment.
Long-term prospective studies are required to accurately estimate the prognosis of each 
specific seizure disorder. It is important that studies of prognosis consider each epilepsy 
syndrome separately (Commission, 1993). If an approach o f ‘lumping’ is followed in 
such studies, the observed outcome will be skewed towards that of the most frequent 
syndrome in the cohort. Certain benign epilepsy syndromes with onset in childhood have 
an excellent prognosis and enter remission regardless of drug treatment. Syndromes such 
as Juvenile Myoclonic Epilepsy (JME), on the other hand, respond relatively easily to 
treatment but have a high rate of recurrence if treatment is withdrawn. The long-term 
prognosis of adult onset epilepsy is less clear. Data from longitudinal studies suggest that 
patients diagnosed with epilepsy largely fall into two categories- those who enter 
remission early on and those who remain refractory from the outset (Goodridge and 
Shorvon, 1983; Kwan and Brodie, 2000). Patients who are difficult to control initially can 
still enter remission several years after starting AED treatment, albeit in small numbers. 
Similarly, those who enter remission early on can relapse and be subsequently difficult to 
control. A recent study in patients undergoing temporal lobectomy for refractory epilepsy 
found that 26% of patients had a history of one-year remission, and 8.5% had a history of 
5-year remission, prior to developing refractory epilepsy (Berg et al, 2003). Thus, there 
appears to be a small group of patients in whom the seizure disorder displays a changing 
behaviour over time. Nonetheless, in the majority of patients, early course of epilepsy is a 
reliable indicator of the long-term treatment outcome (Hauser et al, 1996; Dlugos et al, 
2001).
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1.1.3. Drug treatment of epilepsy
Effective treatment for epilepsy has been available since the latter half of the 19th century, 
since the discovery of anticonvulsant properties of bromides. The number of drugs 
available to treat epilepsy increased through the 20th century; thanks mainly to 
serendipitous discovery of antiepileptic drugs (AEDs). In the 1980s and 1990s, rational 
drug discovery programmes saw several new compounds with novel mechanisms of 
action added to the therapeutic armamentarium against epilepsy. This has resulted in an 
improved outlook for most patients with epilepsy, with a realistic prospect for a full 
productive life for most patients diagnosed with epilepsy. The ideal outcome in the 
treatment of epilepsy would be complete control of seizures with no adverse effects from 
medication enabling patients to return to full productive lifestyle consistent with his/her 
abilities (Engel, 2004). However, many patients in whom complete seizure control is not 
achieved are able to maintain a near normal lifestyle with only minimal restrictions. This 
concept of “acceptable control” aims at limiting the number and severity of seizures with 
tolerable drug burden and adverse effects. Acceptable seizure control in such situations 
varies depending on patients’ expectations and social circumstances as well as the type of 
epilepsy.
In some severe epilepsy syndromes of infancy and childhood, usually associated with 
neurological morbidity and intellectual impairment, complete seizure control is often an 
unrealistic expectation (Shields, 2000). Reduction in seizure frequency and severity can 
improve the quality of life and prevent further intellectual impairment in such patients. 
Nonetheless, in the majority of patients with epilepsy, even relatively infrequent and mild 
seizures can have a significant impact on quality of life (Gilliam, 2002). Academic 
achievement and intellectual development of children with epilepsy is significantly
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improved if seizures are well controlled (Austin et al, 1999; Zelnik et al, 2001). In adults, 
the diagnosis of epilepsy often results in loss of driving privileges and employment. 
Regaining these require demonstration of complete control of seizures over an extended 
period of time in most countries. Seizure freedom is thus the all-important treatment goal 
for the majority of patients with epilepsy.
1.1.4. Drug resistant epilepsy
There is now convincing epidemiological data to show that over 30 % of patients 
diagnosed with epilepsy will never achieve lasting control of seizures with currently 
available AEDs (Annegers et al, 1979; Cockrell et al, 1995; Mattson et al, 1996; Kwan 
and Brodie, 2000). There is, however, no consensus in the literature as to what constitutes 
drug resistant epilepsy. In epidemiological studies, the definition of drug resistant 
epilepsy varies, both in terms of the number of AEDs tried and time from diagnosis (Berg 
et al, 1996; Camfield and Camfield, 1996; Casetta et al, 1999; Lindsten et al, 2001). The 
terms refractory epilepsy, intractable epilepsy and drug resistant epilepsy are usually used 
interchangeably in this context. Whichever term is used, it encompasses a 
multidimensional disorder in which uncontrolled seizures cause deleterious neuronal 
plasticity with progressive cognitive decline, psychosocial dysfunction, reduced quality 
of life and increased mortality (Kwan and Brodie, 2002). Early identification and 
prediction of intractable epilepsy is of the greatest importance in deciding the timing of 
epilepsy surgery in patients with suitable seizure types. There is now robust clinical data 
to support the early use of surgical treatment in patients with refractory temporal lobe 
epilepsy (Weibe et al, 2001). In appropriately chosen patients surgery can result in 
seizure freedom, restoring quality of life and productivity. Yet, epilepsy surgery remains 
one of the most underutilised treatment modalities in the world (Engel, 2001). The
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irreversible nature of surgery, along with fear of complications induces a degree of 
reluctance in patients and physicians to consider this treatment option until all 
pharmacological options have been exhausted. This approach to epilepsy surgery as a 
‘last resort’ has resulted in patients suffering uncontrolled seizures for years before 
having curative surgery (Sperling et al, 1996). Defining a situation where additional 
medical treatment is unlikely to be successful can help optimise the timing of surgical 
referral as well as help in clinical decision-making.
1.2. ‘Pseudo’-intractability
Patients fail pharmacotherapy for seizures for a variety of reasons. Non-compliance with 
treatment, diagnostic error, failure to attend follow up for adjustments in AED dosage 
and life-style factors can all cause AED therapy to be ineffective. While these patients 
could be considered treatment failures, they are not pharmacoresistant in the true sense of 
the word. Genuinely drug resistant patients form a hard core of all patients failing AED 
therapy. When non-pharmacological treatments are being considered, pharmacoresistance 
should be diagnosed only in patients who have a secure and accurate diagnosis of 
epilepsy, are on adequate doses of appropriate AEDs, are compliant with treatment with 
adequate serum, and therefore, presumably brain concentrations of AEDs.
1.2.1. Errors of diagnosis and classification
Diagnostic error is the most frequent cause of seizures failing to respond to treatment. 
Failure to respond to appropriate doses of standard AEDs should, in the first instance, 
prompt a review of the diagnosis. Common diagnostic pitfalls include wrong diagnosis of 
epilepsy (NEAD, syncope) and incorrect diagnosis of seizure types. Video-EEG 
monitoring is the only reliable method by which accurate diagnosis and classification of
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seizures can be carried out, and should be available to all patients failing drug therapy, 
before non-pharmacological treatments are considered.
Non-epileptic attack disorders (NEAD) are common conditions (Benbadis and Hauser, 
2000) and constitute a large proportion of cases referred for evaluation of possible seizure 
disorders (Francis and Baker, 1999). Diagnosis of NEAD can be challenging as they can 
co-exist with epilepsy, or may develop as substitute for seizures once epilepsy is 
controlled (Kuyk et al, 1997). Psychological factors such as anxiety or stress, depression, 
physical / sexual abuse and dysfunctional relationships are present in the majority of 
patients (Moore and Baker, 1997). Many patients have an underlying conversion or 
dissociation disorder or a borderline personality disorder. NEAD are classified into 
episodes of apparent loss of awareness with convulsive movements or with little or no 
obvious motor activity (swooning). These movements can involve uncoordinated 
thrashing, back arching and pelvic thrusting. Patients do not have conscious awareness of 
the attacks except in factitious disorder or malingering which are relatively rare (Betts 
andBoden, 1991).
Syncope resulting in prolonged reduction in blood flow to the brain can cause 
convulsions, which may be mistaken for seizures (Devinsky, 1994). History of attacks 
provoked by pain or anxiety or on assumption of upright posture and preceded by facial 
pallor and diaphoresis suggests a diagnosis of vasovagal syncope. The vast majority of 
these attacks are associated with some motor activity, myoclonic jerking is observed most 
commonly, but tonic and clonic movements or apparent automatisms may also be seen 
(Lempert et al 1994). Anoxic convulsions can occur if the patient remains upright during 
syncope or if cardiac out put remains low for a prolonged period of time, as may happen
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with cardiogenic syncope. These may not have any or very short lived premonitory 
symptoms. ECG is mandatory in all patients presenting with episodes of collapse and 24- 
hour tape, implantable loop recorders and tilt table testing may be indicated if a cardiac 
cause or malignant vasovagal syncope is suspected.
Wrong classification of seizure types and syndromes can result in unsuccessful 
pharmacological treatment. Physicians are reliant on descriptions given by third parties to 
arrive at a diagnosis, but these are often highly unreliable. Diagnostic error arising from 
this (e.g.: - complex partial seizures misdiagnosed as absences) can lead to inappropriate 
drug selection. Wrong choice of antiepileptic drugs can potentially exacerbate epilepsy -  
carbamazepine and GABA-ergic drugs can exacerbate idiopathic generalised epilepsy 
especially myoclonic jerks and absences (See part II, section 3.4). EEG employing 
provocation (eg: sleep deprived EEG) or video-EEG monitoring should enable accurate 
classification of seizures and rationalisation of drug therapy.
1.2.2. Non-compliance and lifestyle issues
Non-adherence to prescription is a major factor in failure of drug treatment. Non- 
compliance is present in up to 50% of patients attending epilepsy clinics (Leppik, 1988). 
Compliance can be assessed by asking patients about medication taking habits, serial 
blood levels or by using automated monitoring devices. It has been suggested that once 
steady state concentration has been achieved, if the variability between three separate 
serum levels is less than 20-25%, compliance is likely (Leppik, 1988). Anti-epileptic 
drug treatment in most cases lasts years and many patients miss the occasional dose. 
Patients’ motivation to continue regular treatment depends on the degree of control 
achieved (efficacy), adverse effects and possible consequences of loss of seizure control.
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It is often impossible to separate these elements. Thus, the eventual effectiveness of any 
antiepileptic treatment is determined by both its efficacy and tolerability. As many 
patients diagnosed with epilepsy will have a mild disorder, drugs with fewer adverse 
effects are more likely to ensure better compliance than more potent but side-effect prone 
drugs, and therefore more likely to produce a favourable treatment outcome. Abuse of 
alcohol and drugs such as cocaine can cause seizures. Similarly, sleep deprivation and 
stress can also precipitate seizures in some epilepsy patients. A history of substance abuse 
is accompanied by non-adherence to prescription in large proportion of patients. Social 
and lifestyle factors should therefore be taken into account when evaluating the efficacy 
of drug treatment for epilepsy.
1.3. Refractory epilepsy -  progressive or de novo?
Whether drug resistance occurs de novo in patients with epilepsy or arises as a result of 
repeated seizures is a subject of debate. The concept of “seizures beget seizures” was 
introduced by Gowers in the 19th century (Gowers 1881) and reinforced by the writings 
of Rodin in the 1960s. A long history of seizures and high numbers of pre-treatment 
seizures were thought to correlate with a poor outcome. This view was supported by 
Reynolds and colleagues in the early 1980s and early treatment of seizures was 
considered key to preventing the emergence of drug resistant epilepsy (Reynolds et al, 
1983). Repeated seizures have been shown to cause neuronal loss and mossy fibre 
sprouting in the hippocampus, which in turn can cause seizures by forming excitatory 
recurrent circuits (Dalby and Mody, 2001, Holmes 2002). In humans, neuropsychological 
studies have shown cognitive decline in patients with refractory epilepsy; the severity of 
which is correlated with duration of epilepsy (Jokeit and Ebner, 2002). Cross-sectional 
MRI studies have demonstrated smaller hippocampal volumes ipsilateral to seizure focus
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in patients with temporal lobe epilepsy and uncontrolled seizures (Theodore et al, 1999, 
Kalviainen and Salmenpera, 2002). The degree of hippocampal volume loss was related 
to the duration of epilepsy. Longitudinal studies employing repeat MRI scans have 
demonstrated progressive hippocampal and temporal neocortical volume loss and have 
suggested that neuronal loss is correlated to number of seizures (Briellmann et al, 2002, 
Fuerst et al, 2003). Thus in mesial temporal lobe epilepsy, hippocampal sclerosis does 
appear to be both the cause and consequence of seizures. Prevention of repeated seizures 
by effective drug treatment could theoretically prevent neuronal apoptosis and synaptic 
reorganisation, which cause further seizures.
On the other hand, studies in patients who have suffered seizures for several years, 
sustaining 100 or more generalised seizures before coming to medical attention have 
shown that a similar proportion go into remission as patients treated early after only a few 
seizures (Feksi et al, 1991). Moreover, treatment with AEDs after the first unprovoked 
seizure has been shown not to affect the long-term outcome, in spite of preventing 
seizures in the short term (Hauser et al, 1990; Musicco et al, 1997; Camfield et al, 2002). 
Several studies have shown a relationship of high initial seizure frequency with poor 
outcome (Juul Jensen, 1964; Rodin, 1968; Reynolds, 1987; Beghi and Tognoni, 1988; 
Sillanpaa, 1993). However, detailed analyses of data from observational studies have 
shown that this is true only for patients suffering complex partial seizures (Shinnar and 
Berg; 1996). It is likely that the epileptogenic process responsible for the high frequency 
of partial seizures is inherently pharmacoresistant. Seizure type would thus appear to be 
more important than seizure numbers in determining prognosis. This suggests that the 
prognosis of each seizure disorder is an inherent property of that syndrome.
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1.4. Causes of true drug resistance
Despite advances in the field of cell biology, our understanding of the process of 
epileptogenesis at the molecular level remains incomplete. A few well-defined epilepsy 
syndromes of infancy and childhood have clear genetic basis, mainly mutations in ion 
channel genes. These results in altered ion channel structure and function and are often 
associated with catastrophic seizures (Berkovic and Scheffer, 2001). Disorders of 
neuronal migration are also associated with drug resistant epilepsy, as are cerebral 
tumours and trauma. Why such lesions result in hyperexcitability of neurons and 
hypersynchronised discharge of a large number of neurons, however, is not fully 
understood. The basic mechanisms that operate in rendering epilepsy pharmacoresistant, 
therefore, also remain largely unclear. Several hypotheses on the mechanisms involved in 
the evolution of drug resistant epilepsy have been proposed (Regesta and Tanganelli, 
1999). These include ontogenic abnormalities in brain maturation, epilepsy induced 
alterations in network neuronal and glial properties in seizure prone areas such as the 
hippocampus, the phenomenon of kindling and reorganisation of cortical tissue in 
response to seizure induced disturbances in oxygen supply. These however have to be 
confirmed by studies in appropriate models of drug resistant epilepsy.
1.4.1. Neurobiology
Structural brain lesions have for long been known as a cause for epilepsy, these are 
summarised in Table 1 (Vinters et al, 1993). The nature of the underlying lesion has a 
strong influence on the prognosis of the seizure disorder (Semah et al, 1998; Stephen et 
al, 2001). Modem imaging techniques allow accurate characterisation of structural 
lesions, but histological diagnosis may be required to exclude malignancy in some cases
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1.4.2. Malformative
Disorders if cortical development have been increasingly recogonised as the underlying 
cause for epilepsy since the advent of MRI. They include a spectrum of disorders of 
abnormal cortical development and/or architecture with varying severity of epilepsy 
summarised in Table 2. In recent years, there has been a greater understanding of their 
genetic bases, clinical presentations and the mechanisms involved in epileptogenesis 
(Guerrini and Carrozzo, 2002). Lissencephaly, the most severe abnormality of neuronal 
migration, is characterised by absent (agyria) or decreased (pachygyria) convolutions. 
Subcortical band heterotopia (SBH) is at the mild end of the agyria-pachygyria spectrum 
and shows simplified gyral pattern with increased cortical thickness. Bilateral 
periventricular nodular heterotopia (BPNH) consists of confluent and symmetrical 
subependymal nodules of grey matter located along the lateral ventricle, particularly 
along the ventricular body. Focal Taylor type cortical dysplasias have high intrinsic 
epileptogenicity (Palmini et al, 1995). The epileptogenic zone often extends beyond the 
visualised area and acute intraoperative electrocorticography is required to ensure 
adequate resection. Tuberous sclerosis (TS) is an autosomal dominant, multisystem 
disorder with a prevalence of 1:30000 to 50000. Most patients with TS have epilepsy; 
infantile spasms are often an early manifestation. In the brain, TS is characterised by 
cortical tubers, subependymal tubers and giant cell tumours (Guerrini and Carrozzo,
2002). Cortical tubers are directly related to epileptogenesis and show pathological 
features similar to focal cortical dysplasia. They are well visualised on MRI as abnormal 
gyri with atypical shape and abnormal signal intensity.
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1.4.3. Neoplastic
Intracranial mass lesions can be identified in around 15% of patients with intractable 
epilepsy (Spencer et al, 1984). Low-grade gliomas and gangliogliomas constitute the 
majority of lesions. Dysembryoplastic neuro-epithelial tumour (DNET) is a benign 
tumour involving the cerebral cortex, which was first recogonised as a cause for epilepsy 
in 1988 (Daumas-Duport, 1988). They appear as hypodense intracortical lesions on CT 
scans and on MRI scans have a decreased T1 signal and high T2 signal. Lack of mass 
effect and lack of surrounding oedema are characteristic features (Stanescu Cosson et al, 
2001).
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Table 1. Structural brain lesions associated with epilepsy (adapted from Vinters et al, 
1993)
Malformative______________________________________
Cortical dysplasia
Microdysgenesis 
Focal cortical dysplasia 
Polymicorgyria
Lissencephaly / pachygyria Hemimegalencephaly 
Vascular malformations
Arteriovenous malformation
______ Cavernous haemangioma__________________________
Familial and metabolic_______________________________
With focal lesions, phacomatosis 
Tuberous sclerosis 
Neurofibromatosis
Encephalotrigeminal angiomatosis, Sturge-Weber disease 
With diffuse lesions
Lysosomal enzyme deficiencies 
Peroxisomal disorders 
Mitochondrial enzyme disorders 
Lipofuscinosis 
Myelinopathies
______ Miscellaneous myoclonic epilepsies__________________
Neoplastic_________________________________________
Gliomas Gangliogliomas 
Metastatic tumours
Dysembryoplastic neuroepithelial tumour
Others________________________________________________
Cerebrovascular disease and trauma_____________________
Ischaemic
Haemorrhagic
Post-traumatic__________________________________________
Inflammatory / Infectious_____________________________
Infective: Herpes encephalitis 
Paraneoplastic: Limbic encephalitis 
Autoimmune: Rasmussen’s encephalitis 
Multiple sclerosis
______ Cerebral vasculitis________________________________
Degenerative_______________________________________
 Eg: Alzheimer’s disease___________________________
Ammon’s horn (hippocampal) sclerosis_____________________
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1.4.4. Hippocampal sclerosis
Hippocampal sclerosis (HS) is the most common pathological finding in temporal lobe 
epilepsy in surgical studies (See part II section 2.4). It is the most common underlying 
cause for medically refractory temporal lobe epilepsy (Semah et al, 1998; Bocti et al,
2003). HS is characterised by tissue shrinkage, cell loss and reactive gliosis in all 
hippocampal subfields as well as the entorhinal cortex. This process is triggered by an 
initial precipitating injury, which is likely to be seizures in infancy (Mathem et al, 2002). 
Occurrence of prolonged and / of complicated febrile seizures is associated with 
hippocampal injury and can lead to the development of mesial temporal sclerosis in later 
life (Lewis et al, 2002a). MRI scanning employing coronal slices perpendicular to the 
long axis of the hippocampal structures can identify HS. The characteristic features are 
atrophic hippocampus, increased signal on T2 weighted images and fluid attenuated 
inversion recovery (FLAIR) sequences and decreased signal on inversion recovery 
sequences (Kuzniecky et al, 1987; Cascino et al, 1991). HS coexists with a second 
pathology, most commonly cortical dysplasia, in a high proportion of cases. (Bocti et al, 
2003; Mohamed et al, 2001)
1.4.5. Infectious/Inflammatory
Inflammatory disorders affecting the brain often cause epilepsy that is difficult to treat. 
Encephalitis usually causes neocortical epilepsy; however, both encephalitis and 
meningitis can result in mesial temporal sclerosis if they occur early in life. The risk of 
epilepsy is greater in patients with residual neurological deficits (Pomeroy et al, 1990). 
Infections and infestations are an important aetiological factor in epilepsy in the 
developing world. Neurocysticercosis is widely prevalent in several countries of Latin 
America, Asia and sub-Saharan Africa. It is thought to be the most common cause of
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acquired epilepsy in many areas, although no studies have examined its relative 
contribution to all incident cases (Pal et al, 2000). Generally, prognosis for seizure 
control in neurocysticercosis is good and many patients are able to stop AEDs after 
successful anti-helminthic treatment (Carpio, 2002). Nevertheless, the preventable nature 
of cysticercosis offers the opportunity of reducing the disease burden of epilepsy in less 
developed countries.
1.4.6. Immunologic
Autoimmune mechanisms, both cellular and humoral, have been known to cause seizures. 
Rasmussen’s encephalitis, a rare disorder mainly of childhood, is characterised by 
intractable partial seizures, unihemispheric inflammation with progressive neurological 
deficit (McLachlan et al, 1993). It is thought to have an immunological basis. Antibodies 
directed against the glutamate receptor GluR3 have been identified in some patients with 
Rasmussen’s syndrome but this is not useful for diagnosis. It responds to treatment with 
intravenous immunoglobulins and other immunomodulants, but some patients require 
radical surgery for control of seizures. One study had reported increased prevalence of 
antibodies to GluR3 receptors in patients with partial epilepsy who do not have 
Rasmussen’s encephalitis (Wiendl et al, 2001). Patients with other autoimmune 
conditions such as SLE are at increased risk of developing epilepsy (Palace and Lang, 
2000, Table 3). Higher prevalence of glutamic acid decarboxylase, anticardiolipin and 
antinuclear antibodies has been reported in patients with epilepsy compared to controls 
(Eriksson et al, 2001; Verrotti et al, 2003). These have however not been convincingly 
associated with pharmacoresistance. Studies to date have not demonstrated a major role 
for immunologic mechanisms in the pathogenesis of pharmacoresistant epilepsy.
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1.4.7. Drug transporter proteins
Patients with pharmacoresistant epilepsy are by definition unresponsive to all AEDs. This 
raises the possibility of a common mechanism underlying pharmacoresistance. The 
removal of AEDs from their intended site of action by multidrug transporter proteins has 
received much attention in recent years. Multidrug transporters are ATP dependent efflux 
proteins, which include the P-glycoprotein (PGP) and multidrug resistance-associated 
protein (MRP) family. PGP is a transmembrane glycoprotein, which is naturally present 
in many organs (e.g.: - intestine, kidney) as well as the blood brain barrier and blood 
testis barrier. Its natural function is believed to be absorptive or excretory and/or 
protection from toxins and xenobiotics (Jette et al, 1995). Many traditional and new 
AEDs are believed to be substrates for PGP (Loscher and Potschka, 2002). Studies in 
mice have shown that deletion of the MDR1 gene, which codes for PGP, results in higher 
brain concentrations of several lipophillic drugs (Schinkel et al, 1996). The MRP family, 
which at present has seven members (MRP-1 - 7), act as organic anion transporters but 
can also transport neutral organic drugs. They have overlapping substrate specificity with 
PGP with several AEDs being substrates for both. Increased expression of MDR1 gene 
was first identified in surgically resected tissue from patients with refractory partial 
epilepsy in 1995 (Tishler et al, 1995). Since then, higher MRP1 and MRP2 levels have 
been demonstrated in brains of patients with refractory epilepsy (Loscher and Potschka, 
2002). High levels of expression of PGP and MRP1 have been found in reactive 
astrocytes (Sisodiya et al, 2002) and neuronal elements (Aronica et al, 2003) of focal 
cortical dysplasia, DNET and HS compared to histologically normal adjacent tissue. 
These lesions are common causes for refractory epilepsy and PGP and MRP mediated 
efflux of AEDs from the site of origin of seizures resulting in inadequate
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intraparenchymal concentrations could be one of the mechanisms underlying drug 
resistance.
1.4.8. Genetics
Several genetic factors modify the pharmacodynamics and pharmacokinetics of AEDs 
and can influence the response to treatment. Single nucleotide polymorphisms (SNP), 
which are stable heritable alterations of single nucleotides distributed through the 
genome, are the genetic markers of choice in pharmacogenomic studies (Part III, Section 
1.2). They can occur in the coding regions of genes causing translational changes in the 
proteins they encode, or regulate gene expression if they occur in promoter regions. SNPs 
in genes coding for metabolising enzymes of the cytochrome P450 family can alter 
metabolic activity and affect serum levels and brain concentrations for the substrate 
AEDs (Ramachandran and Shorvon, 2003; Table 4). In spite of their influence on AED 
concentrations, SNPs in cytochrome P450 genes have not been shown to be associated 
with drug resistance in epilepsy. A SNP in the MDR1 gene resulting in increased 
expression levels of PGP has been reported to be associated with drug resistant epilepsy 
(Siddiqui et al, 2003). However, this observation has not been replicated (Sills et al, 
2005). The contribution of any one gene in determining response to AEDs is likely to be 
small (see part III, section 1.2). In animal studies, attempts at breeding a population of 
phenytoin resistant amygdala kindled Wistar rats showed that phenytoin resistance could 
be inherited, but does not follow simple Mendelian patterns (Ebert and Loscher, 1999). It 
is likely that a large number of genes interact in complex ways to determine response to 
any given AED. As technology develops, high density SNP and haplotype maps, higher 
throughput genotyping technology and more powerful bioinformatics tools should enable 
greater predictability of response to individual drugs.
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Table 4. AEDs and their metabolising enzymes of the cytochrome P450 family (adapted 
from Ramachandran and Shorvon, 2003).
Cytochrome P-450 subtype AED substrate
CYP1A2 CarbamazepinePhenytoin
CYP2A6
Carbamazepine 
Losigamone 
Sodium Valproate
CYP2B6
Phenytoin 
Sodium Valproate 
Mephobarbital
CYP2C18 Phenytoin
CYP2C19
Phenobarbitone and other barbiturates
Phenytoin
Sodium Valproate
Zonisamide
CYP2C8
Carbamazepine
Phenytoin
Trimethadione
CYP2C9
Phenobarbitone 
Phenytoin 
Trimethadione 
Sodium Valproate
CYP2D6 CarbamazepinePhenytoin
CYP2E1
Felbamate 
Phenobarbitone 
Phenytoin 
Trimethadione 
Sodium Valproate
CYP3A4
Carbamazepine
Clonazepam
Ethosuximide
Ganaxolone
Phenytoin
Tiagabine
Trimethadione
Zonisamide
CYP3A5 PhenytoinZonisamide
CYP3A7 Phenytoin
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1.5. When is epilepsy intractable?
For physicians treating epilepsy, a number of questions need to be answered before a 
diagnosis of drug resistant epilepsy is made and non-pharmacological treatments 
considered. How long should one persevere with AED treatment before diagnosing 
pharmacoresistance? How many regimes should be tried before epilepsy is designated 
refractory? Should combination treatment be tried early on, and if so, which ones? Are 
some combinations better than others? This section will discuss some of the issues 
surrounding these questions.
1.5.1. Duration of treatment
Longitudinal studies of treated epilepsy in children and adults show that the natural 
history of the disorder can be recogonised early in the course of the disorder (Kwan and 
Brodie 2000; Arts et al, 1999; Hauser et al, 1996). Patients who are likely to enter 
remission tend to do so early, generally within the first year or two of starting AED 
treatment. Similar patterns have been observed in other studies (Hauser, 1992). Response 
to drug treatment, therefore, is usually obvious in the first two years of starting treatment. 
Patients who continue to have seizures after this period have a low chance of subsequent 
remission and should be evaluated in a comprehensive epilepsy programme.
1.5.2. Number of drugs
With the number of AEDs currently available, it is not possible to try all AED 
combinations before epilepsy is deemed intractable. The issue is the number of 
treatments the patient has to fail before the chance of success with further 
pharmacological treatment is sufficiently low to consider the seizure disorder 
pharmacoresistant. Historical and clinical trial data regarding the efficacy of individual
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AEDs in various seizure types can only be a guide to therapeutic decision-making. No 
drug can be effective in all patients and patients who have not responded to one standard 
drug might well benefit from alternatives (Camfield et al, 1997; Kwan and Brodie 
2001a).
1.5.3. Polytherapy
Since the early 1980s, monotherapy has been considered the gold standard for 
pharmacotherapy of epilepsy (Reynolds and Shorvon, 1981). Polytherapy was thought to 
produce higher incidence of toxicity, cognitive side effects and drug interactions without 
substantial improvement in outcome. This view has changed in recent years because of 
two factors. The emergence of several new compounds, all initially licensed as adjunctive 
treatment has moved combination therapy higher up the batting order. Moreover, certain 
combinations have been shown to be synergistic (Brodie and Yuen, 1997; Pisani et al, 
1999) and could succeed where monotherapy with individual drugs have failed. Two 
randomised studies comparing alternative monotherapy to polytherapy found no 
differences between the two groups with regard to seizure control and neurotoxicity; 
however both involved small numbers of patients and were underpowered to detect small 
differences (Deckers et al, 2001; Beghi et al, 2003). Thus, patients who develop 
idiosyncratic reactions or have intolerable adverse effects on low doses their first AED 
should be treated with alternative monotherapy. If patients achieve only suboptimal 
seizure control at maximal tolerated dose of the first choice AED, a reasonable approach 
would be to reduce the dose of the first drug and add in a second AED. The first agent 
could then be withdrawn or the patient continued on combination treatment depending on 
clinical response and side effects.
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When combination therapy is used, the selection of individual components should take into 
consideration pharmacokinetic and pharmacodynamic interactions. Among the older AEDs, 
phenobarbitone, carbamazepine and phenytoin are powerful inducers of hepatic microsomal 
enzymes and can augment the elimination of other AEDs. When these drugs are co-administered 
with valproate, lamotrigine, topiramate, tiagabine or oxcarbazepine, the elimination half-life of 
the second drug is reduced (Patsalos et al, 2002). Conversely, when the enzyme inducing AED is 
withdrawn, the serum concentration of the concomitant AED increases. Combinations based on 
mechanism of action of individual AEDs have been proposed as a rational approach to 
combining AEDs. The predominant mechanisms of action are known for the older AEDs and 
mechanisms have been proposed for the newer ones. These are listed in Table 5. 
Pharmacodynamic interactions can improve the efficacy (e.g.: - valproate with lamotrigine) or 
cause adverse effects reducing tolerability (e.g.: - carbamazepine with lamotrigine). There is as 
yet no Class I evidence to prove the superiority of any one combination over others, but studies 
to date suggest that combinations of AEDs with different mechanisms of action are more likely 
to produce favourable outcomes (Deckkers et al, 2000). Thus, combining drugs with sodium 
channel blocking properties with GABA-ergic drugs may be better than the combination of two 
sodium channel blockers.
1.6. Predicting intractability
There is convincing evidence from epidemiological studies that the early course of epilepsy is 
predictive of its long-term outcome in the majority of patients. It should therefore be possible to 
predict the development of intractable epilepsy using information available early in the course of 
the disorder. Predicting the development of intractable epilepsy at the outset can help target early 
specialist intervention and optimise patient outcomes. Several studies have addressed this issue
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over the years. There is considerable conflict among them in the factors found associated with 
refractory epilepsy. This is mainly due to the differences in study populations, inclusion and 
exclusion criteria, and definition of the individual factors. Ideally, studies of prognosis should be 
population based, prospective and should follow patients up form the same point in the course of 
their epilepsy (first seizure, start of treatment) to minimise bias (Shorvon 1984). However, such 
studies require immense resources and few have been carried out. Separate univariate analysis of 
prognostic factors is simplistic and can give distorted picture of the importance of each factor. 
Multivariate analysis techniques will allow the relative importance of each factor to be assessed.
1.6.1. Seizure type and epilepsy syndrome
As stated above, seizure types and the underlying epilepsy syndrome probably have the strongest 
influence on the prognosis of epilepsy. Several studies, especially in adults, have found that 
patients with localisation related epilepsy are more likely to be drug resistant than those with 
idiopathic generalised epilepsy (Annegers et al, 1979; Goodridge and Shorvon 1983; Elwes et al, 
1984; Mattson et al, 1996; Cockrell et al, 1995; Aikia et al, 1999). Similarly, the presence of 
mixed seizure types has been found associated with a poor outcome in studies in both adults and 
children. (Goodridge and Shorvon, 1983; Brorson 1987; Beghi et al, 1988; Arts et al, 1999;
Aikia et al, 1999).
1.6.2. Aetiology
Remote symptomatic seizures (those occurring more than a week after cerebral insult) have 
consistently been associated with a poor outcome in several studies. (Sillanpaa, 1993; Ko et al, 
1999; Hauser et al, 1996; Casetta et al, 1999; Aikia et al, 1999; Berg et al, 2001). Perinatal 
hypoxia or intracranial injury, associated with neonatal seizures can cause epilepsy in later life in
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approximately 30% of infants (Watanabe et al, 1980). The relevance of perinatal injury to the 
prognosis of adult onset epilepsy is doubtful. Moreover, obtaining accurate birth history from 
adult patients is difficult and is prone to inaccuracies. Studies in patients attending epilepsy 
centres have found wide variation in response rates amongst patients with symptomatic epilepsy 
due to various causes (Semah et al, 1998; Stephen et al, 2001). This suggests that the nature of 
the cerebral insult has a bearing on the prognosis of epilepsy.
1.6.3. Age at onset
Studies in children suggest that onset of epilepsy before the age of 12 months is a poor 
prognostic factor (Camfield et al, 1993; Ko et al, 1999; Casetta et al, 1999). Some studies in 
adults have found an association young age at onset with a poor prognosis (Aikia et al, 1999). It 
is likely that the difference in prognosis with age is a reflection of the epilepsy syndromes that 
are prevalent in the various age groups. Multivariate analyses of prognostic factors in both 
children (Berg et al, 2001) and in adults (Elwes et al, 1984, Lindsten et al, 2001) have found no 
independent correlation of age at onset with prognosis after other factors were accounted for.
1.6.4. Number of pre treatment seizures
Some authors have found high seizure numbers indicative of a poor prognosis in children (Beghi 
et al, 1988, Arts et al, 1999). Camfield and colleagues observed this effect only in patients 
suffering more than 20 seizures (Camfield et al, 1993). Studies in the developing world have 
suggested that good response to treatment could be obtained in patients who have suffered 
several generalised tonic clonic seizures prior to coming to medical attention (Feksi et al, 1991). 
Time from onset to starting treatment also has no significant impact on outcomes. However, 
some studies in adults and children have found a correlation of number of seizures over unit time
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(seizure frequency) with prognosis (Elwes et al, 1984; Brorson et al 1987; Casetta et al, 1999; 
Berg et al, 2001).
1.6.5. Concomitant morbidity (Neurologic, Intellectual, Psychiatric)
Studies in children have found the presence of neurological deficit, especially associated with 
mental retardation indicative of a poor prognosis (Brorson et al, 1987; Hauser et al, 1996; Arts et 
al, 1999; Berg et al, 2001). The effect is less pronounced in adults although some studies have 
reported such an association (Elwes et al, 1984). Psychiatric problems are more frequent in 
patients with epilepsy, and association with refractory epilepsy has been reported before (Elwes 
et al, 1984). It is possible that the presence of a psychiatric co-morbidity early in the course of 
epilepsy points to a greater underlying cerebral dysfunction and is therefore predictive of a poor 
outcome.
Epilepsy is a multifaceted disorder. Seizures are just one manifestation of an underlying cerebral 
dysfunction. A high percentage of patients with epilepsy have other neuropsychiatric disorders, 
especially depression. There is emerging evidence to support a close relationship in the 
pathogenesis of epilepsy and depression (Kanner and Balabanov, 2002). It is likely that the same 
or related process is responsible for the coexistence of the two disorders. Similarly, many 
patients have impaired memory function. Impaired memory performance at the outset has been 
reported to be predictive of poor outcome (Aikia et al, 1999). There is no evidence to suggest 
that currently available AEDs modify the underlying processes. The therapeutic effect is merely 
suppression of the external manifestation, namely seizures and they are perhaps more accurately 
described as anti-seizure drugs. This being so, one could argue that all epilepsy is in essence 
refractory, as all that is achieved is control of symptoms (Hauser, 1992).
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1.6.6. Febrile seizures
Febrile seizures have an almost uniformly benign prognosis. Epidemiological studies have found 
no causative association between febrile seizures and epilepsy. However, approximately 3% of 
patients develop epilepsy in later life (Knudsen, 2000). Complex febrile seizures (i.e. those that 
are prolonged, focal or recur within the same day), those occurring in children with pre-existing 
neurological deficit, and family history of epilepsy in a first degree relative all confer a higher 
risk of developing epilepsy. As discussed above, there is an association between febrile seizures 
in infancy and the development of HS in later life. However, the effects of seizures on the 
developing brain remain incompletely understood.
1.6.7. Family history of epilepsy
Studies in children (Berg et al, 2001) and adults (Elwes et al, 1984) have reported association of 
family history of epilepsy and a poor prognosis. In generalised epilepsy syndromes, this could be 
explained by genetically mediated mechanisms causing epilepsy, which might also be 
responsible for determining response to drugs. However, the occurrence of genetically mediated 
malformations of cortical could influence response to treatment in patients with focal epilepsies 
(Guerrini and Carrozzo, 2001). The relative contribution of these lesions to intractable epilepsy 
is unknown (see part II, section 2.4). Many patients, especially in the pre-MRI era, could have 
had undetected malformations of cortical development, causing intractable seizures.
1.6.8. EEG findings
Some studies, mainly in children, have found correlation of background slowing and focal spike 
and wave activity with a poor outcome (Ko et al, 1999; Aikia et al, 1999; Berg et al, 2001). EEG 
performed soon after seizures are more likely to detect such abnormalities, and are likely to have
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greater prognostic value. Studies in adults have not found EEG to be independently predictive of 
outcome after adjusting for other factors (Elwes et al, 1984, Lindsten et al, 2001). Thus, in 
adults, the prognostic value of routine interictal EEG remains uncertain.
1.6.9. Response to first drug
Several studies have found the response to the first AED to be the strongest predictor of long­
term outlook (Sillanpaa 1993; Camfield and Camfield 1996; Kwan and Brodie 2000; Dlugos et 
al, 2001). Patients whose seizures continue despite adequate doses of an appropriate AED have a 
significantly lower chance of subsequent seizure remission. Moreover, those who fail the first 
drug due to lack of efficacy seem to have a worse prognosis compared to those who do not 
tolerate the initial monotherapy agent (Kwan and Brodie, 2001).
1.7. Conclusions
Epilepsy is the most common serious neurological disorder affecting 0.5 to 1% of the population. 
Approximately one in three of patients diagnosed with epilepsy will never achieve lasting 
remission of seizures with currently available AEDs. These patients continue to suffer the 
physical, psychological and social consequences of intractable seizures and adverse effects from 
escalating drug burden. They also represent a massive burden on health care resources the world 
over. While there is a clear need for new AEDs with novel mechanisms of action, there is also a 
need to target available treatments, especially epilepsy surgery, more effectively. Early 
identification and prediction of patients likely to be unresponsive to drug therapy will allow 
earlier specialist intervention. Advances in cerebral imaging and molecular biological techniques 
have allowed a greater insight into the mechanisms underlying seizure generation and 
propagation. However, this knowledge is far from complete. The basic mechanisms of drug
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resistance in epilepsy also remain largely unclear. Epidemiological data over the years have 
identified several factors that correlate with a poor prognosis in children and adults, although 
some of this data is conflicting. Similarly, pharmacogenomic studies employing more 
sophisticated genotyping and bioinformatics technologies promise greater predictability of 
response to individual AEDs. More long-term studies are required to assess the prognosis of each 
epilepsy syndrome.
Studies to date show that the early response to treatment is a powerful predictor of the long-term 
outlook of newly diagnosed epilepsy. Thus, a patient who does not achieve complete seizure 
control with the first two to three regimes (including combinations) of AEDs in the first one to 
two years after starting treatment, is unlikely to achieve complete control of seizures and could 
be considered to have drug resistant epilepsy. A uniform definition of intractable epilepsy that 
will fit all patients is, however, elusive. When drug therapy produces only less that complete 
control of seizures, the decision to pursue non-pharmacological treatments should be made on an 
individual case basis, taking into account the patients’ expectations, social circumstances and 
likely prognosis of the specific seizure disorder.
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2. Assessing the efficacy of antiepileptic drugs
2.1. Introduction
The epilepsies are a group of heterogeneous, multifaceted disorders that have physical, 
psychological and social implications (Engel, 2001a). Nine new chemical entities have been 
licensed world wide for the prevention of seizures since the late 1980s (Dichter and Brodie,
1996; Brodie and French, 2000). Nevertheless, only 60-65% of patients achieve remission with 
currently available antiepileptic drugs (AEDs, Annegers et al, 1979; Cockrell et al, 1995; 
Mattson et al, 1996; Kwan and Brodie, 2000). There is clearly a need for more new AEDs with 
novel mechanisms of action (Brodie, 2001). Trials conducted to assess AEDs vaiy in their 
design, methodology and end points depending on who wants the information from them. 
Regulatory authorities look for evidence of efficacy and safety, while patients and doctors seek 
data on longer-term clinical utility and tolerability. The pharmaceutical companies hope to meet 
the requirements of all parties. Most trials aimed at demonstrating efficacy to meet regulatory 
demands do not provide clinicians with the information necessary to make treatment decisions 
(Haynes et al, 2002).
The setting for regulatory clinical trials is necessarily artificial, the findings from which might 
not be reproducible in ‘real life’. Nevertheless, stringent patient selection based on strict 
protocols and exclusion criteria are necessary to safeguard patients in these trials and to provide 
unequivocal evidence of efficacy for regulatory authorities (Moher et al 2001). Once efficacy in 
controlling seizures and reasonable safety have been demonstrated, a license is obtained, initially 
as adjunctive treatment and then as monotherapy, and clinicians can start to gain experience with 
the drug and decide its place in the therapeutic armamentarium. Indications, titration schedules 
and recommended doses can change and new adverse effects come to light in the post-marketing
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period, which may have important implications for the drug's therapeutic usefulness. To 
adequately evaluate benefits and risks of treatment for chronic diseases, systematic reviews 
should consider data from observational studies in addition to randomised controlled trials 
(Elphick et al, 2002).
Observational studies can be useful adjuncts to randomised, controlled trials to see whether the 
demonstrated efficacy translates into effective treatment in routine clinical practice (Pocock and 
Elboume, 2000). The following section will touch on some of pre- and post-licensing efficacy 
issues that need to be addressed before the value and usage of a drug can be determined with any 
degree of certainty.
2.2. Regulatory issues
While regulatory authorities require proof of efficacy and safety before a license can be granted, 
there are differences in what is acceptable in different parts of the world. The requirements for 
licensing an AED as add-on in patients with refractory epilepsy are largely non-controversial. 
Placebo-controlled, add-on studies usually include a range of randomised doses for the new 
AED. The aim is to show a clinically useful dose-response relationship, ideally including a non- 
effective dose, which will help identify the effective dosage range.
When a monotherapy claim for newly diagnosed epilepsy is requested, the Food and Drug 
Administration (FDA) in the United States usually insists on two randomised double blind trials 
showing evidence of superiority of test drug over control as proof of efficacy (Temple, 1982).
As many patients with newly diagnosed epilepsy will have their seizures controlled with the first 
AED chosen (see part II, section 1.3) often at modest or moderate dosage (part II, section 4.3) a
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dose response relationship can be difficult to identify in this population (Chadwick, 1998; 
Privitera et al, 2003).
The European Agency for Evaluation of Medicinal Products (EMEA) recommends trials using 
established AEDs as controls (active control). Demonstration of ‘no difference’ between the new 
drug and established treatment can be accepted as evidence of efficacy. Although no placebo- 
controlled trials have been carried out using the traditional AEDs, sufficient historical evidence 
exists to support their efficacy (Chadwick, 2001a). Active control trials can, therefore be 
considered valid if they reproduce the setting in which the comparator has been shown to be 
effective and for which it has been licensed by the regulatory authority. One advantage of active 
control studies is that they allow the new agent to be tested as monotherapy for the population of 
patients in whom it will later be licensed. The FDA takes the view that "equivalence" between 
the test drug and active control could be simply due to lack of efficacy of both or because the 
trial lacked sufficient sensitivity to differentiate between them (Leber, 1989). A number of 
strategies have been developed to overcome this dilemma, including high dose versus low dose 
or "pseudoplacebo" in withdrawal to monotherapy designs.
2.3. Adjunctive trials
All new AEDs are initially studied as adjunctive treatment in patients who continue to have 
seizures despite treatment with one or more AEDs. The use of placebo in this setting is not 
considered unethical as patients are already on treatment with conventional drugs and are 
protected from status epilepticus by their baseline medication. They are required to have a 
defined number of seizures per unit time (e.g. 4 per month) to be eligible for inclusion in a 
regulatory trial. In the pre-treatment phase, existing therapy remains stable and baseline seizure
58
frequency is recorded usually over 8 weeks. Modem studies tend to follow a parallel group 
design. Crossover studies have largely gone "out of fashion" because they are regarded as 
methodologically less sound. Patients with partial seizures with or without secondary 
generalisation are recruited initially, since there still is substantial need for effective treatment in 
this patient population (Semah et al, 1998; Stephen et al 2001). Similar studies in the generalised 
epilepsies are sometimes undertaken later although these are often slow to recruit (Biton et al, 
1999). Efficacy against typical absences or myoclonic jerks can be difficult to demonstrate.
2.3.1. Crossover studies
This design involves patients receiving the drug and placebo randomly in two separate treatment 
phases separated by a washout period. Vigabatrin (Mumford and Dam, 1989) and lamotrigine 
(Stephen and Brodie, in press) underwent European regulatory programmes based on 
randomised, placebo-controlled, crossover studies. This design allows the effects of drug and 
placebo to be studied within subjects and can be particularly useful early in the development 
programme (Richens, 2001). There is a fundamental requirement for seizure numbers to remain 
stable and predictable. Only if seizure frequency returns to baseline when the first treatment is 
stopped can the second be evaluated under identical conditions. This can be a problem as many 
patients tend to be recruited during a period of exacerbation of their seizures which may remit 
over time irrespective of therapy. Furthermore, if there has been a clear beneficial effect during 
the first period of treatment, there are ethical concerns about switching patients and consent for 
the second period might not be forthcoming. Carry over effects can also influence results from 
the second period. In addition, if the response to or toxicity with the test drug is clearly different 
from that of placebo, blinding can be difficult to maintain. For these reasons, regulatory 
authorities are unlikely to accept crossover trials as primary proof of efficacy. However, useful
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information on dose ranging, pharmacokinetic interactions and side-effect profiling can be 
obtained using this design (Leach et al, 1997).
2.3.2. Parallel group studies
This is regarded as the design of choice for the regulatory assessment of efficacy of new AEDs 
as adjunctive therapy in difficult-to-control epilepsy. Patients are randomised to receive one of 
several doses of drug or matched placebo. Groups are compared for measures of efficacy and 
tolerability. This design has the advantage that it is suitable for all stages of drug development 
and a range of dose levels can be included in the same study. The necessity for the seizure 
disorder to be stable is not vital in this design because the comparison is between rather than 
within subjects. Dose-response studies need to be carried out with compounds seeking approval 
as adjunctive therapy and demonstration of a clear-cut dose-response relationship reassures all 
concerned that efficacy has been demonstrated.
Results from these trials can be complicated by potential pharmacokinetic and pharmacodynamic 
drug interactions. Some limitations may be placed on the number and types of baseline AEDs to 
help minimise these problems, but they cannot be wholly eliminated. It can be argued, indeed, 
that such studies assess the efficacy and tolerability of AED combinations rather than the drug 
under study. Giving lamotrigine to patients already taking sodium valproate will produce a 
better response than those established on carbamazepine or phenytoin (Brodie et al, 1995). 
Indeed, synergism between sodium valproate and lamotrigine has been confirmed in an open, 
response-conditional, crossover design employing concentration measurement (Pisani et al,
1999). The combination of carbamazepine and lamotrigine, on the other hand, is more likely to 
produce neurotoxic side-effects due to an adverse pharmacodynamic interaction between the
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drugs (Brodie et al, 1995; Pisani et al, 1999; Patsalos et al, 2002). Combination effects may also 
explain the substantial efficacy of the GABA-ergic AEDs, vigabatrin and tiagabine, as add-on 
therapy in refractory epilepsy; (Marson et al, 1997; Deckers, 2001) which was less impressive 
when the drugs were used as monotherapy in newly diagnosed localisation-related epilepsy 
(Brodie et al, 1997; Chadwick, 1999).
2.4. Monotherapy trials
Evidence of efficacy from add-on studies has to be available before such studies can be 
contemplated. Most patients with untreated epilepsy can expect to have their seizures controlled 
with one AED (Kwan and Brodie, 2000). The use of placebo control in patients with newly 
diagnosed epilepsy can be regarded, therefore, as ethically dubious (Chadwick and Privitera,
1999). For regulatory purposes, the FDA accepts only evidence of superiority over control as 
proof of efficacy. There are difficulties in designing clinically relevant monotherapy trials that 
meet their requirements. Randomising patients to placebo alone could be interpreted as being at 
odds with the Declaration of Helsinki which stated that, “In any medical study all patients - 
including those in the control group, if any - should be assured of the best proven diagnostic and 
therapeutic method”. A revised version, issued in October 2000, included a new section (section 
29) which stated “The benefits, risks, burdens and effectiveness of a new method should be 
tested against the best current prophylactic, diagnostic and therapeutic methods” 
(www.wma.net/e/policy/17-c_e.html). If interpreted literally, this would appear to rule out 
placebo-controlled trials, whenever licensed therapeutic options already exist.
However, judicious use of placebo is sometimes essential to establish the efficacy of new 
treatments (Lewis et al, 2002). A further "clarification" of this section issued in October 2001
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stated that placebo controlled trials may be justifiable even when effective treatments are 
available if there are compelling and scientifically sound methodological reasons for their use 
with the caveat that patients subjected to placebo treatment are assured of no serious or long- 
lasting harm. In the context of epilepsy, this could be interpreted to mean that the use of placebo 
alone is justified only when genuine doubt exists as to the effectiveness of the treatment being 
evaluated (e. g. following first unprovoked seizure), or when the risks from further seizures are 
low (e.g. absence seizures).
In an attempt to avoid the ethical problems of using placebo controls, low doses of the study drug 
or suboptimal doses of a standard AED have been used as a “pseudoplacebo”. The rationale for 
this has been that while a low dose will protect against catastrophic seizures, it will have little 
effect on the overall number of partial seizures (Schwabe, 2001). There is, however, no evidence 
to support this. In addition, it can be argued that the using a drug at a dose intended to be 
ineffective is equivalent to using a placebo. A number of innovative study designs have been 
used to satisfy regulatory requirements while maintaining patient safety. These “therapeutic 
failure” paradigms require the demonstration of worse seizure control in the low dose compared 
to the high dose group (Pledger, 2001). Even with tightly defined exit criteria, ethical concerns 
remain with such approaches (Perrucca and Tomson, 1999).
2.4.1. Pre-surgical withdrawal
These studies are carried out in patients who have had their AEDs discontinued as part of seizure 
localisation investigations prior to possible epilepsy surgery. Patients are randomised to the study 
drug or placebo control and are monitored until they meet pre-defined exit criteria. These can 
include a specified number of seizures, worsening of seizure severity, or completion of a period
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on treatment. Primary efficacy variables are usually time to exit and the percentage of patients 
completing the study. This design can be used as "proof of concept" for AED efficacy.
Such protocols tend to last short periods (hours to days) and yield little clinically relevant 
information. Drugs that exhibit delay in onset of full clinical effect (e.g. sodium valproate) and 
those that show tolerance (e.g. benzodiazepines) may not be suitable for this design. Once the 
patient has had sufficient number of seizures for the purpose of localisation and video­
monitoring has been discontinued, any further episodes will be for the benefit of the study alone. 
Modifications have been suggested to address such remaining ethical issues (Bien and Eiger, 
2001; Binnie, 2001a).
2.4.2. Conversion to monotherapy
Patients with difficult-to-control epilepsy taking AEDs are randomised to receive active drug or 
control. The original AEDs, usually one or two, are then tapered off in responders who are then 
maintained, if possible, on the new monotherapy. The use of placebo would be unacceptable in 
this population of patients and, therefore, suboptimal comparators (low dose of study drug or of 
another AED) are used instead as controls. The aim is to show that significantly more patients 
can be maintained on monotherapy with the study drug at high than on low dosage (Gilliam et al, 
1998). Exit criteria are defined in terms of number and severity of seizures. This follows clinical 
practice to a limited extent inasmuch as it seeks to withdraw concomitant AEDs in patients 
whose seizures are controlled when a new drug is added (Kalviainen, 2001). However, target 
doses of the study drug are usually fixed and the substitution protocol is often rigid. Maintaining 
responders on monotherapy for an extended period can yield valuable safety information. These 
studies have a variable track record in demonstrating efficacy of new AEDs as monotherapy and
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ethical concerns surrounding the use of pseudoplacebos remain. A recent proposal under 
discussion is to drop the low dose comparator and compare the withdrawal rate on high doses of 
new AEDs with "historical” controls from previous trials.
2.4.3. Active control
These trials are carried out in drug-naive patients with newly diagnosed epilepsy. The study drug 
is compared to standard doses of an established AED using a randomised, double-blind design. 
This approach has the advantage of comparing the new drug head-to-head with standard 
treatment without the confounding effect of co-medication withdrawal. As the majority of newly 
diagnosed patients experience seizure remission with the first AED chosen, often at low or 
moderate dosage, demonstrating superior efficacy will require large numbers of patients 
followed-up over long periods of time using a flexible dosage design. Demonstrating 
'equivalence' is usually accepted as evidence of efficacy by European regulators. These active- 
control studies aim to show that the study drug is not inferior to the standard AED which has 
historically been shown to be effective for the seizure type under study. Although the scientific 
validity of this design have been questioned (Beydoun and Milling, 2001), it would seem to be a 
logical method of assessing the effectiveness of AEDs drugs as potential first choice treatment in 
newly diagnosed epilepsy. Furthermore, there are fewer ethical implications in these types of 
studies, which are largely acceptable to patients and doctors (Karlawish and French, 2001).
Methodological integrity is important in equivalence studies. It is not acceptable to carry out the 
trial as a comparative study and interpret the lack of statistically significant difference as definite 
proof of equivalence (Jones et al, 1996). The null hypothesis is that there exists a difference 
between the treatments (delta -  the confidence interval around equivalence). If this is rejected,
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the alternative hypothesis, ie that the treatments are equivalent, is accepted. In demonstrating 
clinical equivalence, the limits of difference with respect to important outcomes such as seizure 
remission should be decided at the design stage. For AEDs, this is usually taken as 10%. If the 
study drug is shown to be no more than 10% different form the active comparator, it can be 
assumed that it is at worst 10% inferior to standard treatment (Chadwick, 2001). Sample sizes 
need to be large, although optimal numbers can be guaranteed by using a sequential design 
(Whitehead, 2001). Intention to treat analysis is no longer conservative and per protocol analysis 
should also be presented (Brodie et al, 2002). European regulators have ruled that delta should 
be set as far as possible from the placebo zone and that the natural history of the disorder should 
be taken into account when deciding it (Chadwick, 2001a).
Active control trials have been criticized in the past over choice of doses and titration schedules. 
If the established comparator is started at a low dose and titrated to moderate dosage in 
accordance with normal clinical practice, this may be interpreted as introducing bias in favour of 
the efficacy of the trial drug. If however more aggressive regimes are employed, the tolerability 
of the new AED can appear exaggerated.
2.5. Clinical end points
All new AEDs are initially evaluated as add-on treatment for patients with seizure disorders not 
controlled with one or more standard agents. Once adjunctive studies have proven the efficacy of 
the trial drug, a monotherapy programme can be initiated. Complete seizure control is not 
regarded as a realistic end point for the majority of patients with refractory epilepsy. Standard 
end points are manipulations in the number of seizures between the baseline and treatment 
periods. Seizures can be difficult to count especially if they occur in clusters (French, 2001). 
Distinguishing between the various types can also be problematic. The non-parametric nature of
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the data can make analysis challenging. While seizure frequency can only be decreased by 100%, 
it can be increased infinitely. Several non-parametric paradigms have been devised to address 
this problem. The response ratio, for example, allows for normalization of the percent change in 
seizure frequency which always falls in the range o f-100 to + 100 (UK Gabapentin study group, 
1990; US Gabapentin study group, 1993).
2.5.1. Changes in seizure frequency
Seizures are counted over a defined period of time, e.g. 1 or 3 months, and the number occurring 
in patients receiving the test drug is compared with that in controls. When analysed as a 
continuous variable, seizure frequency is the most sensitive measure of efficacy and should be 
used whenever possible (Chadwick, 1998). However, skewed distribution can make data 
handling difficult using standard statistical methods without transformation. Percentage 
reduction in seizure frequency between baseline and treatment periods, although superficially an 
attractive alternative, is prone to be unduly influenced by outliers. Analysis using seizure 
frequencies during baseline and treatment periods (transformed if necessary) as covariates can be 
regarded as a better option.
2.5.2. Proportion of responders
When patients exhibit seizures within a wide range suggesting non-normal or multimodal 
distribution, frequency has to be assessed as a dichotomous (binary) variable. Percentage of 
subjects with 50% (or some other arbitrary figure) reduction in seizure frequency can be 
compared among groups. One advantage of such an analysis is that it has been used frequently 
and, therefore, allows comparisons with previous studies using different AEDs (Marson et al, 
1996). A minimum of 50% reduction in seizure frequency is the dichotomous cut off point
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usually quoted in clinical trials. This is arbitrary, however, and may miss important differences 
between treatments. Categorisation of seizure frequencies can be used instead of a single cut off 
point; e.g. 0-19%, 20-39%, 40-59%, >75% reductions etc (Chadwick, 1998). Seizure freedom is 
not generally quoted as a primary outcome measure, because of the refractoriness of epilepsy in 
this population and the use of predetermined titration schedules and fixed doses of AEDs. 
Nevertheless, this observation is probably underused.
2.5.3. Seizure free days
In studying the effect of levetiracetam in patients with refractory epilepsy, French and colleagues 
(French et al, 2000) reported an analysis of seizure-free days to determine efficacy. This was 
carried out by evaluation of seizure diaries. In contrast to standard analyses, where the total 
number of seizures in a set period of time are counted, this approach looks at each day 
individually to see whether or not a seizure has occurred. Such day by day evaluation can allow 
seizure patterns and response timings to be addressed. One aim of this approach is to obtain a 
flavour of the time-to-effect with the test drug compared to placebo control.
2.5.4. Time to nth seizure
Time to first seizure is a commonly quoted end point for monotherapy trials especially in 
presurgical withdrawal studies. It has been shown that this type of analysis can be applied 
equally to adjunctive trials with fixed treatment periods (Pledger and Sahlroot 1993). This 
outcome measure has also been used in active control monotherapy comparisons (Chadwick et 
al, 1999; Brodie et al, 2002). One potential pitfall in newly diagnosed epilepsy is excluding the 
possibility that any difference between the new and established agent in time to first seizure was 
a consequence of differences in titration schedules or maintenance dosing. These values are
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usually well known for the older agents, but not necessarily for the new AED at the time of the 
study. Time to second, third, fourth seizure etc can be more useful endpoints (Brodie et al,
2002).
2.5.5. Seizure severity
Even if a treatment does not abolish seizures completely, reduction in severity can be achieved. 
Examples are fewer secondary generalised seizures in relation to numbers of complex partial 
seizures or fewer complex partial compared to simple partial events with awareness retained. 
Shortening of the post-ictal recovery period could allow patients to return to normal activity 
sooner following a seizure. Three scales are available to measure the severity of seizures. These 
are the Veterans Administration Seizure Severity and Frequency Rating Scale (Cramer et al, 
1983), the Liverpool Seizure Severity Scale (Baker et al, 1991) and the National Hospital Seizure 
Severity Scale (formerly known as the Chalfont Seizure Severity Scale; O’Donaghue et al,
1996). Each has its strengths and weaknesses (Cramer, 2001; Cramer and French, 2001). New 
instruments addressing their shortcomings are in development (Cramer et al, 2002). Seizure 
severity scales need to be reliable, valid and sensitive. Although the psychometric properties of 
these scales are well established, there is little evidence to support their clinical utility. Until 
more data become available, seizure severity scales cannot be recommended as standard 
outcome measures in evaluating the efficacy of AEDs (Baker et al, 1998).
2.5.6. Electroencephalography (EEG)
Once a drug has demonstrated anti-seizure activity in animal models, the decision whether to 
proceed with clinical development is a commercial one. Pivotal studies in man require prolonged 
administration over months in many patients with several types of seizures. This programme
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takes years to complete and demands considerable resources. Preliminary evidence of efficacy is 
valuable to help with decision-making. Surrogate endpoints, such as electroencephalographic 
changes, can provide indications of potential efficacy. Generally, epileptiform discharges do not 
correlate with the severity of the seizure disorder (Binnie and Stefan, 1999). Nevertheless, under 
standard recording conditions meaningful effects of AEDs may be demonstrable in patients with 
suitably high and stable rates of epileptiform EEG discharges (Milligan et al, 1982). Acute 
experiments require a rapidly effective formulation of the drug (preferably intravenous) tested 
under rigorously standardised conditions. The drug is usually compared to both placebo and an 
active control (e.g. diazepam) employing a crossover design. The primary outcome measure is 
the spike count per minute or the percentage of the total recording occupied by discharges. 
Subacute experiments can be carried out over longer time periods (e.g. 24-48 hours) using 
telemetry or ambulatory EEG monitoring. These reduce problems with spontaneous variation in 
the rate of epileptiform discharges. This can also be achieved by measuring evoked responses 
such as the photoparoxysmal response in photosensitive subjects. Reduction in photosensitivity 
can be demonstrated after a single dose of various AEDs at clinically relevant plasma 
concentrations (Rowan et al, 1979). However, less than 1% of patients with epilepsy are suitable 
for such studies and the scarcity of subjects is a major limitation in recruitment (Binnie, 2001b).
Surrogate measures of efficacy using EEG techniques have not been widely used in the 
development of new AEDs, with the possible exception of lamotrigine, which underwent 
assessment for interictal spikes (Jawad et al, 1986) and photosensitivity (Binnie et al, 1986). 
While suppression of epileptiform discharges may encourage further development of the drug, 
lack of such efficacy should not be grounds for termination of development. The decisive test of 
efficacy for any AED is whether it prevents seizures and the earlier that this is demonstrated the
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better. Attempts to use intensive EEG monitoring to support efficacy claims in absence epilepsy 
and severe epilepsy syndromes in infants have been tried with variable success (Frank et al, 
1999; Sundqvist et al, 1999; Mattia et al, 2000; Stodieck et al, 2001; Gaily et al, 2001).
2.6. Effectiveness
2.6.1. Long term retention studies
The effectiveness of an AED is a function of its efficacy and tolerability. The single most 
relevant outcome measure that reflect both these factors is the life table that expresses the 
retention of patients on a particular treatment over a length of time (Mattson, 2001). Treatment 
with the investigational drug is withdrawn when a predetermined combination of insufficient 
seizure control and /or poor tolerability is reached. This approach conforms to everyday practice 
and can provide useful clinical information. Long-term retention on the investigational drug is 
useful for add on and monotherapy studies and in the post marketing phase. In monotherapy 
studies, lack of efficacy would result in inadequate seizure control and therefore lead to 
withdrawal, but in patients with poorly controlled epilepsy undergoing add on trials, a drug with 
only modest efficacy may be continued long term if adverse effects are mild. This needs to be 
taken into account while planning and interpreting these studies (Chadwick, 2001a).
Regulatory authorities seek, over and above everything else, evidence of efficacy. Long term 
retention time alone does not provide this and, hence, life table analysis alone is less suitable for 
regulatory trials. In addition, if patients are withdrawn from the trial for reasons other than those 
related to efficacy and tolerability (e.g. inappropriate titration schedule, poor compliance, lost to 
follow up etc) the results can be misleading. In such circumstances, the analysis can be done
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excluding these data (evaluable population) in addition to including all randomized patients 
(intention to treat, Whitehead 2001).
2.6.2. Measures of efficacy
The main objective of treatment with antiepileptic medication is control of seizures with 
acceptable tolerability. Therefore, an essential outcome measure is the proportion of patients 
achieving a predefined period of seizure freedom (Mattson, 2001). Depending on the syndrome 
and the patient population under study, remission may or may not be a realistic goal. As the 
majority of newly diagnosed adult patients with epilepsy can expect to have their seizures 
completely controlled, seizure freedom from initiation of treatment or after titration is a sensitive 
end-point for this population. This would not be the case if the study population were, for 
instance, infants with Lennox-Gastaut syndrome.
The proportion of patients with complete control of seizures can be measured at one, two or three 
years from treatment initiation. This provides the most clinically meaningful data for predicting 
the long term efficacy of an AED (Chadwick, 1997). Time to achieving one year of seizure- 
freedom (or some similar end point) focuses directly on the main aim of treatment. It has the 
advantage that patients, who continue to have seizures for a period after starting on treatment, 
can also be included (Mattson, 2001). Both the above end points, while lending themselves to 
statistical and intuitive analyses, can be insensitive. They require complete control of seizures as 
evidence of efficacy, and discount patients who experience even a single seizure due, for 
instance, to a lapse in compliance or an intercurrent gastrointestinal infection. Detecting 
differences in efficacy among patients not fully controlled is possible using seizure rates i.e. 
number of seizures over a unit time. This can also be used to compare two treatments. If patients
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are lost to follow up, this approach becomes less valuable. Although an “intention to treat” 
analysis addresses this issue, results can still be distorted.
2.6.3. Measures of adverse effects
While no important differences in efficacy have been shown among AEDs in regulatory trials, 
differences have been seen in tolerability (Mattson et al, 1985; Brodie et al, 1995), which is 
assessed by the incidence, prevalence, severity and the impact of side effects (Chadwick, 1998). 
Adverse events include issues relating to tolerability and safety. The most important outcome 
measure is withdrawal of a drug because of intolerable or life threatening side-effects. 
Surveillance for organ toxicity is maintained by history, physical examination and laboratory 
testing. Life threatening idiosyncratic reactions, with the exception of hypersensitivity rash, are 
extremely rare. Regulatory trials do not involve sufficient number patients to uncover these 
events. Post-marketing surveillance is more important in detecting these uncommon but 
potentially serious problems. Major safety concerns with felbamate and vigabatrin were 
identified in this phase.
Neurotoxic adverse effects such as sedation, dizziness and diplopia tend to resolve with a 
reduction in dose. This may not be allowable in a fixed dose study and so the patient may drop 
out and, therefore, not gain efficacy from the drug (Brodie et al, 1997). These and other 
systemic adverse effects, including gastrointestinal upsets, may also abate with time. The 
development of tolerance to initial neurotoxicity may allow higher doses to be used at a later 
date. An end point that records only the incidence of adverse effects will not make this 
distinction. Patient based scales have been developed to measure the neurotoxic effects of AEDs 
(Aldenkamp et al, 1995).
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Historically, many clinical trials of AEDs have used incidence reporting of adverse events after 
passive inquiry. This is now recognised as inadequate (Chadwick, 1998). Studies have relied on 
spontaneous reporting of adverse effects by patients. While having the advantage of highlighting 
clinically relevant problems, this method is associated with substantial variability in sensitivity 
and detection. Spontaneous reporting tends to underestimate side-effects, as patients may not 
make the association between subtle problems and AED therapy. Patients might also not recall 
transient mild symptoms. Therefore, some form of standardisation in interview and examination 
has been recommended to supplement spontaneous reporting (Chadwick et al, 1998). Checklists 
should be used for recording adverse events during randomised trials.
Efficacy and tolerability of an AED cannot be sensibly separated in the setting of a clinical trial. 
They combine to form effectiveness. If a patient develops a rash or drops out of a study due to 
neurotoxicity, data from this individual will not contribute to the drug's efficacy. A major 
difference in tolerability can distort the clinical or scientific relevance of efficacy end-points. 
Thus, in a recent double-blind trial of carbamazepine versus lamotrigine in the elderly, no 
differences in efficacy could be demonstrated even though twice as many patients taking 
lamotrigine remained seizure-free due to its better tolerability and, therefore effectiveness 
(Brodie et al, 1999).
2.6.4. Dosage
Doses used in regulatory trials are frequently different from those subsequently found to be 
effective in routine clinical practice. Thus, gabapentin is now prescribed in higher amounts (up 
to 4800mg daily) than those doses originally studied (900-1800mg daily) and subsequently 
licensed (up to 2400mg daily) (Sivenius et al 1991; Anhut et al, 1994; Wilson et al, 1998;
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McLean et al, 1998; Beran et al, 2001). On the other hand, the titration schedules (50mg weekly) 
and maintenance doses (200-800mg daily) for topiramate in regulatory studies were more robust 
than now recommended producing high responder rates but at the expense of numerous adverse 
events (Faught et al, 1996; Privitera et al, 1996; Sharief et al, 1996; Tassinari et al, 1996; Ben- 
Menachem et al, 1996; Rosenfeld et al, 1996). Prospective observational studies have shown that 
good outcomes can be obtained in many patients with substantially lower amounts of topiramate 
(50-200mg daily) than those used in regulatory trials (Stephen et al, 2000; Kelly et al, 2002). The 
recommended titration schedule now starts with 25mg topiramate daily with weekly or 2 weekly 
increments of 25-50mg daily. As the primary aim of a regulatory trial is to demonstrate efficacy, 
the tendency will be to err on the side of fast titration and higher dosing. Well-designed post­
marketing studies can allow clinicians to gauge the optimal titration schedules and effective 
doses for less severely affected patients taking the drug in everyday clinical practice.
2.6.5. Concentration measurement
Serum levels of AEDs can be used to augment the daily dose in controlled clinical trials. 
Concentration-defined trials were used in the unsuccessful development of flunarizine (Pledger 
et al, 1994) and with lamotrigine (Binnie et al, 1989). The basis for this approach is the empirical 
observation that serum concentrations may correlate better with clinical response than does dose. 
This could reduce interpatient variability and make the trial statistically more efficient (Pledger, 
2001). Drug levels are monitored and controlled in an effort to identify a concentration-effect 
relationship. Such data were helpful in supporting the license claim for zonisamide as add-on 
therapy in the US (Leppik et al, 1993). A concentration-response trial has also been carried out 
with sodium valproate as monotherapy in partial epilepsy (Beydoun et al, 1997). Many of the
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newer AEDs, however, do not exhibit clinically relevant concentration-effect-toxicity 
relationships (Kilpatrick et al, 1996; Wilson et al, 1998; Stephen et al, 2000)
2.6.6. Quality of life
Health related quality of life (HRQOL) measurements have been an area of increasing interest in 
recent years (Jacoby, 1996). Several generic instruments measuring HRQOL can be used in 
patients with epilepsy (Baker et al, 1998). In addition, a number of scales specific to epilepsy 
have been devised. The latter include the Liverpool HRQOL battery (Baker et al, 1993), 
Epilepsy Surgery Inventory (Vickery et al, 1992) and QOL in Epilepsy (QOLIE) instruments 
(Devisky et al, 1995). These attempt to quantify emotional, functional and psychosocial 
wellbeing. They are heavily dependent on seizure freedom, however, and are unlikely to be 
independent outcome variables in clinical trials of AEDs (Birbeck et al, 2002).
2.7. Observational outcome studies
Epilepsy is a chronic condition. Most patients take AEDs for many years and many receive 
lifelong treatment. Studies that follow patients up over prolonged periods of years can provide an 
insight into the natural history of treated epilepsy. These data can help identify patients who are 
likely to enter remission and those who have a more progressive seizure disorder. These studies 
require substantial resources and do not usually attract the same level of commercial or grant 
funding as regulatory or comparative trials. However, they can help identify the best way of 
utilizing new treatments. The modem AEDs are, not surprisingly, more expensive than the older 
agents. A recent cost-benefit assessment of lamotrigine has, for instance, suggested that the costs 
associated with newer AEDs might be unjustifiably high (Messori et al, 1998). The assumptions 
in this study have been challenged (Bialer et al, 2002), but the fact remains that significant
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proportion of health care budgets for epilepsy is taken up by the newer AEDs. There seems little 
doubt that they have helped patients whose seizures might otherwise have remained 
uncontrolled. In addition, the use of individual drugs can be of substantial value in specific 
epilepsy syndromes eg vigabatrin for infantile spasms (Appleton et al, 1999). It would, therefore, 
make economic sense to invest in studies of sufficient scope and magnitude that could help 
identify the optimal place and usage of AEDs in clinical practice.
2.7.1. Methodology
The basic requirement for any long-term outcome study is that it follows routine clinical practice 
as closely as possible. Exclusion criteria should be kept to a minimum. Patients with newly 
diagnosed epilepsy differ from those with difficult-to-control seizures in terms of expected 
outcomes, side effect profiles and quality of life issues. These groups should be studied 
separately. Patient care should not vary from normal except for closer follow up and more 
objective assessment of efficacy and tolerability. Rating systems should be used for 
documenting seizures and side-effects, taking into account their number and severity together 
with objective assessments of behavioural and cognitive status. Individual seizure types or 
epilepsy syndromes should be studied separately and rigorous standards applied to diagnosis and 
classification. Pre-defined protocols should be followed in investigating and monitoring patients. 
Sample sizes required to answer specific questions should be calculated prior to commencement, 
and anticipated losses due to non-drug related events should be taken into consideration. In 
newly diagnosed epilepsy, the incentive to continue treatment and attend follow up appointments 
may not be as persuasive as in patients with reffactoiy seizures.
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These studies can be observational where each patient’s treatment is deliberately chosen or 
randomly assigned. Dosing schedules should be flexible tailoring therapy for the individual 
patient. This allows the therapeutic potential of each AED to be maximised. There is an 
unavoidable risk of selection bias and differences in outcomes might not always be due to 
differences in treatment. Adjustments for identifiable variation in patient characteristics at the 
analysis stage can mitigate this. However, unsophisticated post-marketing surveillance tends to 
cause more problems than it solves and these studies are best undertaken for safety than efficacy 
reasons (French, 2002).
2.7.2. End points
In monotherapy studies in newly diagnosed epilepsy, the majority of patients can be expected to 
enter remission with appropriate therapy. Time to first seizure can, therefore, be a relevant end 
point assuming appropriate AED titration and dosing. The number of patients who have not 
suffered a first seizure would represent the number who have remained fully controlled. In 
longer term studies of outcomes, the proportion of patients remaining free of seizures after one, 
two and three years of follow up will provide a useful indication of effectiveness. These 
measures, combined with quality of life issues such as employment, driving etc, reflect the real 
impact of AED treatment on the lives of people with epilepsy.
As discussed above, the incidence, prevalence and severity of adverse effects are important 
determinants of the success of AED treatment. Withdrawal of a drug because of adverse effects 
is a definitive end point in a clinical study. For patients with difficult-to-control epilepsy, drug 
burden can significantly impair quality of life. In the VA co-operative study a complex approach 
was used to quantify the efficacy and toxicity of phenytoin, carbamazepine, phenobarbital and
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primidone (Mattson et al, 1985). Seizure frequency and severity, neurotoxicity, systemic and 
behavioural toxicity, and retention time on treatment were the primary variables. These were 
computed into a single composite score, which allowed relative effectiveness of each of the four 
drugs to be compared (Cramer et al, 1993).
2.8. Meta-analysis
In the absence of comparative studies, meta-analyses of individual clinical trials can give 
clinicians an impression of how new drugs might compare in terms of efficacy and side- effects. 
Meta-analyses of adjunctive clinical trials showed no significant differences in efficacy among 
the various new AEDs studied (Marson et al, 1996; Marson et al, 1997). These analyses were 
based on odds ratios, and it has been suggested that number-needed-to-treat might be better 
suited to demonstrate differences in efficacy (Elferink et al, 1997). This is the number of patients 
requiring treatment in order to achieve a single occurrence of a specified outcome. This measure 
has the advantage of being readily interpretable by clinicians, although it does have some 
undesirable statistical properties (Lesaffre et al, 2000).
In meta-analyses of AED trials, it is not possible to compare newer AEDs with traditional ones, 
as none of the older agents (with the exception of sodium valproate) has been evaluated as add­
on treatment in a controlled clinical trial (Marson et al, 2002). Moreover, as most of these trials 
were restricted to adjunctive treatment for partial onset seizures, few conclusions can be drawn 
about the use of these drugs as monotherapy or in the treatment of other seizure types.
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2.9. Conclusions
The epilepsies are a range of multifaceted disorders that can affect many aspects of a person's 
life. No single outcome measure can reflect their complex nature and impact in the individual 
patient. The aim of drug treatment is the prevention of seizures with no or tolerable side-effects. 
While this is possible for the majority of patients, there remains a significant proportion in whom 
ongoing seizures and increasing drug burden exact a heavy toll. Efficacy has to be the first 
consideration in the development of any new AED. However, trials aimed at demonstrating 
efficacy to meet regulatory requirements rarely produce data that are helpful to doctors who treat 
people with epilepsy. The outcome measures in these trials, while admirably suited to 
demonstrating statistical differences, are of dubious clinical relevance. The real test is how a new 
AED stands up to scrutiny in clinical practice. Well-designed observational studies can help 
doctors decide their value. The end points in these studies should include both global outcome 
measures, such as the life table of retention on treatment, as well as specific measures of efficacy 
and tolerability. Analyses should explore effects in different seizures types and epilepsy 
syndromes. Measures of subjective health status can be used as secondary endpoints. A 
combination of randomised and observational studies will help decide the eventual place of a 
new AED in the therapeutic armamentarium.
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Part II
Clinical outcome studies in newly diagnosed epilepsy
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1. Diagnosing refractory epilepsy
1.1. Introduction
Over 30% of people with epilepsy never achieve remission with antiepileptic drug (AED) 
therapy (Annegers et al, 1979; Cockrell et al, 1995; Mattson et al, 1996; Kwan and Brodie,
2000). These individuals suffer the physical, psychological, and societal consequences of 
intractable seizures with a heavy drug burden and an increased mortality (Kwan and Brodie,
2000). Refractory epilepsy, in addition, represents a significant drain on health care resources 
(Devinsky, 1999). Some of these patients could benefit from non-pharmacological treatment 
modalities, especially epilepsy surgery (Sisodiya, 2000; Engel et al, 2003; Murphy and Patil, 
2003; Theodore and Fisher, 2004). Indeed, resective surgery in refractory temporal lobe epilepsy 
has been shown in a randomised trial to provide substantially better outcomes than continued 
manipulation of AED therapy (Wiebe et al, 2001). Many patients with remediable syndromes 
suffer seizures for more than 20 years before coming to surgery (Trevathan and Gilliam, 2003). 
Defining a situation where the epilepsy is likely to be pharmacoresistant will help identify early 
those patients who should be referred for further evaluation to an epilepsy service. We analysed 
outcomes in patients with newly diagnosed epilepsy followed up at a single centre over a 20-year 
period with the objective of correlating response to sequential drug schedules with prognosis.
1.2. Methods
1.2.1. Study design
We conducted a retrospective analysis of treatment outcomes in all patients diagnosed with 
epilepsy at the Epilepsy Unit, Western Infirmary in Glasgow over a 20-year period. Patients 
presenting with suspected seizure disorders were referred to the First Seizure Clinic by general 
practitioners, accident and emergency physicians and other clinicians. At the initial clinic visit,
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detailed history and description of the episodes were obtained from patients and witnesses. A 
structured protocol was used to collect clinical information. Investigations including 
electroencephalography and brain imaging were carried out as clinically indicated (Brodie and 
French, 2000). When a diagnosis of epilepsy was made, patients were prescribed their first AED. 
Research notes were maintained for each patient in the Epilepsy Unit. Reviews were carried out 
at 4-6 weekly intervals. Serum anticonvulsant concentrations were measured routinely to guide 
dosage changes and monitor compliance. Adherence to treatment was assessed by direct 
questioning and serum concentration measurement.
1.2.2. Classification of seizures and epilepsy syndromes
Seizure types and epilepsy syndromes were classified according to criteria of the International 
League Against Epilepsy. Seizures were categorised as generalised, partial or unclassified based 
on history and semiology (Commission 1981, appendix 1). Epilepsy was broadly classified as 
idiopathic generalised and localisation-related (focal). Localisation-related epilepsies were 
further categorised into symptomatic and cryptogenic depending on the presence or absence of 
an underlying neurologic lesion (Commission 1989, appendix 2). Idiopathic epilepsies are 
presumed to have a genetic basis. Symptomatic partial epilepsies are considered to be the 
consequence of an identified structural abnormality. Cryptogenic epilepsy is presumed to have 
an underlying but unidentified focal onset on the basis of seizure semiology and results of 
investigations. Idiopathic and symptomatic epilepsies were further classed into specific 
syndromes taking into account clinical, EEG and cerebral imaging data (Engel 2001, appendix 
3). Symptomatic and cryptogenic epilepsies were combined as localisation-related (focal) 
epilepsies for some analyses (Wolf, 1997).
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1.2.3. Patients
A total of 890 patients were given a diagnosis of epilepsy and prescribed their first AED 
between July 1982 and May 2001. None had previously received an AED for any indication. 
One hundred and ten patients (12%) were excluded from analysis owing to lack of sufficient 
follow up information. Their demographic and clinical parameters did not differ significantly 
from those who continued in the study. Alcohol and/or drug abuse were present in 24% of those 
lost to follow up and in 18% of those continuing in the study (x2 2.13, p=0123). Outcomes were 
known for the remaining 780 (88%) patients. Of these 405 (52%) were male and 375 (48%) 
female. The median age at onset of epilepsy was 29 years (range 1 to 93 years) and at diagnosis 
was 31 years (range 9 to 93 years). Of these 709 (91%) had EEG, 649 (83%) had had brain 
imaging. CT scans were performed for 508 (65%) and MRI scans in 321 (41%); 180 had had 
both CT and MRI. Imaging studies were normal in 445 patients, based on radiology reports. 
Abnormalities were considered relevant if they were thought to be responsible for the patients 
seizure disorder. Abnormalities on cerebral imaging included gliosis (n=45), atrophy (n=43), 
tumour (n=25), infarction and ischaeima (n=42), hippocampal sclerosis (n=15), cortical 
dysplasia (n=15), vascular lesion (n=7), hydrocephalus (shunted) (n=3) porencepahlic cyst 
(n=2) calcification (n=2), arachnoid cyst(n=2), fat deposit (n=l), fracture (n=l), pineal 
Cyst(n=l), plagiocephaly (n=l). Cerebral atrophy was mentioned as a feature of patients with a 
history of cerebrovascular disease (without infarction), alcohol abuse, trauma and degenerative 
disease, who had partial onset seizures clinically and/or on EEG. EEG examinations were 
performed on the day of the first clinic visit or within a week, but were often several weeks after 
the clinical episode leading to the referral.
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Overall, 244 patients had symptomatic epilepsy and 314 had cryptogenic epilepsy. Of the 
remaining 222 many had generalised tonic clonic seizures with no localising features, and only 
104 had clinical or EEG evidence of idiopathic generalised epilepsy. However, all of these 
patients were classified as having idiopathic generalised epilepsy for purposes of deciding choice 
of treatment, including recruitment into randomised controlled trials and were included as such 
in this analysis. Patients had suffered a median of 4 seizures (range 1 to >100) before starting 
treatment. Median duration of follow up was 79 months (range 24 to 252 months). Patients were 
followed up until 1st May 2003, when all had received treatment for at least 2 years. A total of 
93 patients died during the study period (Part IV, section 2).
1.2.4. Treatment schedules
Monotherapy was employed initially in all patients. Treatment schedules were modified as 
necessary based on clinical response and drug tolerability. Patients were asked to maintain 
seizure diaries to facilitate objective assessment of response. Those developing idiosyncratic 
reactions, such as rash, or experiencing intolerable side effects, such as sedation, at low AED 
doses, were deemed to have failed treatment due to adverse effects. Adverse effects were 
considered significant only if they led to discontinuation of the AED. Patients who continued to 
experience seizures despite tolerating target doses of medication were designated as treatment 
failures due to lack of efficacy. Patients not tolerating their first AED were prescribed an 
alternative. Those failing treatment due to lack of efficacy either had the original drug 
substituted or were offered combination therapy. Not all patients failing to achieve seizure 
control for 12 months or more had their AED regime changed. This was because partial response 
was acceptable for patients if generalised seizures had been abolished and partial seizures were 
relatively infrequent, and many defaulted from follow up at this stage.
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1.2.5. Data collection and analysis
End of follow up was May 2003, when the last patient in the study had been followed up for a 
period of 2 years. Data were collected by review of case notes and seizure diaries. Classification 
of epilepsy was reviewed at the time of data collection. The primary end point was the 
achievement of 12 months seizure freedom. This is the minimum period of seizure control 
required to regain driving privileges in the United Kingdom, and was, therefore, deemed a 
clinically relevant and easily measured outcome. Response to treatment was defined as 
achievement of 12 months’ seizure freedom on an unchanged treatment schedule. Remission was 
defined as having no further seizures after responding to treatment till the end of follow up. 
Responders who suffered a recurrence of seizures and subsequently remained uncontrolled till 
the end of follow up were classed as relapse. Those who did not experience any 12-month 
seizure free periods were categorised as uncontrolled.
Data were collated on an electronic spreadsheet and analysed using Minitab for Windows 
statistical software (version 13.31). Categorical data were analysed using the x2 test and the 
Bonferroni method was used to correct for multiple comparisons. The Mann-Whitney test was 
used for analysis of non-parametric continuous data. Life table analysis using the actuarial 
method was employed to calculate time to achieving remission. The risk of relapse was 
quantified using Kaplan-Meier analysis. All statistical tests were two tailed.
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63 controlled
105 recurrence
110 lost to follow up
42 (5%) relapse
399 remission
504 responders
462 (59%) remission 276 (36%) uncontrolled
780 analysed for outcomes
890 started on first antiepileptic drug 
between July 1982 and May 2001
Definitions: Responder = seizure free for at least 12 months
Remission = control maintained until the end of follow up
Relapse = refractory epilepsy after initial response to treatment
Uncontrolled = never free of seizures for any 12 months
Figure 2. Outcomes in patients with newly diagnosed epilepsy over a 20-year period
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1.3. Results
1.3.1. Response to treatment
Overall, 504 (64.6%) patients became seizure free for at least 12 months, 399 (79%) of whom 
remained in remission until the end of follow up (Figure 2). The remaining 105 (21%) 
responders reported further seizures after being free of attacks for 12 months or more. Seizure 
freedom was regained in 63, in whom the epilepsy remained controlled till the end of follow up. 
The other 42 initial responders (5.4% of the total population) developed refractory epilepsy and 
were classed as relapse. The remaining 276 patients (35.4%) never obtained adequate control of 
seizures for any 12-month period from the outset (uncontrolled). A total of 462 (59.2%) patients, 
therefore, achieved remission, 5% of whom subsequently had AED therapy withdrawn.
1.3.2. Time to achieving response
The majority of patients who responded to treatment did so early with 54% of responders 
achieving 12 months seizure freedom within the first 12 months of starting treatment. Overall, 
93% of responders had done so within 3 years of initiation of therapy (Figure 3). Remission was 
achieved in 88% of cases who reported no seizures during the first 3 months of treatment (Table 
6).
1.3.3. Immediate responders
Of those entering remission, 245 suffered no further seizures after starting on AED treatment. 
These immediate responders constituted 53% of all patients entering remission and 31% of the 
entire cohort. Immediate response is discussed in more detail in section 4.4.3.
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1.3.4. Time to relapse
The median time to relapse was 25 months (range 12 to 97 months). Sixty nine 
percent of relapses occurred within 3 years of achieving initial response. Kaplan 
Meier plot of time to relapse showed a rate of 4.2% at 2 years rising to a maximum of 
10.4% after 8 years of follow up (Figure 4). There were no further relapses after a 
further median observation period of 38 months (range 0-144).
1.3.5. Treatment leading to remission
Of the 504 patients responding to treatment, 462 (92%) did so on monotherapy 
usually with the first (n=393) or second (n=57) AED. Only 12 patients became 
seizure free with subsequent monotherapies. Forty patients responded to duotherapy. 
Combinations of 3 and 4 drugs produced seizure freedom in just one patient each. 
Thus, only 8% of responders (5.4 of total population) were controlled on more than 
one AED. Response rates with the first, second and third treatment regimens were 
50%, 32% and 25% respectively. The chance of achieving seizure control was 
significantly better with the first regime compared to subsequent ones (Table 7).
1.3.6. Outcomes after failing the first AED
Of the 387 patients not responding to the first AED, 305 failed due to lack of efficacy 
and 82 because of adverse effects. Patients failing initial monotherapy were 
significantly less likely to enter remission with alternative monotherapy (n=179) or 
duotherapy (n=81) if the reason for failure was lack of efficacy rather than adverse 
effects (Table 8). The chance of success with a second monotherapy was lower if the 
reason for failure with the first was lack of efficacy rather than adverse effects (25% 
versus 41%, p=0.027). Similarly, patients who failed on the first AED due to lack of
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efficacy rather than poor tolerability were more likely to fail a second monotherapy 
for the same reason (66% versus 48%, p=0.016). No patients failing 2 well-tolerated 
drugs became seizure free with further monotherapies, whereas 7% achieved control 
on AED combinations.
1.3.7. Outcomes after failing each AED regime
Remission rates were examined in patients failing sequential schedules to determine 
the number needed to be tried before pharmacoresistant epilepsy could be diagnosed. 
Only 8 (7%) of 117 patients failing 2 well-tolerated regimens achieved remission and 
for those failing 3 this figure fell to 3%. This pattern was observed when idiopathic 
and localisation-related (focal) epilepsy cohorts were analysed separately (Table 9). 
When considered as a proportion of the entire cohort, remission rates with the first, 
second and third regimen were 46%, 10.1% and 2.3% respectively with just 6 (0.8%) 
entering remission with further attempts at pharmacotherapy.
1.3.8. Factors affecting response to treatment
Patients with idiopathic epilepsies had higher remission rates (66%) than those with 
cryptogenic (57%, p=0.041) or symptomatic (56%, p=0.035) epilepsies (Figure 5). 
When analysed by age at starting treatment, a bimodal distribution was apparent 
(Figure 6), with the greatest likelihood of remission occurring in the youngest and 
oldest patients (Table 10). Increasing numbers of pre-treatment seizures was 
significantly associated with uncontrolled epilepsy (p=0.024, Figure 7). However, 
duration of epilepsy prior to starting treatment had not effect on outcomes (Figure 8). 
Influence of the various risk factors on the prognosis for achieving remission by 
logistic regression analysis is shown in Table 11. History of alcohol abuse, head
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injury, febrile seizures, family history of epilepsy, presence of psychiatric co­
morbidity and multiple seizure types were significantly associated with uncontrolled 
epilepsy in the univariate analysis. The presence of neurological deficits, learning 
disabilities, abnormalities on EEG and cerebral imaging had no adverse effect on 
prognosis in this analysis.
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Table 6. Likelihood of remission in patients remaining seizure free for the first 3, 6,
12 and 24 months after starting treatment
3 Months 6 Months 12 Months 24 Months
Remission 296 (88%) 276 (90%) 257 (92%) 246 (94%)
Uncontrolled 41 (12%) 31 (10%) 23 (8%) 17 (6%)
Total number 337 307 280 263
Table 7. Response to each of the first three regimes in newly diagnosed epilepsy
First Second Third
Responders 393* 50% 84* 32% 21* 25%
Failure due to adverse effects 82 11% 20 8% 13 15%
Failure due to lack of efficacy 305 39% 156 60% 51 60%
Total 780 260 85
* Responder rate for first regime is higher than that for second (p<0.001, ^=25.66) 
and third (pO.OOl, ^=20.25) regimes, but there is no significant difference between 
responder rates for second and third regimes
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Table 8. Outcomes after failing the first AED, according to the reason for failure
Reason Remission Uncontrolled
Lack of efficacy 64f 21% 241 79%
Adverse effects 39| 48% 43 52%
All patients 103 27% 284 73%
Prognosis for remission significantly better in patients failing due to adverse effects 
compared to those failing due to lack of efficacy (48% v/s 21% p <0.001)
Table 9. Likelihood of remission after sequential treatment failures due to lack of 
efficacy
Type of epilepsy n First drug Second regimen Third regimen
Idiopathic epilepsies 222 21% 4% 0%
Localisation-related epilepsies 558 21% 8% 4%
All epilepsies 780 21% 7% 3%
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Table 10. Treatment outcomes by age at starting treatment
Patient groups n Remission Relapse Refractory
Adolescent (<20 
years)
170 110 65% 21 12% 39 23%
Adult (20-64 years) 520 276 53% 20 4% 224 43%
Elderly (>64 years) 90 76 85% 1 1% 13 14%
* Adolescent have greater likelihood of entering remission compared to adults (p=0.008) 
fElderly patients more likely to enter remission compared to adolescent and adult (pO.OOl)
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Figure 7. Outcomes in newly diagnosed epilepsy by number o f  seizures prior to 
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1.4. Discussion
Most patients with newly diagnosed epilepsy responded rapidly and completely to 
AED treatment. Indeed, 31.4% of our population never had another seizure after 
taking the first dose of medication. Of the entire cohort, 56% of patients achieved 
remission with the first or second AED regimen while 35% of patients never achieved 
lasting control of seizures. Thus, more than 90% of this patient population either had a 
good response to their first or second treatment schedule or never achieved control.
In the majority of cases, early response to treatment correlates with a good long-term 
prognosis. Patients who remained seizure free during the first 3 months of treatment 
achieved remission in 88% of cases, with the figure rising to just 94% after 2 years of 
seizure freedom. The minority of patients who relapsed following a period of good 
control largely did so in the first three years. These results suggest that the prognosis 
of epilepsy is evident within the first few years after starting treatment.
Only 42 patients (5.4%) developed refractory epilepsy after having been seizure free 
for 12 months or more. The relapse rate peaked at 10.4% after 8 years of follow up. 
This scenario has been recognised retrospectively in patients with refractory epilepsy 
undergoing work-up for epilepsy surgery (Berg et al, 2003), but has not previously 
been documented in newly diagnosed epilepsy. Interestingly, outcomes in the elderly 
were better than those in younger patients. This observation requires validation, but 
may be important since old age is now the commonest time in life to develop epilepsy 
(Stephen et al, 2000). Adolescents also appeared to have a better prognosis, although 
the relapse rate was highest in this population.
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For patients failing initial monotherapy due to adverse effects, the subsequent chance 
of remission was similar to that in a drug naive population. Prognosis was less good 
if treatment failed due to lack of efficacy. Thus, response to first AED is a powerful 
predictor of prognosis (Sillanpaa et al, 1993; Kwan and Brodie 2001; Dlugos et al 
2001). Individuals not responding to 2 or 3 well-tolerated regimens had a greater than 
90% or 95% chance respectively of remaining uncontrolled and could, therefore, be 
considered to have refractory epilepsy. These observations held good for both 
idiopathic and localisation-related (focal) epilepsies. Therefore, in patients intolerant 
to their first AED, alternative monotherapy should be tried. In those failing treatment 
due to lack of efficacy, outcomes with substitution and combination therapy were no 
different, either in terms of seizure freedom or tolerability. Thus, duotherapy with 
AEDs possessing different mechanisms of action (Deckers et al, 2000) may be as 
good a choice as alternative monotherapy in this situation (Kwan and Brodie, 2000; 
Deckers et al, 2001; Beghi et al, 2003). Indeed, no patient failing 2 well-tolerated 
AEDs became seizure free with further monotherapy, whereas 7% became seizure 
free on drug combinations.
A large number of seizures before starting treatment was a poor prognostic indicator, 
an observation that has been made previously (Collaborative group for the study of 
epilepsy 1992; Sillanpaa et al, 1993). However, duration of epilepsy was not a 
significant prognostic factor. In the univariate logistic regression analysis a history of 
alcohol abuse, head injury, febrile seizures, family history of epilepsy, presence of 
psychiatric co-morbidity and multiple seizure types were associated with a greater 
likelihood of uncontrolled epilepsy. The presence of abnormalities on EEG and 
cerebral imaging did not adversely affect prognosis in this analysis.
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All patients diagnosed with epilepsy and started on AED therapy were included in this 
analysis, irrespective of underlying pathology, occasional lapses in adherence to 
treatment, and the presence of adverse lifestyle factors such as occasional recreational 
drug usage or high alcohol consumption. Error of diagnosis is an important reason for 
failure of AED treatment. No reliable figures were available for patients in whom the 
diagnosis of epilepsy later proved incorrect in this cohort.
These results, therefore, reflect “real life” outcomes. Clinic based studies are, 
however, liable to introduce a severity bias, as the patients who are lost to follow up 
tend to be those who achieve seizure control. In these patients, the incentive to return 
for clinic appointments is not as high as for those with ongoing seizures. It is possible 
therefore that the 110 patients lost to follow up had good seizure outcomes compared 
to the rest of the cohort. The true seizure free rates therefore are possibly higher than 
what we observed. Moreover, as these patients defaulted from follow up early on in 
the course of their disorder, remission is likely to have occurred immediately after 
starting treatment in this group. Thus, the true proportion of patients entering 
remission in the early years is also likely to be higher.
1.5. Conclusions
The prognosis for the majority of people with newly diagnosed epilepsy, whether 
good or bad, became apparent within a few years of starting treatment. Several 
factors such as age at diagnosis, type of epilepsy, seizure density immediately before 
starting treatment, presence of risk factors such as alcohol abuse, head injury, family 
history of epilepsy and psychiatric co morbidity showed an association with
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uncontrolled epilepsy in this analysis. Their value in predicting the response to 
treatment in newly diagnosed patients needs to be confirmed in a prospective study. 
Early response to AED treatment is a powerful predictor of longer-term outcome.
The elderly, and to a lesser extent teenagers, are more likely to respond to treatment 
than the remainder of the population. Approximately 5% of patients can be expected 
to relapse after initially responding to treatment and remain uncontrolled 
subsequently. Patients who do not attain seizure freedom with the first 2 or 3 well- 
tolerated schedules are unlikely ever to have a useful period of remission and could be 
diagnosed with refractory epilepsy. These patients should be referred to an epilepsy 
service for further evaluation including videotelemetry for diagnostic and 
classification purposes, optimisation of pharmacotherapy, and consideration of other 
therapeutic modalities, particularly epilepsy surgery.
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2. Response to treatment in newly diagnosed localisation related epilepsies
2.1. Introduction
The temporal aspects of the natural history of seizure disorders should be taken into 
consideration in any study of outcome. The key to accurate assessment of prognosis is 
recruitment of patients at the same point in the course of the disorder (Shorvon, 1984). 
Specialist epilepsy clinics have a higher representation of patients with refractory 
epilepsy and cross sectional studies in such populations invariably report very low 
rates of seizure freedom. This factor accounts for the poor prognosis of epilepsy in 
much of the early literature (Gowers, 1881; Rodin, 1968). Longitudinal, population 
based studies in patients with new onset epilepsy provide a more reliable assessment 
of response to treatment (Cockerell et al, 1995; Sillanpaa et al, 1998; Kwan and 
Brodie, 2000; Berg et al, 2001).
With the widespread use of high resolution brain magnetic resonance imaging it has 
been possible to identify an underlying structural abnormality in many patients with 
localisation related epilepsy (Kuzneicky and Knowlton, 2002). Our understanding of 
the prognosis of these symptomatic epilepsies, nonetheless, is largely based on studies 
carried out in specialist centres. Thus, it is widely believed that certain types of 
symptomatic epilepsies, such as those associated with hippocampal atrophy and 
malformations of cortical development, frequently encountered in these clinic 
populations, respond poorly to pharmacological treatment (Semah et al, 1998; Kim et 
al 1999, Stephen et al, 2001). However, in most parts of the world epilepsy is treated 
at its onset by non-specialists. Patients who respond to antiepileptic drugs (AED) 
treatment may not undergo brain imaging. It is only when they prove refractory to 
pharmacotherapy that referral to a specialist centre is made and subtle underlying
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structural abnormalities are identified. Populations of patients with newly diagnosed 
epilepsy are, therefore, required to assess accurately the response to antiepileptic 
drugs (AED) treatment in symptomatic epilepsy syndromes. We carried out an 
outcome study in patients with localization-related epilepsies diagnosed, treated and 
followed up at a single centre over a 20 year period.
2.2. Methods
Methods have been described in detail in Part II section 1.2. Data regarding treatment 
outcomes were collected from a series of 890 patients with newly diagnosed epilepsy 
by review of case notes. Classification of epilepsy was reviewed at the time of data 
collection based on all clinical, EEG and cerebral imaging investigations data 
available. Response to treatment was defined as complete seizure control for 12 
months or more. Patients remaining seizure free till the end of follow up were 
considered to be in remission. Patients showing initial response to treatment before 
experiencing seizure recurrence and were subsequently uncontrolled were categorised 
as relapse. The %2 test was used to analyse categorical data and the Bonferroni method 
was used to correct for multiple comparisons. Logistic regression analysis was used to 
analyse the association of various risk factors with uncontrolled epilepsy. All 
statistical tests were 2 tailed. Analyses were carried out using Minitab for windows 
statistical software (version 13.21).
2.3. Results
2.3.1. Patient demographics
Of the total of 890 patients diagnosed with epilepsy and started on AED treatment,
625 (70%) patients were categorised as having localisation-related epilepsy.
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Idiopathic generalised epilepsy could be diagnosed in 128 (15%) and in the remaining 
137 (15%) patients epilepsy could not be classified. This group included patients who 
suffered GTCS with no localising features and had normal EEG and cerebral imaging 
investigations, who nevertheless responded rapidly to treatment and therefore were 
not investigated further. This group was included along with the idiopathic 
generalised epilepsies in the preceding analysis for reasons discussed in section 1.2.3., 
but were left out of analysis of outcomes in specific syndromes. In the cohort of 
patients with localisation related epilepsy, 67 (11%) were lost to follow up and 
treatment outcomes were known for 558 (89%) patients. This cohort comprised 296 
(53%) males and 262 (47%) females. The median age at onset (first seizure) was 33 
years (range 1 to 93 years) and that at diagnosis was 35 years (range 11 to 93 years). 
Patients reported a median of 5 (range 1 to >100) seizures before stating treatment. Of 
these 558 patients, 244 (44%) had a structural lesion identified on brain imaging and 
were classified as having symptomatic epilepsy. Post traumatic epilepsy was 
diagnosed in patients with localisation related epilepsy with onset after head trauma of 
at least moderate severity, with or without structural brain changes on imaging 
studies. The remaining 303 (54%) were designated as having cryptogenic epilepsy. 
Breakdown of the various underlying pathologies in patients with symptomatic 
epilepsy is shown in Figure 9. Of the remaining 11 (2%) with idiopathic localisation- 
related epilepsy, 6 patients had Benign Epilepsy with Centrotemporal Spikes, 4 had 
Benign Occipital Epilepsy, and 1 Benign Partial Epilepsy of Childhood.
2.3.2. Overall outcomes
Of the 558 patients started on AEDs, 343 (62%) responded to treatment by becoming 
seizure free for a period of 12 months or more (Table 12). Of the responders, 39
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(11%) had a recurrence of seizures of which 27 never regained complete control. 
These patients constituted 5% of the entire cohort (8% of responders) and were 
categorised as relapse. Seizures remained well controlled until the end of follow up in 
a total of 316 (57%) patients who were classified as remission. The remaining 215 
(38%) did not achieve seizure freedom for any 12-month period and were categorised 
as uncontrolled. No significant differences were observed in outcomes when 
cryptogenic and symptomatic epilepsies were analysed separately (Table 12).
2.3.3. Treatment leading to response
Monotherapy was successful in 315 (92%) of the 343 responders. Of these 264 (77%) 
were on their first ever AED. In patients failing the initial AED, a second regime was 
successful in 59 (17%) of patients, 42 of which were alternative monotherapy. 
Combination treatment with two AEDs was successful in 26 (8%) patients only. 
Carbamazepine (n=265), sodium valproate (n=200) and lamotrigine (n=175) were the 
most commonly used monotherapy agents. Successful monotherapy could be 
achieved with modest doses in most cases. The median daily doses in responders 
were: Carbamazepine 400mg/day (n=l 14), Lamotrigine 150 mg/day (n=93) and 
Valproate lOOOmg/day (n=72).
2.3.4. Outcomes in individual syndromes
Outcomes in the various epilepsy syndromes are listed in Table 13. Patients with 
mesial temporal lobe epilepsy (MTLE) with hippocampal atrophy (HA) (50% 
remission) and those with malformations of cortical development (MCD) (60% 
remission) did not fare significantly worse than those with other types of symptomatic 
epilepsy. A number of patients responded immediately to treatment and suffered no
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further seizures after starting on AED treatment. These immediate responders 
constituted between 20 and 40% of all patients with each specific epilepsy syndrome 
(Table 13). Interestingly, even patients with MTLE with HA and MCD responded 
mmediately to treatment in 21% and 33% of cases respectively. The clinical 
characteristics of patients with newly diagnosed epilepsy and underlying hippocampal 
sclerosis or cortical dysplasia are shown in Tables 15 and 16. The probability of 
achieving immediate response to treatment was highest for patients with epilepsy due 
to cerebrovascular disease (40%) or cerebral atrophy (40%). These patients also had 
the best prognosis for remission overall.
2.3.5. Risk of refractory epilepsy
Patients failing two appropriate well-tolerated AED regimes remained uncontrolled in 
over 90% of cases and these patients could be diagnosed with drug resistant epilepsy 
(Part II, section 1.2.7). We examined the risk of failing two AED regimes due to lack 
of efficacy in patients with various localisation related epilepsy syndromes in the 
present cohort of newly diagnosed patients. Patients with MTLE and HS, MCD, 
cerebral tumours and post traumatic epilepsy had the highest relative risk for failing 
two well tolerated regimes compared to other causes of LRE (Table 14). These 
differences, however, did not reach statistical significance.
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Table 12. Treatment outcomes in localisation related epilepsy syndromes
All localisation related 
epilepsies
Cryptogenic epilepsies * Symptomatic epilepsies
Remission 316 57% 179 57% 137 56%
Relapse 27 5% 16 5% 11 5%
Uncontrolled 215 38% 119 38% 96 39%
Total 558 100% 314 100% 244 100%
* Idiopathic localisation-related epilepsies were included with cryptogenic group for 
analysis of outcomes
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2.4. Discussion
In our study population, 62% of patients started on AED responded to treatment by 
becoming seizure free for 12 months or more. This early response was maintained in 
92% of responders who remained in remission till the end of follow up. 38% never 
achieved complete seizure control for any 12-month period. Response to treatment was 
achieved with standard AEDs used as monotherapy in the majority of cases. A number 
of patients with LRE showed immediate and complete response to AED therapy and 
suffered no further seizures since starting on treatment. The probability of immediate 
treatment response was highest for patients with cerebrovascular disease or cerebral 
atrophy, and lowest for patients with post-traumatic epilepsy. Patients with MTLE and 
HA, cerebral tumours, MCD and post traumatic epilepsy showed a higher tendency to 
develop refractory epilepsy, defined as failure of two well tolerated AED regimes. 
Thus, we observed two major categories of patients, those who responded to moderate 
doses of standard AED monotherapy (immediate responders) and those who did not 
achieve seizure control in spite of several alterations in therapy (refractory epilepsy). 
By contrast, patients who achieved seizure control with high dose monotherapy or 
combination of AEDs were relatively few. This suggests that the majority of patients 
diagnosed with epilepsy would be either easy to treat or unlikely ever to gain complete 
seizure control. Interestingly, both these groups were distributed across the various 
seizure syndromes although certain syndromes appeared to be more likely to be 
pharmacoresistant than others.
Temporal lobe epilepsy is the most common epilepsy syndrome (Engel et al, 1998) and 
hippocampal sclerosis occurs in 50-70% of patients with refractory temporal lobe 
epilepsy (Babb et al, 1987). The incidence of refractory epilepsy in all subjects with
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HS, however, is unknown. Hospital based case series have reported remission rates 
ranging from 11% to 42% with AED treatment in patients with MTLE and HS (Semah 
et al, 1998; Kim et al, 1999; Kobayashi et al, 2001; Stephen et al, 2001; Kumlien et al,
2002). Recent studies employing hippocampal volumetry have identified HA in MTLE 
patients with good seizure control (Andrade Valenca et al, 2003; Kobayashi et al,
2003). MR evidence of HS has also been observed in patients without clinical or EEG 
evidence of MTLE (Kobayashi et al, 2002; Benbadis et al, 2002). Thus the relationship 
of HS with refractory epilepsy, and indeed seizures themselves, is far from clear. The 
majority of patients who undergo surgical treatment for MTLE with HS develop the 
seizure disorder in adolescence and typically have periods of remission before 
becoming refractory to treatment. In the present study, the age of onset of epilepsy is 
significantly higher and therefore these patients could not be said to be typical of those 
with MTLE and refractory epilepsy. However, our data suggests that the presence of 
HS does not necessarily predict poor outcomes in newly diagnosed epilepsy.
Similar to HS, MCD have been increasingly recognised as the underlying cause for 
localisation related seizures with the widespread use of high quality MR imaging in 
patients with epilepsy (Sisodiya 2004). In recent years, there has been a greater 
understanding of their genetic bases, clinical presentations and the mechanisms 
involved in epileptogenesis (Guerrini and Carrozzo, 2002). However the true 
prevalence of these abnormalities in the general population and in patients with 
epilepsy in not known. Subtle cerebral abnormalities have been demonstrated in 
asymptomatic relatives of patients with MCD and epilepsy (Merschhemke et al 2003). 
As with MTLE and HS, the relative contribution of MCD to refractory epilepsy 
remains unclear.
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An important factor introducing bias into our analysis is the fact that MRI scanning 
was not available in the early years of the study period. Patients first seen during this 
period underwent MRI scanning only if they had poorly controlled epilepsy and 
continued to attend the epilepsy clinic for several years. This means that patients with 
underlying HS and MCD who responded to treatment in this period did not have the 
condition diagnosed. This biases the study towards detecting more MRI-diagnosed 
lesions in patients with uncontrolled seizures and inflates the relative risk of 
developing refractory epilepsy in patients with HS and MCD. Thus the true risk of 
pharmacoresistance in these conditions is likely to be lower than that found in our 
analysis.
The mechanism of action of the traditional AEDs and some of the newer ones are 
known (Kwan et al, 2001). However, the reason why they show varying efficacy in 
patients with the same underlying pathology is unclear. Several hypotheses on the 
mechanisms involved in the evolution of drug resistant epilepsy have been proposed 
(Regesta and Tanganelli, 1999). These include ontogenic abnormalities in brain 
maturation, epilepsy induced alterations in network, neuronal and glial properties in 
seizure prone areas such as the hippocampus, the phenomenon of kindling and 
reorganisation of cortical tissue in response to seizure induced disturbances in oxygen 
supply. These however remain largely speculative. Similar to the pathogenesis of the 
majority of epilepsy syndromes, it is likely that response to drug treatment is also 
governed by a number of genetic and environmental influences. Genetic 
polymorphisms cause variations in the levels and activity of drug metabolising 
enzymes and transporter molecules and affect the distribution and concentration of
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AEDs (Sisodiya, 2003). Polymorphisms of drug targets may affect the affinity and 
activity of specific drugs (Hiratsuka and Mitzugaki, 2001). Similarly environmental 
factors including lifestyle issues such as abuse of proconvulsant recreational drugs can 
affect the efficacy of AEDs. In such a complex multifactorial outcome individual 
factors are likely to have only limited predictive value. The specific underlying 
epilepsy syndrome is only one such variable.
2.5. Conclusions
Prognosis for newly diagnosed patients with localisation related epilepsy might be 
better than what is assumed from studies in patients with refractory epilepsy. There 
were no significant differences in remission rates between patients with symptomatic 
and cryptogenic epilepsies and between the various types of symptomatic epilepsies. 
Patients with certain types of symptomatic epilepsies however did appear to be at a 
higher risk of developing refractory epilepsy.
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3. Prognosis of newly diagnosed Idiopathic Generalised Epilepsies in the non- 
paediatric setting
3.1 .Introduction
3.1.1 Definition
Idiopathic generalised epilepsies (IGE) are clinically characterised by seizures in 
which the first clinical changes indicate the initial involvement of both hemispheres. 
The International League Against Epilepsy (ILAE) Commission on Classification And 
Terminology defines IGE as ‘forms of generalised epilepsies in which all seizures are 
initially generalised (absences, myoclonic jerks and generalised tonic-clonic seizures; 
GTCS), with an electroencephalographic (EEG) expression that is a generalised 
bilateral, synchronous, symmetrical discharge’ (Commission, 1989). The inter-ictal 
EEGs show normal background activity and generalised discharges, such as spikes, 
polyspike, spike-wave and 3 Hz polyspike-waves. Intellectual and neurologic deficits 
are absent and no structural brain abnormalities can be demonstrated by cerebral 
imaging. The aetiology is believed to be a genetic predisposition modified by 
environmental influences.
3.1.2 Pathophysiology of IGE
Jasper and Penfield first proposed the central role of interaction between cortical and 
subcortical structures in the generation of generalised seizures. The abrupt onset and 
cessation of the 3Hz generalised spike and wave discharges (GSWDs) out of a normal 
background led them to hypothesise the existence of a central pacemaker with diffuse 
cortical connections — the so called centrencephalic theory (Penfield and Jasper 
1954). The evidence for this first came from animal studies in which stimulation of the
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midline and intralaminar nuclei of the thalamus at 3 Hz in the cat produced bilaterally 
synchronous GSWDs on the cortical EEG (Jasper and Drogleever-Fortuyn 1947). The 
demonstration of bilaterally synchronous 3Hz GSWDs originating from the thalamus 
of a child with absence epilepsy using depth electrodes provided support for 
subcortical involvement in human IGE (Williams, 1953). However other studies in 
animals point to a leading role for the cortex in generation of generalised seizures 
(cortical theory). It has been shown that application of proconvulsants to the surface of 
the frontal lobes can produce rhythmic GSWDs, which in unanesthetised monkeys 
produced absence like attacks (Marcus and Watson, 1968). Studies in the feline 
generalised penicillin epilepsy model have suggested that generation of GSWDs 
require the presence of a functional cortex as well as a thalamus (Gloor, 1968), leading 
to the hypothesis that discharges from certain deep structures escalate the epileptic 
state of the cortex and cause GSWDs (corticoreticular theory). Seminal work by Janz 
and colleagues found microdysgenesis of cortical neurons in the brains of patients with 
IGE (Meencke and Janz, D 1984). It has been suggested that the morphologic 
abnormalities that constitute microdysgenesis result in faulty development of synaptic 
connections in the cerebral cortex, which may result in a generalized state of 
hyperexcitability, leading to clinical seizures and generalized spike-wave discharges on 
the EEG (Blumenfeld, 2003). Thus, generalised seizures appear to result from 
bilaterally synchronous burst firing of a group of reciprocally connected neurons 
located in the thalamus and the cortex (Futasugi and Riviello, 1998).
3.1.3 Genetics of IGE
Genetic factors are believed to play a greater role in the causation of IGE than in 
localisation related epilepsy (Ottman et al, 1998). Since 1995, several susceptibility
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genes have been identified in IGE syndromes by linkage analysis and association 
studies employing family, twin and candidate gene based approaches (Scheffer and 
Berkovic, 2003). The genetic bases of many IGE syndromes are mutations in voltage- 
and ligand-gated ion channel genes, which affect the structure and/or function of the 
channel encoded on the gene (Mulley et al, 2003). These ‘channelopathies’ result in 
altered ion channel kinetics and predispose to abnormal neuronal excitation. A list of 
identified mutations in IGE syndromes is shown in Table 17. The correlations of 
genotype to phenotype are however not simple. In the syndrome of GEFS+ for 
instance, mutations have been identified in SCN1A (Escayg et al, 2000), SCN2A 
(Sugawara et al, 2001), SCN1B (Wallace et al, 1998) and GABRG2 (Baulac et al, 
2001, Wallace et al, 2001) genes. However, several familial cases with similar 
phenotypes lack any of the previously described mutations (Bonanni et al, 2004). 
Similarly, in families of patients with GEFS+, a spectrum of seizure disorders have 
been observed ranging from febrile seizures to syndromes such as Severe Myoclonic 
Epilepsy of Infancy (Singh et al, 2001; Marini et al, 2004). Thus considerable genetic 
heterogeneity and phenotype variability exists for this IGE syndrome. Resolving the 
complexities of genotype-phenotype correlations is likely to be the principal challenge 
in genetic studies of mono- and oligo-genic seizure disorders in the next few years.
The vast majority of IGE syndromes are, however, polygenic or complex disorders. 
The epilepsy phenotype in individual patients is the result of interaction amongst 
several susceptibility genes as well as environmental factors. It is likely that a range of 
polymorphisms, rather than mutations, in candidate genes confer the genetic 
susceptibility to seizures (Scheffer and Berkovic, 2003). Search for these will need to 
employ higher throughput genotyping technology and more sophisticated 
bioinformatics paradigms.
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3.1.4 Prevalence and age distribution of IGE
IGE constitutes 20-40% of all new diagnoses of epilepsy (Gastaut et al, 1975, Joshi et 
al, 1977, Loiseau et al, 1990, Zarrelli et al, 1999). Although seizures generally begin 
in childhood and adolescence, onset of IGE after the second decade of life has 
previously been described (Gastaut, 1981). Panayiotopoulos and colleagues described 
a syndrome of adult onset IGE with phantom absences (3-4 second lapses in 
consciousness), infrequent generalised tonic clonic seizures (GTCS) and frequent 
absence status in 13 of a series of 86 patients with adult onset IGE (Panayiotopoulos 
et al, 1997). Gilliam and colleagues have described 11 patients with onset of 
myoclonic epilepsy at a mean age of 39 years, some of whom had absences (Gilliam 
et al, 2000). A recently published case series from a regional epilepsy clinic in the UK 
identified 8.5% patients with onset of IGE after the age of 20 years, based on clinical 
features and seizure types (Nicolson et al, 2004a). A similar series from New York 
based on retrospective review of clinical and EEG data identified 13.3% patients with 
adult onset of IGE (Cutting et al, 2001). A more rigorous approach to classification 
could identify many more such patients, as demonstrated by Marini and colleagues. 
They employed post ictal EEG within 24 hours of the initial seizure followed by sleep 
deprived EEG if necessary to classify epilepsy and identified adult onset of IGE in 
28% of cases (Marini et al, 2003). There can be difficulties with identifying IGE 
based on EEG characteristics. Certain partial epilepsies, especially those caused by 
lesions in the mesial frontal lobe can cause generalised spike and wave abnormalities 
on surface EEG (Kubota et al, 1997; Tezer et al, 2004). True coexistence of IGE and 
partial epilepsy is rare. Nicolson and colleagues found that only less than 1% of 962 
patients with IGE attending a specialist clinic had coexisting partial epilepsy 
(Nicolson et al, 2004c)
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3.1.5 Prognosis of IGE
IGE is believed to have a better prognosis for remission than localisation related 
epilepsies. In a large clinic based series (n=2200) significantly more patients with IGE 
achieved seizure control for one year (82%) than those with cryptogenic (45%) or 
symptomatic (35%) partial epilepsy (Semah et al, 1998). There is no evidence to 
suggest that the adult onset IGE has a different underlying pathophysiology from 
childhood IGE, indeed, available data indicates that they share common biological 
determinants and are part of a life long spectrum of classic IGE (Yenjun et al, 2003; 
Marini et al, 2004). Studies of adult onset IGE have suggested that the prognosis 
remains good in older patients (Cutting et al, 2001). The prognosis for control does 
vary among the various seizure types. In a retrospective cohort study examining the 
response to treatment in patients with JME, Prasad and colleagues reported remission 
rate of 68-80% for GTCS and 58-59% for myoclonic seizures depending on the 
treatment used (Prasad et al, 2003). A recently reported study from a regional epilepsy 
clinic in the UK found 54% response rate (one year seizure freedom) overall for 
patients with IGE (Nicolson et al, 2004b). This, however, was a cross sectional study 
in a clinic population and would therefore be expected to have an overrepresentation 
of patients with drug-resistant epilepsy. Studies recruiting patients from the time of 
diagnosis and incorporating a diagnostic scheme designed to identify IGE are required 
to accurately assess the prognosis of various IGE syndromes. Moreover, in the non- 
paediatric setting different life style and environmental factors operate and treatment 
outcomes might not be translatable from studies in a younger population. We 
examined the response to treatment in an unselected series of adolescent and adult 
patients with newly diagnosed IGE at a single centre to assess the prognosis of IGE in 
a non-paediatric practice.
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3.2. Methods
The protocol for evaluation of patients presenting with seizures has been described in 
Part II, section 1.2. A total of 890 patients were diagnosed with epilepsy after 
presenting to the first seizure clinic between August 1981 and May 2001 of whom 
sufficient follow up was available for 780 patients. Classification of seizure types and 
syndromes were reviewed at the time of data collection based on clinical and EEG 
data. Epilepsy was classified as IGE based on clinical and EEG criteria. Response to 
treatment was defined as complete seizure control for 12 months or more. Patients 
remaining seizure free till the end of follow up were considered to be in remission. 
Patients showing initial response to treatment before experiencing seizure recurrence 
and were subsequently uncontrolled were categorised as relapse. Logistic regression 
analysis was used to ascertain the influence of various risk factors on prognosis for 
remission. Categorical variables were compared using the x2 test on one degree of 
freedom. Analyses were carried out using Minitab for windows statistical software 
(version 13.21).
3.3. Results
3.3.1 Patient demographics
Of the entire cohort of 890 adult and adolescent patients, 128 (15%) fit the criteria for 
a diagnosis of IGE.. In the IGE cohort 15 were lost to follow up and the remaining 
103 were analysed for treatment outcomes. This cohort consisted of 56 females and 
47 males. The median age at onset was 17 years (range 5-51) and that at diagnosis 
was 18 years (range 9-71). The age distribution of the patients with various IGE 
syndromes is shown in Figure 10. Mild learning disability was present in 5 patients.
Of these, 4 patients had Down’s syndrome (trisomy 21), 3 of whom had a diagnosis of
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late onset myoclonic epilepsy. JME was the most common IGE syndrome and was 
present in 55 (53%) of cases, followed by Epilepsy with GTCS Only in 28 (27%) 
patients. The other syndromes identified were Epilepsy with GTCS on awakening 
(n=7), Juvenile absence epilepsy (n=4), Epilepsy with GTCS during sleep (n=3), Late 
onset myoclonic epilepsy (n=3) Childhood absence epilepsy (n=2) and Epilepsy with 
myoclonic absences (n=l).
3.3.2 Response to treatment
Overall, 76 (74%) patients responded to treatment of whom 66 (64%) achieved 
remission and 10 (10%) relapsed. The remaining 27 (26%) patients did not achieve 
complete seizure control for any 12-month period. Treatment outcomes in the 
individual IGE syndromes are shown in Table 18. Treatment response was achieved 
with one AED (monotherapy) in 64 (84%) cases. Of these 53 (51%) responded to 
their first AED. When used as the first AED, VPA (66%) was more likely to produce 
treatment response than LTG (45%), however this difference did not reach statistical 
significance (p=0.076, x2=3.22). When response to the first AED in individual 
syndromes was analysed, treatment with VPA was significantly more likely to be 
successful than that with LTG (75% v 39%, p=0.014,j^=5.99) in patients with 
juvenile myoclonic epilepsy. Numbers of patients with other IGE syndromes were too 
small to make meaningful comparisons.
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3.3.3. Remission of seizures
Patients with JME achieved remission in 40 (73%) cases. The remission rate for JME 
was significantly better compared to the rest of the cohort (p=0.05, x2= 3.83). The 
number of patients with other subtypes of IGE was insufficient to demonstrate 
significant differences in outcomes among the various syndromes (Table 18). Relapse 
occurred in 4 (7%) of patients with JME and 5 (18%) of patients with IGE with GTCS 
only, however the differences in relapse rate were not significant. Life style factors 
that could affect seizure control such as drug and alcohol abuse were present only in 5 
patients in the cohort, all of whom remained uncontrolled. No patient with Down’s 
syndrome and late onset myoclonic epilepsy achieved remission, although one patient 
responded to treatment for a 12-month period.
3.3.4. Treatment leading to remission
Patients who achieved remission were receiving monotherapy in 56 (85%) of cases. 
Valproate (=30) and lamotrigine (n=17) were the most common AED monotherapy 
resulting in remission, and were generally used in modest doses (Figure 11). Of the 
patients achieving remission, 33 (50%) were immediate responders, suffering no 
further seizures after starting on AED treatment. The prognosis for immediate 
response was not influenced by the syndrome classification or the choice of the first 
AED. Patients failing monotherapy achieved remission with duotherapy in 10 (15%) 
patients.
3.3.5 Factors affecting prognosis
We analysed the influence of risk factors such as age at onset, sex, family history of 
epilepsy, history of febrile seizures, psychiatric co-morbidity, epileptiform
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abnormalities on EEG and types of seizures on the prognosis for remission (Table 19). 
In the univariate analysis, a history of febrile seizures was the only factor associated 
with a significantly lower remission rate (OR 0.18, 95% Cl 0.03-0.96, p=0.032).
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3.4. Discussion
Recognition of IGE syndromes in the non-paediatric setting has important implications for 
management of patients. In this group of patients where onset of seizures raises concerns 
regarding potentially serious cerebral pathology, early accurate diagnosis can provide 
reassurance. If electrographic evidence of IGE is obtained, unnecessary imaging 
investigations can also be avoided. Identification of these patients is also important in 
clinical genetic studies and drug trials of AEDs. The greatest importance of accurate 
classification is in guiding choice of treatment. Certain AEDs such as phenytoin and 
carbamazepine have been shown to exacerbate seizures in patients with IGE (Berkovic, 
1998, Genton, 2000). There have also been reports of exacerbation of myoclonic seizures by 
lamotrigine (Guerrini et al, 1999; Trinka et al, 2002). A recent study found that 48% of 
patients diagnosed with IGE in an epilepsy program had previously been started on AEDs 
known to worsen IGE (Benbadis et al, 2003). Valproate has traditionally been regarded as 
the drug of choice in the treatment of IGE syndromes. A recent meta-analysis found no 
evidence to support the use of VPA in the treatment of generalised epilepsies, however the 
studies analysed were possibly confounded by misclassiflcation of epilepsy type (Marson et 
al, 2002). In our study, the highest response rates to initial monotherapy were observed with 
VPA. This was especially so in the case of JME where response to treatment with VPA was 
clearly superior to that with other drugs including LTG.
Patients with Downs’ syndrome are known to have a bimodal pattern of onset of seizures 
with approximately 40% of epilepsy starting in the first year of life and another 40% in the 
3rd decade (Pueschel et al, 1991). Late onset myoclonic epilepsy in Down’s syndrome 
(LOMEDS) has been previously described (Li et al, 1995; Moller et al, 2001). This usually 
presents with rapidly progressive dementia in patients aged over 40 years (Genton and
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Paglia, 1994). With increased survival of patients with Down’s syndrome into middle age, 
this presentation is being increasingly recognised. In our series, 3 patients with Down’s 
syndrome presented with myoclonic epilepsy at the ages of 42,45 and 51 years. None of 
these patients achieved remission although one patient had 12 months of seizure freedom on 
treatment before relapsing.
Although IGE syndromes respond better to treatment than localisation related epilepsy, there 
remains a significant proportion of patients who do not achieve seizure remission with 
currently available treatment. Identifying these patients early could help optimise treatment 
strategy. Several studies have investigated the influence of risk factors in determining the 
prognosis of IGE syndromes. The findings from these studies are varied and reflect the 
methodological differences among studies in the definition of risk factors and classification 
of epilepsy. From their study of 962 paediatric and adult patients with IGE, Nicolson and 
colleagues found atypical presentation to be associated with a significantly worse response 
to treatment (Nicolson et al 2004b). This was defined as IGE with onset outside the 
expected age group of 3- 20 years or with atypical absence or myoclonic seizures. Prognosis 
for response to treatment also differs among the sub-syndromes of IGE. This study found 
that patients with GTCS only (64.5% remission) or GTCS on awakening (78% remission) 
had significantly better remission rates compared to prognosis for remission in the entire 
cohort. Femando-Dongas and colleagues reported a higher prevalence of EEG asymmetry, 
atypical seizure characteristics and intellectual deficiency in patients with JME who failed to 
respond to valproate treatment (Femando-Dongas et al 2000). Psychiatric problems have 
also been reported to be associated with drug resistant IGE (Gelisse et al, 2001; Cutting et al, 
2001). In our cohort of patients, history of febrile seizures was the only factor associated 
with a failure to achieve remission. Febrile seizures are known to have a genetic component
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and some of the genetic factors associated with IGE can give rise to febrile seizures (Baulac 
et al 2004). It is possible that the IGE syndromes associated with febrile seizures have a 
different pathophysiology and therefore require a different therapeutic approach to other 
forms of IGE.
3.5. Conclusions
The majority of patients with IGE have an excellent prognosis and can be expected to 
achieve lasting seizure remission. Prospective studies recruiting patients from the time of 
diagnosis and employing diagnostic schemes designed to identify IGE are required to 
elucidate the natural history of specific IGE disorders.
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4. Pharmacological outcomes in newly diagnosed epilepsy over a 20-year period
4.1. Introduction
Several randomised studies have examined the efficacy and tolerability of standard 
antiepileptic drugs (AEDs) in the treatment of partial and generalised seizures in adults with 
epilepsy (Turnbull et al 1982, Mattson et al 1985, Callaghan et al 1985, Mattson et al 1992, 
Richens et al 1994, Heller et al 1995). However, there has been an explosion of newer 
AEDs licensed since these landmark studies reported (Dichter and Brodie, 1996). This has 
had a major impact on treatment choices the world over. Some traditional AEDs, such as 
phenobarbital, are no longer prescribed routinely in most developed countries and some 
newer AEDs, such as lamotrigine and oxcarbazepine, have acquired first line status. 
Currently there are few data available outside of regulatory clinical trials to guide treatment 
decisions in this changing milieu. The setting of such trials is artificial with strict exclusion 
and exit criteria, which are necessary to safeguard patients receiving investigational agents. 
These limitations prevent extrapolation of the results to the majority of patients with 
epilepsy who receive the drugs and these studies rarely help decision making in clinical 
practice (Mohanraj and Brodie 2003). Long-term prospective randomised studies comparing 
new and standard agents and newer agents with one another in patients with new onset 
epilepsy are needed, and, indeed, some are underway. Data from longitudinal observational 
studies can complement these projects. We conducted an observational study of treatment 
outcomes in newly diagnosed patients to assess the response to individual AEDs in various 
seizure types and epilepsy syndromes.
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4.2. Methods
Methods of data collection and end points of efficacy and tolerability have been described in 
part I, section 1. 2. Tolerability and efficacy for each AED was analysed separately in 
patients with idiopathic generalised epilepsies and localisation related epilepsies. Results 
were compared using the %2 test with Bonferroni correction for multiple comparisons. Doses 
were compared using the Mann-Whitney test for non-parametric observations. The actuarial 
life table method was used to compare times to first seizure after starting on AED treatment.
4.3. Patients
A diagnosis of epilepsy was made in 890 patients, 110 (12%) of whom were lost to follow 
up. The remaining 780 were included in the analysis for efficacy and tolerability of 
individual AED regimes. This cohort comprised of 405 (52%) males and 375 (48%) 
females, who had a median age of 31 years (median 9-93 years) at initiation of treatment. 
Overall, 103 (13%) patients had idiopathic generalised epilepsy syndromes and 558 (72%) 
had localisation related epilepsies. The remaining 119 (15%) patients had generalised tonic 
clonic seizures with no localising features, and had been classed as having generalised 
epilepsy for purposes of deciding treatment. These patients were included with those with 
idiopathic generalised epilepsy in this analysis. Carbamazepine (CBZ, n=268), valproate 
(VPA, n=198) and lamotrigine (LTG, n=198) were the most commonly used first choice 
antiepileptic drugs in this population. The trends in the usage of the three main agents over 
the study period are shown in Figure 12. Other AEDs such as Felbamate (n=13), 
Gabapentin (n=30), Tiagabine (n=25), Oxcarbazepine (n=18) and Remacemide (n=16) 
were used as initial monotherapy as part of regulatory RCTs. Pheytoin was used in 11 
patients and Topiramate in 3, outside of RCTs. Most patients diagnosed since 2000 have 
been entered into a randomised study comparing valproate and lamotrigine.
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4.4. Results
4.4.1. Monotherapy
Overall, 504 (65%) of patients starting on AEDs responded to treatment. Of these, 462 
(91.7%) were on treatment with one AED (monotherapy) and 40 (7.9%) were receiving two 
AEDs. Treatment with combinations of 3 and 4 AEDs produced seizure freedom in only one 
patient (0.2%) each. In total, 1020 attempts were made to treat patients with monotherapy. 
CBZ (n=312), VPA (n=315) and LTG (n=249) and others (n=144) were the drugs used. Of 
the 462 patients responding to monotherapy, 393 were on the first AED, 57 on the second, 8 
on the third and 2 on the fourth. Only one patient each responded to 5th and 6th attempts at 
monotherapy. The response to each drug used as initial monotherapy in specific syndromes 
is shown in table 20.
4.4.2. The first AED
The rank order in which it is given is an important determinant of the effectiveness of any 
AED (Nicolson et al 2004). If the first appropriate AED does not succeed in controlling 
seizures, subsequent pharmacotherapy is less likely to be successful (Dlugos et al 2001, 
Kwan and Brodie 2000, Sillanpaa 1993). We analysed in detail the response to initial 
monotherapy in the various epilepsy syndromes. Of the 780 patients started on AED therapy, 
392 (50%) responded to the first drug. Demonstrable differences in responder rate existed 
only between LTG (61% response) and CBZ (44% response, p<0.001, Figure 13). Adverse 
events leading to withdrawal of treatment was more frequent with CBZ (16%) compared to 
LTG (7%, p=0.018) and VPA (7%, p=0.03). Adverse events leading to failure of each AED 
used as first monotherapy is listed in Table 21. CBZ was more likely to cause rash than any 
other drug (p<0 .001), but there were no significant differences in the occurrence of other 
adverse effects among the various drugs. No differences were observed in the incidence of
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adverse effects between patients with idiopathic generalised and localisation related 
epilepsies.
4.4.3. Immediate response
A total of 245 (31%) patients suffered no further seizures after starting on AED treatment. 
These immediate responders constituted 49% of all responders and included 164 (29%) 
patients with localisation related epilepsies, 33 (32%) patients with idiopathic generalised 
epilepsies and 48 (40%) patients with unclassified seizures. There were no significant 
differences in the probability of achieving immediate response among patients with various 
types of epilepsy. The choice of AED did not significantly influence the probability of 
achieving immediate response.
4.4.4. Effectiveness in idiopathic generalised epilepsy
In patients with idiopathic generalised epilepsy, VPA produced the highest response rate 
(66%). LTG (45% response rate) and CBZ (31% response rate) were less efficacious but the 
numbers were insufficient to show statistically significant differences. Withdrawal due to 
adverse effects was more likely with CBZ (38%) than with VPA (5%, p=0.006) and LTG 
(6%, p=0.036) in this group of patients. When specific syndromes were analysed separately, 
significant differences were observed in responder rates for juvenile myoclonic epilepsy, 
with patients more likely to respond to VPA (75%) than LTG (39%, p = 0.014, Table 22).
4.4.5. Effectiveness in localisation related epilepsy
In patients with localisation related epilepsy, LTG (63% response rate) was more likely to 
achieve seizure control than VPA (42% response rate, p=0.006), CBZ (45%, p=0.006) and 
other drugs (p=0.001). There were no significance differences in tolerability among the
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various drugs in these patients. Among the various localisation related epilepsies, 
cryptogenic seizures showed better response to treatment with LTG (67%) compared to CBZ 
(47%, p=0.036) and VPA (40%, p=0.012). No significant differences in response rates could 
be demonstrated in other types of localisation related epilepsies, however the number of 
patients in each subgroup was small (Table 23).
4.4.6. Dosing
Successful monotherapy could be achieved in most cases with modest doses of all AEDs. 
The median daily doses resulting in remission were CBZ 400 mg/day, VPA 1000 mg /day 
and LTG 150 mg /day (Figure 14). There were no significant differences in successful 
monotherapy dosing between patients with idiopathic generalised and localisation related 
epilepsies. We examined the time to first seizure after starting on AED treatment in 551 
patients in whom this data was available from seizure diaries (Figure 15). No significant 
differences could be demonstrated among the 3 first line agents in this analysis.
4.4.7. Substitution versus combination of AEDs
In patients failing initial monotherapy, alternative monotherapy was attempted in 179 
patients and combination therapy with two AEDs in 81 (Table 22). The remission rates and 
withdrawal due to adverse effects were not significantly different between the two treatment 
strategies. Over the study period, 139 attempts were made to use combination of two drugs. 
The response rates with each regime are shown in (Table 23). The most commonly 
employed combination based on mechanism of action was of a sodium channel blocking 
AED and one with multiple mechanisms of action. Numbers of patients treated with other 
types of combinations were insufficient for comparison of efficacy based on mechanisms of 
action.
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Table 21. Adverse effects leading to withdrawal o f each drug used as first monotherapy
Carbamazepine 
(n = 268)
Valproate 
(n = 198)
Lamotrigine 
(n= 198)
Others
(n=116)
Rash 22 1 5 2
Sedation 7 0 0 2
Tiredness 3 1 2 1
Ataxia 0 2 0 4
Headache 3 1 0 0
Nausea/vomiting 5 5 3 1
Mood changes 2 0 1 1
Tremor 0 3 1 0
Weight gain 0 2 0 0
Others 3 2 3 2
Total 45 17 15 13
Table 22. Response to substitution and combination in patients failing initial monotherapy
Idiopathic generalised Localisation related
Response Substitution Combination Substitution Combination
Remission 16 42% 10 48% 43 31% 19 32%
Not tolerated 2 5% 0 0% 17 12% 2 3%
No efficacy 20 53% 11 52% 81 57% 39 65%
Grand total 38 21 141 60
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Table 23. Response to individual two-drug combinations
Combination Number Responders Response rate
Valproate + Lamotrigine 61 25 41%
Carbamazepine + Gabapentin 11 2 18%
Carbamazepine + Lamotrigine 10 1 10%
Carbamazepine + Topiramate 9 3 33%
Carbamazepine + Vigabatrin 7 1 14%
Carbamazepine + Valproate 7 2 29%
Valproate + Topiramate 5 1 20%
Carbamazepine + Levetiracetam 3 1 33%
Carbamazepine + Phenytoin 3 0 0%
Lamotrigine + Topiramate 3 1 33%
Lamotrigine + Vigabatrin 3 0 0%
Valproate + Gabapentin 3 1 33%
Lamotrigine + Levetiracetam 2 0 0%
Valproate + Vigabatrin 2 0 0%
Others 10 2 20%
Grand Total 139 40 29%
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4.5. Discussion
Our understanding of the underlying epileptogenic process in the majority of the patients 
with epilepsy is rudimentary (Regesta and Taganelli, 1999). Similarly, the mechanisms of 
action of AEDs, especially newer ones, are not completely known (Kwan et al, 2001). 
Therefore, in contrast to many areas of therapeutics, pharmacological treatment of 
epilepsy is not a process of correcting a specific functional or biochemical deficit 
(Perucca, 2003). Rather, drug selection in epilepsy is an empirical process based on 
previous clinical observations in representative patient groups. As new treatments 
emerge, ongoing observational and randomised studies will be required to guide drug 
selection in patients with new onset epilepsy.
In this cohort of 780 patients with newly diagnosed epilepsy, we compared responder 
rates defined as complete seizure control for a year or more with various AED regimes 
and treatment schedules. Patients with idiopathic generalised epilepsy were significantly 
more likely to achieve response to treatment than those with localisation related epilepsy. 
Most patients who achieved remission were on treatment with one AED (monotherapy) 
generally at moderate doses. In patients failing initial monotherapy response to a 
combination of two AEDs was not significantly different from that to alternative 
monotherapy.
An interesting observation was of immediate response to treatment wherein patients 
suffered no further seizures after starting on AED treatment. Overall, 31% of patients 
starting on treatment were in this category. The probability of immediate response tended 
to be higher in patients with idiopathic generalised epilepsy. The choice of AED did not 
influence the probability of immediate response. Similarly, no significant differences
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were observed among patients started on CBZ, VPA and LTG when time to first seizure 
was compared. This, along with the fact that response could be obtained with moderate 
doses of AEDs in most cases, suggests that prognosis for response to treatment is an 
inherent property of the specific epilepsy syndrome.
In all patients we started on antiepileptic medication, the overall response rates were 
significantly different only between LTG and CBZ. CBZ was also more likely to cause 
intolerable adverse effects compared to LTG and VPA. This has previously been 
observed in 2 randomised controlled trials comparing LTG and CBZ monotherapy in 
newly diagnosed patients (Brodie et al 1995; Brodie et al, 1999). The differences in 
effectiveness were ascribed to difference in tolerability as patients on CBZ had a higher 
incidence of intolerable adverse effects. Gillham and colleagues studied 260 patients with 
newly diagnosed epilepsy who were randomised to treatment with carbamazepine and 
lamotrigine using health related quality of life as the main outcome measure and found 
that lamotrigine was associated with better tolerability and quality of life (Gillham et al, 
2000). In the present analysis, we found significant differences in tolerability in patients 
with idiopathic generalised epilepsy, in whom CBZ was more likely to cause adverse 
effects than any other drug. CBZ is known to worsen certain types of idiopathic 
generalised epilepsy syndromes and cause seizure exacerbation (Perucca et al, 1998). It is 
thus inappropriate choice as a first line monotherapy agent for patients with idiopathic 
generalised epilepsy (Benbadis et al, 2003). It is possible that the lack of efficacy or even 
exacerbation of seizures caused by such inappropriate treatment reduces the subjective 
tolerability to otherwise trivial adverse effects. Thus, even when an AED has been 
withdrawn ostensibly due to adverse effects, efficacy reasons often have had a role to 
play.
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In idiopathic generalised epilepsies, treatment with VPA produced the highest responder 
rates although the differences in responder rate with LTG and CBZ did not reach 
statistical significance. However, when specific syndromes were analysed responder rates 
in Juvenile Myoclonic Epilepsy was significantly higher with VPA than with LTG. There 
is relatively little controlled trial data on the comparative efficacy of VPA and LTG in 
idiopathic generalised epilepsy. One randomised open label study of patients with typical 
absences reported a greater proportion entering remission on treatment with VPA (63%) 
compared to those treated with LTG (37%, Coppola et al, 2004). The difference was not 
statistically significant mainly owing to the small size of the study (n=38). The results of 
the ongoing SANAD study, comparing new and standard AEDs in newly diagnosed 
epilepsy in a prospective randomised design should clarify the issue further.
For localisation related epilepsy syndromes overall, LTG produced significantly better 
responder rates than any other AED. When subtypes were analysed, this observation held 
true for cryptogenic seizures. For other types of localisation related epilepsy syndromes 
including those resulting from cerebral trauma, cerebrovascular disease, cerebral atrophy, 
neuronal migration disorders and mesial temporal sclerosis, numbers were insufficient to 
show significant differences amongst the various drugs. Superior outcomes have been 
reported previously in patients with partial epilepsy treated with lamotrigine compared to 
those treated with carbamazepine. Nieto-Barrera and colleagues studied 618 patients 
randomised to CBZ and LTG and found comparable rates of seizure control (75% and 
65% respectively), but significantly more patients withdrawn due to adverse effects in the 
CBZ treated group (8% versus 13%; Nieto-Barrera et al, 2001).
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Ours is an unrandomised retrospective observational study and is prone to bias from 
varying treatment policies over the study period of 20 years. The data presented cannot, 
therefore, be considered reliable evidence of superiority of any particular AED over 
others, but do compliment observations made in randomised control trials discussed 
above. Our findings suggest that LTG is likely to produce better response rates in 
localisation related epilepsies, especially cryptogenic seizures than CBZ or VPA. In 
idiopathic generalised epilepsies, treatment with VPA produced the best response rates, 
although statistical superiority in response rate could be demonstrated only in patients 
with juvenile myoclonic epilepsy. These findings, appropriately validated, could help 
guide treatment decisions in patients with new onset epilepsy.
4.6. Conclusions
Patients with localisation related epilepsies, especially cryptogenic seizures responded 
better to LTG than CBZ or VPA. For idiopathic generalised epilepsies, especially juvenile 
myoclonic epilepsy, highest response rates were seen with VPA. The majority of patients 
who responded to treatment did so rapidly and completely with modest doses of AEDs.
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Part III
Genetic influences on response to treatment in epilepsy
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1. Pharmacogenomic studies in epilepsy 
1.1 Introduction
Pharmacogenomics (or pharmacogenetics) is the study of genetic variations affecting 
response to drugs (Roses, 2001). Pharmacogenomics specifically refers to the study of all 
of the many different genes that determine drug behaviour, where as pharmacogenetics 
refers to the study of inherited genetic variation in drug metabolism and response. The 
distinction between the two terms is considered arbitrary, however, and the two terms are 
used interchangeably. It has been known for several decades that genetic differences are 
responsible for inherited variability in response to drugs (Weinshilboum, 2003). The 
identification of drug metabolising enzymes and drug target molecules, the genes that 
encode them, and sequence variants that correlate with drug response, have made it 
possible to elucidate the genetic basis for a variety of drug effects, such as idiosyncratic 
adverse reactions (Patsalos, 2000; Pirmohamed and Park, 2001). This has opened up the 
possibility of individualising drug therapy.
1.1.1. Clinical relevance of predicting drug response in epilepsy
Epilepsy is the most common serious neurological disorder with an annual worldwide 
incidence o f40-70 per 100,000 population (Sander, 2003). Long-term epidemiological 
studies have shown that approximately one in three patients with newly diagnosed 
epilepsy do not achieve useful control of seizures with currently available antiepileptic 
drugs (AEDs; Annegers et al, 1979; Cockrell et al, 1995; Mattson et al, 1996; Kwan and 
Brodie, 2000). In most patients, the diagnosis of epilepsy has social and economic as well 
as health implications. In children, uncontrolled epilepsy results in impaired intellectual 
development and reduced academic achievement. In adults, a diagnosis of epilepsy can 
result in the loss of driving privileges and employment. Regaining these requires
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demonstration of complete control of seizures for an extended period of time. Thus, from 
the patients’ perspective, prognosis for control of seizures is especially important in 
returning to a full functioning life. Studies have shown that the most powerful predictor 
of long-term treatment outcome in epilepsy is the response to the first AED (Sillanpaa, 
1993; Camfield and Camfield, 1996; Dlugos et al, 2001; Kwan and Brodie, 2001). If 
response to AED treatment can be predicted, choice of drug therapy and long term 
prognostication can be improved. Identifying genetic markers correlating with specific 
drug effects could help predict effectiveness of individual AEDs.
1.1.2. Types of genetic variation
The completion of the Human Genome Project and data from the ongoing HapMap 
project has resulted in the cataloguing and annotation of a large number of variants of the 
human genome (Cravchik et al, 2001). The DNA sequence in all humans is 99.9% 
identical. Variations occur as a result of single nucleotide polymorphisms (SNPs), 
insertions, deletions, substitutions and simple tandem repeats (STRs). Any variation of 
the human genetic sequence from normal is considered a mutation; this however assumes 
a normal variant that is prevalent in the majority of the population. A polymorphism, on 
the other hand, is relatively common in the population. No single allele is considered 
normal, but there are 2 or more equally acceptable variants. The arbitrary cut off in 
prevalence between a mutation and polymorphism is 1% (Clancy and Kass, 2003).
1.1.3. Single nucleotide polymorphisms
SNPs are the simplest form of genetic polymorphism and are estimated to occur every 
100 to 300 base pairs in the human genome (Chakravarty, 1999). They constitute 90% of 
the variability in the human genome and are the genetic markers of choice in
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pharmacogenetic studies (Gray et al, 2000). They can occur in the non-coding regions of 
the genome (promoter regions, introns, 3’ and 5’ untranslated regions (UTR) and 
intergenic regions) or in the coding regions. Coding SNPs (cSNPs) could potentially 
affect the structure of the protein encoded on the gene. The degenerate nature of the 
genetic code (64 possible triplet sequences encoding 20 amino acids) means that the same 
amino acid can be specified by more than one triplet code. Thus, some cSNPs do not 
alter the amino acid sequence of the encoded protein (synonymous SNPs). Those cSNPs 
that alter the triplet code to specify a different amino acid are referred to as non- 
synonymous SNPs. Non-synonymous SNPs can have significant biological effects. It 
alters the primary structure of the protein, by changing the amino acid sequence. This can 
result in diminished activity or diminished quantity of the protein encoded 
(Weinshilboum and Wang, 2004). This could in turn affect the pharmacokinetics and 
pharmacodynamics of drugs that are metabolised or transported or those that bind to these 
proteins. Non-coding SNPs can also have biological consequences (e.g.: - influence gene 
expression if they occur in the promoter regions) or may simply serve as markers in 
linkage disequilibrium (LD, see section 1.2.1 below) with an unidentified susceptibility 
allele in association studies (Roden, 2001).
1.2. Methodological considerations
1.2.1. Study design
Genetic influence on drug responsiveness is complex and multifactorial. Studies in 
animals have suggested that pharmacoresistance to AEDs is genetically determined, but 
does not follow simple inheritance patterns. There is likely to be considerable 
environmental modification of genetic factors in determining response to drugs (Ebert 
and Loscher, 1999). Pharmacogenomic studies are therefore similar to genetic studies of
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polygenic diseases inasmuch as there is no simple correlation between genotype and 
phenotype. The favoured design in genetic studies of complex diseases is family based 
association study (Romero et al, 2002). Polymorphisms co-segregating with the disease 
phenotype are considered to be in linkage disequilibrium (LD) with the susceptibility 
gene. This approach uses polymorphisms as genetic markers rather than ascribing a 
causative role and has the advantage of not making assumptions about the genes involved. 
However, in pharmacogenomic studies, the possibility of recruiting sufficient numbers of 
related individuals receiving treatment with the same drug is remote. In studies of 
polygenic diseases, familial inheritance, homogenous populations and relatively 
straightforward ascertainment of affected individuals allow for LD mapping. When 
unrelated individuals are being studied, the extent of LD can be affected by several 
factors including population admixture, genetic drift, mutation and natural selection. LD 
mapping methods in pharmacogenomic studies therefore have given rise to concerns 
regarding sample sizes, extent of LD, number of SNPs needed in a map and interpretation 
of results. Evidence to date suggests that this is likely to be an unreliable paradigm 
(McCarthy and Hilfiker, 2000).
Pharmacogenomics generally employs association studies based on a candidate gene 
approach (Ring and Kroetz, 2002). This utilises a priori knowledge of the biological basis 
of disease pathogenesis and mechanism of action of drugs to identify genes relevant to 
drug responsiveness. Polymorphisms identified in these genes are then tested for 
statistical association with the outcome of interest (responsiveness, adverse effects) in 
patients enrolled in case-control or cohort studies. Cohort studies are less prone to 
ascertainment bias but require a longer study period and more resources. Case-control
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studies are easier to perform, but the definition of cases and controls has to be 
standardised as rigorously as possible to ensure that the populations are comparable.
1.2.2. Sample size and power in candidate gene studies
The number of patients required to find statistically significant association between the 
presence of a SNP and drug response depends on a number of factors including the 
frequency of drug response, proportion of patients possessing the SNP allele, a minimum 
detectable effect, the level of statistical significance (p value) and the power (ability to 
detect a true association; McCarthy and Hilfiker, 2000). Therefore, the selection of 
candidate SNPs will have to take into account not only the presumed biological relevance, 
but also the expected prevalence of the minor alleles and heterozygosity to ensure 
adequate power of the study without having to recruit impracticably large numbers of 
patients. On average cSNPs have a minor allele frequency of only about 7% (Halushka et 
al, 1999); and possibly even lower for those cSNPs of biological relevance (Cargill et al, 
1999). This factor limits the predictive value of any single cSNP.
1.2.3. Hardy-Weinberg equilibrium
The Hardy-Weinberg model describes and predicts genotype and allele frequencies in a 
non-evolving population. The model has five basic assumptions: 1) the population is 
large; 2) there is no gene flow between populations, (e.g.-from migration); 3) mutations 
are negligible; 4) individuals mate randomly; and 5) natural selection is not operating on 
the population. Given these assumptions, a population's genotype and allele frequencies 
will remain unchanged over successive generations, and the population is said to be in 
Hardy-Weinberg equilibrium. The Hardy-Weinberg equation states that for a single gene
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trait with two alleles, A and a, with allele frequencies of p (A) and q (a) where p + q = 1, 
the frequencies of the three possible genotypes are given by
p2 (AA) + 2pq (Aa) + q2 (aa) = 1
In pharmacogenomic studies, the genotype frequencies of the population studied should 
be within Hardy-Weinberg expectations for the results to be interpretable. Deviations 
from Hardy-Weinberg equilibrium can inflate the chance of a false-positive association 
(Schaid and Jacobsen, 1999).
1.2.4. Haplotypes
Haplotype is a way of denoting the collective genotype of a number of closely linked loci 
on a chromosome (www.ornl.gov/TechResources/Human_Genome/glossary). Several 
SNPs may be inherited together as a haplotype so that identifying the state of one would 
allow prediction of the state of others. Analysis based on haplotypes of a gene can have 
advantages over analysis based on individual SNPs (Judson et al, 2000), especially if 
multiple susceptibility alleles are being studied (Morris and Kaplan, 2002). Haplotype 
based analysis has been shown to reduce variations in the strength of genotype-phenotype 
association in candidate gene studies (Saunders et al, 2001). However, if the number of 
SNPs being studied is less than the number of haplotypes, analysis based on haplotypes 
may not be advantageous (Bader, 2001).
1.2.5. Definition of the phenotype
The definition of drug response in pharmacogenomic studies has to be precise and 
accurate for the results to be valid. This is often not straightforward. Imperfect adherence
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to prescribed treatment, partial response, pharmacokinetic and pharmacodynamic 
interactions with other prescription and non-prescription drugs, diet and lifestyle factors 
can all cloud the issue (Clancy and Kass, 2003). It is necessary therefore that standardised 
definitions for categorising response be set before the study is undertaken and that these 
are applied uniformly in the population under study. Study personnel involved with 
categorising treatment response should be blinded to the outcome of genotyping studies.
1.2.6. Analysis
In case control studies the magnitude of the effect of the SNP on drug response is 
commonly estimated and expressed as an Odds Ratio. Owing to the multifactorial nature 
of drug response, the magnitude of the effect conferred by a single SNP is likely to be 
low, in the range of 1.5 to 3.0 (McCarthy and Hilfiker, 2000). Studies testing for multiple 
SNPs will need to employ higher significance levels depending on the number of 
hypotheses being tested. However, the usual methods of correcting for multiple testing 
(e.g.: - Bonferroni correction) will be too conservative as they assume independence 
between the factors. The effects of multiple SNPs may not be independent and the risk of 
a Type II error (of not finding an association where one exists) is high. Special statistical 
techniques need to be used to address this (Romero et al, 2002).
1.2.7. Selection of candidate genes
Several genes influence the pharmacokinetics and pharmacodynamics of AEDs. Genes 
involved in pharmacokinetics encode drug metabolising enzymes and transport proteins. 
Polymorphisms in these genes can alter the expression and function of these proteins 
(Hiratsuka and Mizugaki, 2001; Ramachandran and Shorvon, 2003). Altered metabolism 
affects serum and therefore brain concentrations of AEDs. Similarly, polymorphisms
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resulting in increased expression levels and activity of drug transporter proteins can result 
in lower intraparenchymal concentrations of AEDs and can contribute to the failure of 
drug therapy (Siddiqui et al, 2003). For commonly used AEDs, blockade of voltage 
dependent sodium channels and potentiation of y-aminobutyric acid (GABA) mediated 
inhibitory transmission are the two principal mechanisms of action (Kwan et al, 2001; 
Rogawski and Loscher 2004). Genes encoding the subunits of voltage gated sodium 
channels and GABA receptors therefore influence the pharmacodynamics of AEDs. 
Polymorphisms in these genes, affecting the structure and/or function of the subunits they 
encode, could potentially render specific mechanisms inoperative and cause failure of 
AED treatment.
1.3. The voltage gated sodium channel
1.3.1. Molecular biology of the voltage gated sodium channel
Voltage-gated sodium channels are mainly responsible for the generation and propagation 
of action potentials in the nervous system. Mammalian sodium channels are 
heterotrimers, with a central 260 kDa a  subunit, linked non covalently to a 36 kDa (31 
subunit and through a disulphide bridge to a 33kDa (32 subunit (Whittaker et al, 2000). 
The a  subunit is necessary and sufficient to confer the principal properties of the voltage 
gated sodium channel: voltage-dependent activation, rapid inactivation and selective ion 
conductance (Yu and Caterall, 2003). The (3 subunit modulates channel expression and 
function (Patton et al, 1994; Ragsdale and Avoli, 1998). Co-expression of (31 subunits 
with the a  subunit in the developing brain has been associated with an increased 
appearance of voltage gated sodium channels on the cell surface (Isom et al, 1992). 
Coexpression of both (31 and (32 subunits with the a  subunit serves to increase the 
functional expression of ionic currents, by influencing the gating kinetics of the channel
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(Isom et al, 1995; Hanlon and Wallace, 2002). The p2 subunit, which is exclusively 
expressed in neurons, also has structural homology to cell adhesion molecule contactin/F3 
(Joho et al, 1990; Isom, 2000). This suggests a potential role for the p2 subunit in the 
localisation and stabilisation of the sodium channel on the cell membrane.
Nine a  subunits have been functionally characterised and denoted Navl.l  -  Nav1.9, and a 
tenth related isoform, NaVx may also function as a sodium channel (Yu and Catterall, 
2003, Table 24). Three different p subunits have also been identified —  pi- p3. The 
various isoforms of the a  subunit exhibit a high degree of sequence homology and likely 
share a similar tertiary structure (Ragsdale and Avoli, 1998). Sequence analysis suggests 
four repeats of a structural motif each consisting of six putative a  helical transmembrane 
segments. The four channel domains are believed to form a square array with the ion- 
conducting pore located in the centre. The S4 segments in each domain function as the 
voltage sensors for voltage-dependent activation of the channel. The S5 and S6 segments 
in each domain and the short SS1/SS2 segments between them form the pore of the 
channel. The intracellular loop between domains III and IV forms the inactivation gate, 
which folds into the pore and occludes it within 1 ms of channel opening (Catterall,
1999).
1.3.2. Voltage gated sodium channels as AED targets
The neuronal voltage-gated sodium channel is arguably the most important molecular 
target of currently available AEDs. It represents the principal site of action of phenytoin 
(PHT), carbamazepine (CBZ), lamotrigine (LTG) and oxcarbazepine and a potentially 
important contributor to the pharmacology of sodium valproate, felbamate, gabapentin, 
topiramate and zonisamide. It also serves as a drug target for Class I antiarrhythmic drugs
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and local anaesthetics. The activity of such diverse classes of drugs on the voltage gated 
sodium channel is brought about by preferential binding of these agents to the various 
subtypes in the open and inactivated channel states. CBZ, the archetypal sodium channel 
blocking AED, has been shown to exert both a voltage- and use- dependent block of 
sodium channels (Ragsdale et al, 1991). It exerts a modest block of sodium channels in 
their resting state at hyperpolarised membrane potentials. This effect is enhanced when 
the membrane is depolarised. The blocking properties of CBZ are most pronounced when 
the membrane is repeatedly and rapidly depolarised. It stabilises the inactivated state of 
the channel and by slowing recovery from the inactivated state, reduces the ability of the 
channel to maintain high frequency action potential firing during sustained membrane 
depolarisation. As use-dependent block causes a preferential reduction in the availability 
of sodium channels during high but not low frequency firing, this mechanism is thought 
to be key to the antiepileptic properties of CBZ. Use- and voltage- dependent block is 
brought about by binding to specific sites on the inactivated sodium channel. There is 
experimental evidence to suggest that this site is probably on the a  subunit at the 
transmembrane segment S6 in domain IV (Catterall, 1999). Studies also suggest that this 
site is common to LTG, PHT and CBZ (Kuo, 1998). Alteration to the amino acid 
sequence at this site by experimental mutagenesis has been shown to dramatically alter 
the affinity of drugs that act by binding to voltage dependent sodium channels (Ragsdale 
et al, 1996).
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Table 24. Voltage gated sodium channel a  subunits (adapted from Wood and Baker, 
2001)
Channel Previous name Gene symbol Chromosome (human) Pharmacology
Navl.l Type I SCN1A 2q24 TTX-s
Na»1.2 Type II SCN2A 2q23-24 TTX-s
Nayl .3 Type III SCN3A 2q24 TTX-s
Nav1.4 SkM SCN4A 17q23-25 TTX-s
Nav1.5 Cardiac SCN5A 3p21 TTX-r
Nav1.6 NaCh6 SCN8A 12ql3 TTX-s
Navi.7 PN1 SCN9A 2q24 TTX-s
Nav1.8 SNS/PN3 SCN10A 3p21-24 TTX-r
Nav1.9 NaN SCN11A 3p21-24 TTX-r
Nax NaG SCN6A/SCN7A 2p21-23 ?
TTX-s Tetrodotoxin sensitive
TTX-r Tetrodotoxin resistant
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1.3.3. Genes encoding sodium channel subunits
Genes encoding sodium channel a  subunits Navl.l ,  Nav1.2, Navi.3 and Nav1.7 are 
located on chromosome 2 (Yu and Caterall, 2003). These isoforms share sequence 
homology and biophysical characteristics, are blocked by nanomolar concentrations of 
tetrodotoxin and are widely distributed in the nervous system. A second cluster of genes 
on chromosome 3p21-24 encode sodium channels Nav 1.5, Nav 1.8 and Nav 1.9 which are 
characterised by varying degrees of tetrodotoxin resistance, although they have 
approximately 75% sequence homology with the channels encoded on chromosome 2. 
Nav 1.5 is the principle cardiac isoform and mutation in this gene has been implicated in 
Brugada syndrome, an autosomal dominant disorder of potentially fatal cardiac 
dysrhythmia. Nay 1.8 and Nav 1.9 are preferentially expressed in peripheral sensory 
neurons. Of the remaining isoforms, Nay 1.4 is mainly expressed in muscle cells and 
Nav 1.6 is abundant in glial cells in the CNS. Phylogenetic analysis suggests a distant 
evolutionary relationship as these isoforms are encoded on human chromosome 11 and 15 
respectively. However, both have a high degree of sequence homology and share the 
biophysical properties and tetrodotoxin sensitivity with the chromosome 2 encoded 
isoforms.
1.3.4. Expression patterns of a  and (3 subunit isoforms
There is considerable variation in the spatial and temporal patterns of expression of 
voltage gated sodium channel subtypes in human brain (Wood and Baker, 2001; Kohling, 
2002). At least 20 exons code for the nine a  subunit isoforms and several splice variants 
are also expressed (Yu and Caterall, 2003). The differential distribution of sodium 
channel subtypes suggests that they have distinct roles that are likely to be important in 
maintaining the functional heterogeneity of central nervous system neurons. Several
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studies have examined the distribution of the various subtypes in rat brain using 
immunoprecipitation, Northern blot, RT-PCR, and immunohistochemistry. Studies using 
human brain tissue from epilepsy surgical specimens and normal post-mortem samples 
have been performed using the ligase detection method (Lombardo et al, 1996) and in situ 
hybridisation (Whittaker et al, 2000). The distribution of the various subtypes in rat and 
human brain is broadly similar, the major exception being Nav1.3. This isoform is 
embryonic and is present only in negligible amounts in adult rats but it is widely 
distributed in the human adult brain (Chen et al, 2000; Whitaker et al, 2001a). The 
distribution of various isoforms of a  and p subunits estimated by assay of mRNA levels 
is shown in Table 25.
Several conditions including epilepsy cause changes in the expression patterns of sodium 
channels. The ratio of Navl.l  to Nav1.2 was found to be higher in surgical specimens 
from patients with refractory temporal lobe epilepsy (Lombardo et al, 1996). Further 
studies have suggested that this could be due to a down regulation of the Nav1.2 subtype 
rather than up regulation of the Navl.l subtype (Whitaker et al, 2001b). This study also 
found a significantly increased expression of Nav1.3 subtype in the human epileptic 
hippocampus compared to normal controls. Sodium channels isolated from surgically 
excised brain tissue of patients with refractory epilepsy have been shown to be insensitive 
to the blocking effects of CBZ (Remy et al, 2003). This suggests that sodium channel 
functionality may be an important factor in pharmacoresistant epilepsy.
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Table 25. Expression comparisons between sodium channel and subunits in human 
parahippocampal gyrus, cortex, and cerebellum (adapted from Whitaker et al, 2000)
Subtype
Brain Region Navl.l Nav 1.2 Navl.3 (31 (32
Parahippocampal gyrus
CA4 + + + ± + + + +
CA3 + + + + + +++ ++
CA2 + -H -+ ± + + -H -
CA1 + + + ± 4-h + +
Dentate gyrus + + + + + -H - -H -+ + -H -
Subiculum + + + + + + + + ++
Cortex
Layers II/III + + + + + + + + +
Layers V/VI + + -H -+ + + + + -H -
Cerebellum
Granular layer + + 1 1 M + + -H -H - + + +
Purkinje cells + + - - -HH- + +
Deep cerebellar nuclei + + - - + + + -
Molecular layer + + - ++ +
-H -+ + Very strong expression
+++ Strong expression
++ Moderate expression
+ Weak expression
± Very weak/scattered expression
- No expression.
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1.4. Summary
Non-synonymous SNPs in the genes encoding drug targets could influence response to 
antiepileptic drug treatment. Given the central role of the voltage gated sodium channel in 
neuronal excitation and its function as the principal target for several AEDs, genetic 
variations affecting the structure and function of these proteins could play a role in 
resistance to AEDs. Evidence to date suggests that Nay 1.1, Nav1.2, Nav1.3 and Nav1.6 are 
the most widely distributed voltage-dependent sodium channel a  subunit isoforms in the 
human brain. Genes encoding these isoforms, SCN1A, SCN2A, SCN3A and SCN8A are 
therefore candidate genes in pharmacogenomic studies of AEDs.
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2. Association between a polymorphic variant of SCN2A and response to 
antiepileptic drug treatment
2.1. Introduction
In the normal human brain, Nav 1.2, encoded on SCN2A is the most widely expressed 
voltage gated sodium channel a subunit in the seizure prone areas such as the 
hippocampus and the cerebral cortex. (See Part II, section 1.3.4.). A specific non- 
synonymous SNP on this gene (R19K) has previously been reported to be associated with 
Generalised Epilepsy with Febrile Seizures Plus (GEFS+) in Japanese patients (Sugawara 
et al, 2001). The polymorphism is defined by a G-to-A transition at nucleotide position 56 
(relative to the ATG start codon), resulting in the substitution of an arginine (R) residue 
with lysine (K) in the encoded protein. We have investigated the prevalence of this 
polymorphism in responders and non-responders to AED treatment, to determine whether 
SCN2A genotyping might help in predicting response to drug treatment in patients with 
epilepsy.
2.2. Methods
2.2.1. Patients
This study was approved by the West Research Ethics Committee, North Glasgow 
University Hospitals NHS Trust and all participants provided informed consent. All 
patients attending the Epilepsy Unit at the Western Infirmary, Glasgow, Scotland were 
requested to participate in the study. Patients who had stopped attending the clinic as they 
had achieved remission of seizures were contacted by letter and invited to participate in 
the study. A total o f400 adult and adolescent patients (200 male; median age 40 years, 
range 14 to 84 years) were recruited. Specific exclusions were significant learning
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disability, a history of alcohol-related seizures, infrequent seizures (less than 4 seizures in 
a year) and evidence of non-compliance with medication. The epilepsy was classified as 
localisation-related in 270 (67.5%) patients, idiopathic generalised in 118 (29.5%) and 
was unclassified in the remaining 12 (3%) individuals. An underlying structural lesion 
was identified in 122 patients with localisation related epilepsy. Patients had received 
treatment with a median of 2 AEDs (range 2-12).
2.2.2. Isolation of genomic DNA
Genomic DNA was isolated from 20ml of venous blood using a 4-step process (Wizard 
DNA Purification kit, Promega, Southampton, UK). Blood samples were obtained in 
EDTA tubes and added to 30 ml of cell lysis solution in a 50 ml centrifuge tube. This was 
incubated for 10 minutes at room temperature mixing once to lyse the red blood cells. The 
solution was then centrifuged at 2000 x g 10 minutes and the supernatant removed. This 
step was repeated until the residual pellet was white. The tube was then agitated to 
resuspend the cells and 10 ml of the Nuclei Lysis Solution added to lyse leucocytes. The 
mixture was incubated at room temperature for 2 hours. After incubation, 3.3 ml of 
protein precipitation solution was added to the nuclear lysate, mixed thoroughly and 
centrifuged at 2000 x g  for 10 minutes. The supernatant containing genomic DNA was 
removed into 10 ml of isopropranolol using a pasteur pipette, taking care not to 
contaminate the DNA with the precipitated protein. This precipitated genomic DNA, 
which was centrifuged, air dried for 2 hours and rehydrated overnight using 200 pi of 
sterile H2O. The DNA was then quantified by spectrophotometry based on optical density 
at 260nm and reconstituted in sterile H2O to a concentration of lOOng/pl.
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2.2.3. Polymerase Chain Reaction
Genotyping of the R19K SNP was performed by Polymerase Chain Reaction (PCR), 
followed by restriction enzyme digest and detection of restriction fragment length 
polymorphism on gel electrophoresis (Nakayama et al, 2002). A 400 base-pair strand of 
genomic DNA containing the site of the R19K SNP was amplified using the following 
oligonucleotides; sense 5'-AAT CAC CTT TTA TTC TAA TGG TC-3', antisense 5'-CAG 
TGA AGG CAA CTT GAC TAA GA-3' (MWG-Biotech, Milton Keynes, UK). The PCR 
reaction was performed in a final volume of 20pl with lOOng genomic DNA, lOmM tris- 
HC1 (pH 8.3), 50mM KC1, 2mM MgCh, 250pM each dNTPs, 20pmols each primer and 
1U Taq DNA polymerase (all Invitrogen, Paisley, UK). The PCR conditions were as 
follows: a denaturing step at 95°C for 10 minutes, followed by 36 cycles at 94°C for 30 s, 
60°C for 30 s, 72°C for 30 s, and a final incubation at 72°C for 3 minutes. PCR products 
were electrophoresed on a 3% agarose gel to confirm amplification of the appropriate 
fragment of DNA before restriction digest
2.2.4. Restriction digest and identification of R19K genotype
A 10pl aliquot of the PCR product was digested with 5U of ScrFl endonuclease (New 
England BioLabs, Hitchin, UK) at 37°C for 4 hours. A 5pi aliquot of digest product was 
mixed with 5pl loading dye (bromophenol blue / xylene cyanole in 50% glycerol; all 
Sigma, Poole, UK), electrophoresed on a 2.5% agarose gel, and visualized by ethidium 
bromide staining and ultraviolet transillumination. The R19K SNP was identified by loss 
of the ScrFl restriction site; the R-encoding allele yielding 178,130, 64 and 28 bp 
fragments and the K-encoding allele yielding 206, 130 and 64 bp fragments (Figure 16, 
17).
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2.3. Analysis
Response to treatment was assessed by this researcher in a blinded fashion by review of 
clinical case notes and seizure diaries. Studies of clinical outcomes in newly diagnosed 
epilepsy had shown that responders enter remission by 6 months after starting treatment 
in 90% of cases (see Table 6). Therefore, patients were considered responders if they 
remained seizure free for a minimum period of six months on an unchanged AED regime 
(dosage adjustments to alleviate side-effects permitted). Similarly, patients failing to 
achieve seizure control with two well-tolerated and appropriate AED remain uncontrolled 
in over 90% of cases (see table 8). Thus, patients who had continued to experience 
seizures after treatment with two appropriate AED in adequate doses and had been 
compliant with treatment were classed as non responders. Genotype and allele 
frequencies among responders and non-responders were compared by binary logistic 
regression analysis using Minitab for Windows statistical software (version 13.32). 
Significance level was set at 0.05. The strength of association was expressed as Odds 
Ratios (OR) with 95% confidence intervals.
2.4. Results
2.4.1. Association of R19K SNP with response to treatment
A total of 170 (42.5%) patients were classified as responders and 230 (57.5%) as non­
responders. The ^-encoding allele of the R19K polymorphism was present in 50 patients, 
of whom 45 were heterozygous (GA genotype) and 5 homozygous (AA genotype. 
Genotype frequencies in the cohort were 88% GG, 11% GA and 1% AA, which were 
consistent with Hardy-Weinberg expectations. The K- encoding allele (genotype GA or 
AA) was present in 14 (8%) responders and 36 (16%) non-responders (OR=2.07, 95% Cl
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1.08-3.97, p=0.024; Figure 18). Of the 5 patients who were homozygous for the R19K 
polymorphism (AA genotype), 3 were responders.
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2.4.2. Subgroup analysis -  type of epilepsy
Among the 270 patients with localisation related epilepsy, the K-encoding allele of the R19K 
polymorphism was present in 25 (16%) of 159 non-responders and 8 (7%) of 111 responders 
(OR =2.40, 95% Cl 1.04-5.54, p=0.031). Among those with idiopathic generalised epilepsy, 
the X-encoding allele was present in 11 (17%) of 64 non-responders and 5 (9%) of 54 
responders (OR =2.03, 95% Cl 0.66-6.27, p=0.204).
2.4.3. Subgroup analysis -  type of AED
Subgroup analysis was performed for patients currently or previously treated with PHT,
CBZ, LTG or OXC, as these drugs exert their principal effects on the voltage-gated sodium 
channel. A total of 332 patients had received treatment with one or more of these AEDs. In 
this subgroup, the X-encoding allele was present in 31 (14%) of 208 non-responders and 11 
(9%) of 124 responders (OR =1.80, 95% Cl 0.87-3.72, p=0.102). Most of the remaining 
patients had received treatment with sodium valproate, which has also been reported to 
possess sodium channel blocking properties. When these patients were also included (n=62), 
statistical significance was restored. (OR=2.04, 95% Cl 1.06-3.91, p=0.027).
2.4.4. Predictive value of R19K SNP
We assessed he sensitivity, specificity and efficiency of the R19K SNP as a test for non­
response to AED treatment. Non-responders with at least one X-encoding allele (GA or AA 
genotype) were considered true positives and responders with no X-encoding allele (GG 
genotype) were considered true negatives (Table 26). As a predictor of lack of response to 
AED treatment, the presence of at least one X-encoding allele had a sensitivity of 16% and a 
specificity of 92%. The positive predictive value of the SNP in identifying non-responders 
was 72% and the negative predictive value in excluding non-responders was 45%, resulting 
in a test efficiency of 48%.
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Table 26. Efficiency of iC-encoding allele in predicting non-response to antiepileptic drug 
treatment (TP = true positive, FP = false positive, TN = true negative, FN = false negative).
At least one ^-encoding 
allele
No ^-encoding alleles
Non-responders 36 (TP) 194 (FN)
Responders 14 (FP) 156 (TN)
Sensitivity
Specificity
Predictive value (positive test) 
Predictive value (negative test) 
Test efficiency _
TP 36
TP+FN
TN 
FP+TN
TP 
TP+FP
TN 
TN+FN
TP+TN
TP+FP+TN+FN
36+194
156
14+156
36
36+14
156
156+194
36+156
36+14+156+194
= 16%
= 92%
= 72%
= 45%
= 48%
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2.5. Discussion
We investigated the prevalence of a known SNP in the SCN2A gene, which encodes the a- 
subunit of the Nav1.2 sodium channel, in a series of patients attending a specialist epilepsy 
clinic. There was a significant association between genotype of the R19K polymorphism in 
SCN2A and response to AED treatment, with non-responders twice as likely to have at least 
one copy of the K-encoding allele. This association was maintained in patients with 
localisation-related epilepsies, but was not significant for those with idiopathic generalised 
epilepsies. However, the cohort of patients with IGE in this study was relatively small (n= 
118). Interestingly, there was no significant association between genotype and response to 
treatment in the 332 patients with current or prior exposure to recognised sodium channel 
blockers (PHT, CBZ, LTG, OXC). However, the majority of other patients had received 
treatment with sodium valproate, which also has been reported to posses sodium channel 
blocking properties (Loscher, 1999). Inclusion of these patients in the analysis restored 
statistical significance.
These data suggest that the X-encoding allele of the R19K polymorphism in SCN2A is 
associated with non-response to AED treatment and points to a possible link for this SNP to 
the molecular basis of drug resistant epilepsy, at least in some patients. However, analysis of 
predictive value shows only 48% test efficiency (accurate prediction of treatment response by 
genotype) for the presence of the X-encoding allele in predicting non-response to AED 
treatment. Thus, the use of R19K genotype alone was of limited use in predicting treatment 
outcomes in this cohort of patients. In our population, the minor allele had a prevalence of 
7%, which is consistent with previous reports (Haug et al, 2001; Sugawara et al, 2001; 
Nakayama et al, 2002; Weiss et al, 2003). The genotype was not significantly more 
predictive of response in patients exposed to sodium channel blocking drugs than in the study 
population as a whole. It is likely, however, that the influence of the polymorphism on drug
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response is not directly related to pharmacological mechanisms, but arises as a result of 
subtle alterations in neuronal functioning and network properties.
In this regard, the functional significance of the R19K polymorphism remains to be clarified. 
In terms of genetic sequence, it is somewhat removed from the region corresponding to the 
AED binding site on the a-subunit which might explain the lack of a direct association with 
response to sodium channel blocking drugs. The arginine to lysine substitution at this site 
does not appear to influence the electrophysiological properties of the channel when 
expressed in human embryonic kidney cells (Sugawara et al, 2001). Arginine is a relatively 
conserved residue amongst the major CNS sodium channel a-subunit genes SCN1A, SCN2A 
and SCN3A and also in the SCN4A and SCN5A genes expressed by skeletal and cardiac 
muscle, respectively (Haug et al, 2001). Lysine is, however, present in the corresponding 
position in SCN6A and SCN9A, suggesting that significant functional relevance of this 
sequence variant is unlikely. In clinical studies examining the pathogenesis of seizure 
disorders, the ^-encoding allele appears to be a relatively benign variant (Haug et al, 2001; 
Nakayama et al, 2002; Weiss et al, 2003) although it has been suggested to aggravate the 
disease phenotype in patients with generalised febrile and afebrile seizures (Sugawara et al, 
2001).
Pharmacogenetic studies are analogous to genetic association studies of complex diseases 
inasmuch as there is often no simple correlation between genotype and phenotype (Ring and 
Kroetz, 2002). Expression patterns of several genes, gene-gene and gene-environment 
interactions as well as several non-genetic factors such as drug dosing, diet and other aspects 
of lifestyle undoubtedly influence the response to drug treatment. Expression patterns of the 
various sodium channel subtypes are also subject to spatial and temporal variations in
179
response to a variety of stimuli (Bartolomei et al, 1997, Whittaker et al, 2001) and significant 
differences are reported in the relative expression ofNavl.l and Nav1.2 in the various brain 
regions of patients with epilepsy, when compared to normal brains (Lombardo et al 1996). 
The predictive value of any single genetic polymorphism in determining treatment response 
is therefore likely to be modest and the low test efficiency in spite of a statistically significant 
association in our study is not surprising (McCarthy and Hilfiker, 2000). Given the number 
of factors that could potentially influence response to AED treatment, the possibility of an 
association arising by chance is also exists. These results will therefore need to be replicated 
in other patient populations.
2.6. Conclusions
There are no reported studies of a significant association between a known genetic variation 
in a common AED target and the response to treatment in an unselected epilepsy population. 
If these results are replicated in other patient groups with epilepsy, genotyping of the R19K 
polymorphism in SCN2A, along with identification of other genetic variants that correlate 
with treatment response, could help identify patients at risk of developing refractory epilepsy.
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Part IV 
Mortality of epilepsy
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1. Studies of mortality in epilepsy
1.1. Introduction
Epilepsy is an illness o f various shapes and horrible; in the paroxysms, brutish, very acute 
and deadly; for, at times, one paroxysm has proved fatal Aretaeus
The fact that epilepsy could endanger the life of sufferers has been known since ancient times 
(Aretaeus c.100). The traditionally held view of the medical community, however, had been 
that for the majority of patients, epilepsy was a benign disorder with no important effect on 
life expectancy. Gowers observed that ‘the danger to life of patients with epilepsy is not 
great’ (Gowers, 1885). This view changed in the latter half of the 20th century with several 
epidemiological studies reporting consistently increased mortality rates in patients with 
epilepsy. Rodin in his treatise on epilepsy stated “it is quite obvious that the life expectancy 
of the epileptic individual does not reach that of the average person” (Rodin, 1968). Over the 
last 30 years, a number of studies, both community and institution based, have shed light on 
mortality risks in various subgroups of patients with epilepsy (Sander and Bell, 2004).
1.2. Study methodology and interpretation of results
Results from studies of prognosis and mortality in epilepsy differ substantially according to 
the methods used. The major methodological variations are with selection of the patient 
population for the study, case ascertainment, classification of epilepsy and cause of death. 
These differences complicate interpretation and comparison of results from various studies of 
mortality. A recent systematic review of mortality studies in epilepsy in the last 100 years 
found such wide variation in mortality rates that a summary risk could not be calculated 
(Shackleton et al, 2002). Most of this variation could be explained by differences in the 
source population and case selection.
182
1.2.1. Source population
Community based studies provide the most accurate estimate of risks for the population of 
patients with epilepsy as a whole. Longitudinal studies are necessary to achieve this as cross- 
sectional community surveys can miss new onset cases and fail to account for the high initial 
mortality of epilepsy. This can lead to the mortality risk being underestimated. The ideal 
study of prognosis should be large scale, population based, with comprehensive case 
ascertainment, accurate diagnosis, sound aetiological assignment, long follow up and 
efficient tracing of patients (Gaitatzis and Sander, 2004). No study in the current literature 
meets all of these standards but some, notably the Rochester study (Hauser et al, 1980) the 
National General Practice Survey of Epilepsy (NGPSE, Cockrell et al, 1994), the 
Vaserbotten county study in Sweden (Lindsten et al 2000) and the Iceland study (Rafnsson et 
al, 2001) meet many of these criteria. Results from these population-based studies best reflect 
mortality risks for patients with epilepsy in the general population. The excess mortality 
observed in these studies ranges from 40% to 110%.
Cohort studies that follow up patients attending specialist clinics or in resident care can 
provide detailed information about the group under study, but the results may not be relevant 
to other populations of patients with epilepsy. Generally, higher mortality rates have been 
reported from institutions and specialist centre based studies. Institution- and clinic-based 
studies have the advantage of more accurate diagnosis and classification of epilepsy. They 
are, however, liable to selection bias, as they tend to have an overrepresentation of more 
severe cases of epilepsy.
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1.2.2. Case ascertainment
Community based studies present several difficulties in case ascertainment. Many studies 
rely on patients’ primary care health records for recruiting cases of epilepsy. This is prone to 
error as the diagnosis of epilepsy can be wrong in a high proportion of patients in the non­
specialist setting (Smith et al, 1999). Studies utilising primary care health records thus run 
the risk of including patients who do not have epilepsy. In addition, clinical coding often 
does not make the distinction between provoked seizures and true epilepsy in this setting. 
Death certification is notoriously prone to underreporting epilepsy as a causative or 
contributory factor to death (Hauser et al, 1980; Sander and Shorvon, 1987). Studies relying 
on death certificates to identify deaths in patients with epilepsy could therefore miss a 
significant proportion of cases. Moreover, excess risk cannot be accurately quantified as 
these studies employ the presumed prevalence of epilepsy in the community to estimate the 
population at risk. Some population-based studies use long-term AED prescriptions as a 
surrogate marker for the prevalence of epilepsy (Jick et al, 1992; Derby et al, 1996). This 
method has the advantage of not including patients with provoked seizures, but would also 
recruit patients taking long-term AEDs for other indications, and the issue of diagnostic 
inaccuracies remain unresolved.
1.2.3. Recruitment of patients
As with studies of treatment outcomes, the temporal aspects of seizure disorders also have 
important effects on the mortality statistics. When patients presenting with their first ever 
seizure are included the mortality risks are dramatically higher (Loiseau et al, 1999). In the 
NGPSE, the mortality rates in patients seen after their first ever seizure (where the index 
event was also the first event) was higher than for those patients seen after more than 2 
seizures (Lhatoo et al, 2001). A proportion of first ever seizures would be acute symptomatic 
seizures resulting from an neurological insult, a condition known to be associated with high
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mortality in the short and long term (Logroscino et al, 1997; Logroscino et al, 2002). 
Although many of these patients can develop epilepsy, their natural course tends to be 
different from patients presenting with recurrent unprovoked seizures. Thus, including these 
patients would suggest a higher mortality risk in studies of prognosis of epilepsy.
1.2.4. Identifying cause of death
Ascertaining cause of death in epidemiological studies of epilepsy is often not 
straightforward, owing to inconsistencies and inaccuracies in death certification (National 
sentinel audit of death in epilepsy, 2002; Bell et al, 2004). In many cases, cause of death is 
cited without firm pathological evidence, and in other cases all medical conditions the patient 
suffered are listed even when they had not contributed to death. Sudden Unexpected Death in 
Epilepsy (SUDEP) is now recognised as the most common epilepsy-related cause of death 
(Lhatoo and Sander, 2002). This is typically unwitnessed and tends to be underreported on 
death certification. A firm diagnosis of SUDEP requires post mortem and toxicological data, 
which are not often available to epidemiological investigators. If SUDEP is thought likely 
from clinical information, in the absence of comprehensive post mortem data, deaths are 
considered possible or probable SUDEP as proposed by Leetsma and colleagues (Leetsma et 
al, 1997). Respiratory infections, especially aspiration pneumonia, frequently cause death in 
institutionalised patients with epilepsy, who have coexisting neurological deficits (De Toledo 
et al, 2004). Whether seizures contribute to death from respiratory problems can be difficult 
to ascertain in retrospective death certificate based studies.
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1.2.5. Measurement of mortality
Survival of patients is usually measured using the Kaplan Meier or life table method. 
Standardised Mortality Ratio (SMR) is the most commonly used expression of mortality risks 
in epidemiological studies of epilepsy. This is calculated as the ratio between the number of 
deaths observed in the population under study and the number of deaths expected based on 
the age and sex specific mortality rates for the general population. Contribution of each cause 
of death to the mortality of epilepsy is quantified as the Proportional Mortality Rate (PMR). 
In addition, the ratio of observed and expected deaths from each cause can be calculated and 
expressed as the cause-specific SMR.
1.3. Causes of death in epilepsy
Bacon classified the causes of death in epilepsy (excluding secondary causes) as those arising 
from the long continued effects of the disease on the body, deaths after a rapid succession of 
fits, sudden deaths in a fit, accidents due to fits (Bacon, 1868). Currently deaths due to status 
epilepticus (SE), SUDEP, accidents, treatment related deaths and suicide are considered 
epilepsy related deaths (Langan, 2000). Wannamaker reviewed the literature from 1910 to 
1974 and concluded that on average, 47.2% of deaths in patients with epilepsy could be 
attributed to epilepsy (Wannamaker, 1990). These studies were largely institution-based and 
other studies in similar settings have reported epilepsy as the main cause of death in 19-31% 
of cases (White et al, 1972; Iivaninen and Lehtinen, 1979; Klenerman et al, 1993).
Population based studies such as the Rochester study (3% epilepsy related deaths) and 
NGPSE (4% epilepsy related deaths) have found considerably fewer cases where epilepsy 
was the main contributor to death.
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1.3.1. Epilepsy related deaths
SUDEP is the commonest seizure related cause of death in patients with epilepsy with a 
PMR of 1-13 % in community studies and 18-41% in special populations (see part IV, 
section 1.5). SE has an annual incidence of 18-41 per 100,000 in the general population 
(DeLorenzo et al, 1996; Hesdorffer et al, 1998). It can be the first presentation of epilepsy in 
30% cases (Hesdorffer et al, 1998). Approximately one third of cases are acute symptomatic 
and the remaining occur in patients with established epilepsy. The case fatality rate of SE can 
be up to 20% (Logroscino et al, 2002). SE is thought to account for 12.5% of all deaths in 
epilepsy with SMRs ranging from 2.8 to 3.8 depending on the underlying cause (Gaitatzis 
and Sander, 2004). As with other epilepsy related causes of death, this tends to be lower in 
patients in the community compared to institutionalised patients. Accidents account for 1.2 to 
6.5% of deaths among patients with epilepsy in the community. Epilepsy patients are at 
significantly increased risk of having fatal accidents compared to the general population, as 
evidenced by the cause-specific SMR of 2.4 to 5.6 (Nilsson et al, 1997; Shackleton et al, 
2002). Suicide has also been reported to be more common in certain groups of patients with 
epilepsy (Nilsson et al, 1997; Shackleton et al, 1999), although community based studies 
have not demonstrated a significantly elevated risk (Hauser et al, 1980; Cockerell et al,
1994). This is however an important and preventable cause of death in patients with 
uncontrolled epilepsy in whom co-existing depression is common (Nilsson et al, 1997). 
Pneumonia is a frequent cause of death in patients with epilepsy and could be caused by 
aspiration during a seizure. The PMR of respiratory infections is in the region of 25% in 
institutionalised patients (White et al, 1972; Zielinski et al, 1974; Iivaninen and Lehtinen, 
1979; Klenerman et al, 1993) and approximately 5% in community based studies (Hauser et 
al, 1980). Deaths from respiratory infections are more common in elderly patients and in 
infants and children with severe epilepsy and psychomotor retardation (Klenerman et al,
1993; Harvey et al, 1993; Nilsson et al, 1997).
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1.3.2. Deaths form other causes
Deaths that are unrelated to seizures themselves are predominantly caused by underlying 
conditions causing epilepsy. Malignant neoplasia account for 16 to 29 % of deaths in 
community and hospital based case series, 1/4 to 1/3 of which are brain tumours (Hauser et 
al, 1980; Nilsson et al, 1997; Lhatoo et al, 2001). Cerebrovascular disease has a PMR of 14- 
16% in community studies and 5-6% in hospital studies (Hauser et al, 1980; Shackleton et al,
2002). It is thus responsible for proportionately more deaths in epilepsy patients in the 
community than among those attending epilepsy clinics. This in part owing to the fact that 
patients with epilepsy due to cerebrovascular disease generally respond well to treatment, 
and the majority can be successfully managed in the community (Stephen and Brodie, 2000). 
PMR for ischaemic heart disease follows similar trends to that for cerebrovascular disease. 
The majority of deaths from IHD occur in older patients although the Rochester study did 
find increased heart disease mortality in patients under the age of 65 (Annegers et al, 1984). 
Cause specific SMR for IHD range from 1.1 to 1.6 in community based studies (Hauser et al, 
1980; Shackleton et al, 1999; Rafnsson et al, 2001).
1.4. Risk factors for premature death in epilepsy
1.4.1. Age and sex
The risk or premature death in epilepsy varies depending on factors such as age, sex, type of 
epilepsy, coexisting conditions and response to treatment. Previous studies have shown an 
increased SMR in younger patients, with little excess mortality in patients aged over 50 years 
(Hauser et al, 1980; Nilsson et al, 1997; Shackleton et al, 1999). This is owing to a 
combination of the high mortality observed in children with epilepsy and psychomotor 
retardation and the low number of expected deaths in this age group. One population based 
incidence cohort study found excess mortality risk only in males, and not in females
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(Rafnsson et al, 2001). Some other authors have reported excess mortality in males compared 
to females (Hauser et al, 1980; Shackleton et al, 1999); however other studies have not found 
a significant sex difference for mortality risks (Sperling et al, 1999; Lindsten et al, 2000; 
Lhatoo et al, 2001).
1.4.2. Seizure type and epilepsy syndrome
A major difficulty in interpreting differences in mortality among patients with various 
epilepsy types of is the inconsistency of classification of epilepsy in the various studies. The 
currently used clinical classification of epilepsy (Commission, 1989) has not been followed 
in many studies of mortality. Several older studies employ the terms idiopathic and 
cryptogenic interchangeably. Idiopathic epilepsies have been found to have an increased risk 
of mortality in the Rochester study (SMR 1.8; Hauser et al, 1980) as well as the earlier 
reports from the NGPSE (Cockerell et al, 1997). In the most recent report from the NGPSE, 
though, the SMR for IGE was not significantly elevated (1.3; 95% Cl, 0.9-1.9). However, 
most studies have found a consistently elevated mortality risk in patients with symptomatic 
epilepsy (older studies employ the term remote symptomatic epilepsy). SMR in this group of 
patients in population based studies were 2.2 in the Rochester study, 3.3 in the NGPSE and 
3.7 in the Vaserbotten county study in Sweden (Hauser et al 1980; Lhatoo et al 2001; 
Lindsten et al, 2001).
Seizure type is also important in determining the risk of premature death. Patients with 
absence seizures have no excess mortality risks and those with generalised tonic clonic 
seizures appear to have the highest excess risks (Hauser et al, 1980; Lindsten et al, 2001). In 
the Rochester study SMR for myoclonic epilepsy was found to be significantly elevated (4.1) 
but there was no excess mortality in patients with complex partial seizures. The Vaserbotten
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county study however did find higher mortality rates in patients with complex partial seizures 
(SMR 2.1, 95% Cl 1.2-3.6).
1.4.3. Coexisting intellectual / neurologic handicap
The highest SMRs are seen for patients with remote symptomatic epilepsy associated with 
neurological or intellectual deficit. One study reported an SMR of 22 in children with 
neurological deficit compared to those without (Harvey et al, 1993). In the Rochester study 
those with congenital or perinatally acquired neurological or intellectual impairment had the 
highest long-term mortality, resulting in an SMR of 11. As discussed above, this is due to a 
combination of high fatality and the low expected mortality in this age group
1.4.4. Duration of increased risk
The highest excess mortality is seen in the early years after the onset of seizures (Cockrell et 
al, 1994; Olaffson et al, 1998; Lindsten et al, 2000). In the Rochester study, patients who 
responded to treatment, had an SMR of 2 in the first 5 years, but thereafter there was no 
excess risk of mortality (Hauser et al, 1980). In the NGPSE, mortality rates were seen to fall 
to same level as the general population after 4 to 9 years of follow up (Lhatoo et al, 2001). 
Most of the early excess mortality is ascribable to underlying organic brain lesion (Loiseau et 
al, 1999). However, patients who do not achieve seizure control with AED treatment appear 
to remain at high risk of premature death (Gaitatzis and Sander; 2003)
1.4.5. Severity of epilepsy
Control of seizures has been shown to affect mortality in several studies. In a study in 
learning-disabled patients, Strauss and colleagues found the highest mortality risk of in 
patients with a recent history of status epilepticus followed by those who continued to suffer 
generalised seizures and then by those who continued to experience partial seizures. Patients
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who had not suffered recent seizures did not have excess mortality rate compared to control 
subjects without epilepsy (Strauss et al, 2003). Similarly, no increased mortality risk has been 
observed in post surgical patients who become seizure free while those continuing to suffer 
seizures were at high risk of premature death (Sperling et al, 1999).
1.5. SUDEP
1.5.1. Definition
SUDEP is the most common epilepsy-related cause of death in patients with epilepsy. The 
widely accepted definition of SUDEP is ‘ sudden unexpected witnessed or unwitnessed, non 
traumatic and non drowning death in patients with epilepsy, with or without evidence for a 
seizure and excluding documented status epilepticus, in which post mortem examination does 
not reveal a toxicologic or anatomical cause for death ’ (Nashef, 1997). Post mortem 
examination and toxicological data are often not available to epidemiological investigators.
In these circumstances if SUDEP is suspected on clinical grounds, deaths are categorised as 
probable or possible SUDEP (Nashef, 1997; Leetsma et al, 1997).
1.5.2. Incidence of SUDEP
Several studies have attempted to quantify the incidence of SUDEP in patients with epilepsy. 
Some community-based studies use coroners’ records to identify cases of SUDEP and use 
the presumed prevalence of epilepsy in the community as the denominator. The incidence of 
SUDEP in these studies range from lin 525 to 1 in 2100 patient years (Terrence et al, 1975; 
Leestma, 1984; Langan, 1998). The UK National Clinical Sentinel Audit of Epilepsy Related 
Deaths audited 595 deaths in which epilepsy was mentioned on the death certificate and 
found that 60% all epilepsy related deaths were attributable to SUDEP and a further 7% were 
due to possible SUDEP (National sentinel audit on epilepsy death, Report 2002). However, 
the sensitivity of this method in identifying cases of SUDEP is low. A recent study found that
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epilepsy is mentioned in only 25% of death certificates of patients with epilepsy (Bell et al, 
2004). Moreover, as the prevalence of epilepsy in the community is not accurately estimated 
in these studies, they are prone to erroneous quantification of risk. Studies using AED 
prescriptions to estimate the prevalence of epilepsy in the community report incidence of 
SUDEP ranging from lin 452 to 1 in 1850 depending on definition of cases (Jick et al, 1992; 
Derby et al, 1996). Ficker and colleagues evaluated mortality in all patients diagnosed with 
epilepsy in Rochester, Minnesota between 1935 and 1994 and found a SUDEP incidence of 
0.35 per 1000 patient years (Ficker et al, 1998) while a prospective cohort study of newly 
diagnosed epilepsy patients have found incidence of SUDEP to be 1.2 per 1000 patient years 
(Walczak et al, 2001). The NGPSE in the UK has reported the first case of SUDEP after 
8000 patient years of follow up, suggesting that SUDEP is a rare event in newly diagnosed 
epilepsy populations (Lhatoo et al, 1999).
Incidence of SUDEP is higher in patients with more severe epilepsy. Patients with chronic 
epilepsy attending a tertiary referral centre had incidence of 1/200 patient years (Nashef et al,
1995). Studies in institutionalised patients with epilepsy have shown a SUDEP rate of 1/260 
to 1/290 person years (Klenerman et al, 1993; Nashef et al, 1995). Follow up studies of 
patients in epilepsy surgery programmes have shown SUDEP rates between 1/100 and 1/455 
person years (Dasheiff, 1991; Sperling et al, 1999; Hennessey et al, 2001; Nilsson et al,
2003). Most deaths occur in patients whose seizures are inadequately controlled after 
surgery. SUDEP rates are even higher in patients who are evaluated in a surgical programme 
but do not under go operation (Vickery, 1997; Nilsson et al, 2003).
1.5.3. Risk factors for SUDEP
Most witnessed cases of SUDEP occur shortly following a seizure, which is typically 
generalised in nature (Langan et al, 2000). The majority of SUDEP deaths however are
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unwitnessed (Nashef, 1998). Most patients are found in their beds having died in their sleep, 
but many have features suggestive of the occurrence of a seizure (Langan, 1998). Thus, 
available evidence suggests that SUDEP is a seizure related event. Higher sudden death rates 
have been observed in patients with intractable epilepsy (Langan, 2000 b). Patients are 
generally young with the mean age at death between 20 and 40 in most series (Leestma et al, 
1989; Timmings et al, 1993; Nashef et al, 1995). Most studies have found a higher risk in 
males (Leestma et al, 1989; Lip and Brodie 1992; Timmings et al, 1993) although other 
authors have not found a significant difference in risk between the sexes (Nashef et al, 1995; 
Ficker et al, 1998). SUDEP occurred more commonly among patients with localisation 
related epilepsy than among those with idiopathic generalised epilepsy in most series 
(Annegers et al, 1984; Nashef et al, 1998). One study found the highest incidence of SUDEP 
in males with idiopathic generalised epilepsy (Nilsson et al, 1999). This study also identified 
polytherapy and frequent dosage changes as risk factors for sudden death.
1.5.4. Mechanisms underlying SUDEP
The mechanisms underlying SUDEP have not been fully elucidated. Pulmonary oedema, 
congestion of liver and cardiac enlargement have consistently been observed at post mortem 
examination in cases of SUDEP (Earnest et al, 1992; Stollberger and Finsterer, 2004). The 
degree of pulmonary oedema is however not sufficient to cause death on its own. Suggested 
mechanisms of SUDEP include cardiac arrhythmia due to myocardial damage, autonomic 
imbalance, hypoxia, arrhythmogenic effect of AEDs and central or obstructive apnoea 
(Nashef et al, 1996; Natelson et al, 1998; Hilz et al, 2002; Lathers and Schraeder, 2002). 
Disturbance of cardiac rhythm has been extensively investigated as a possible mechanism 
involved SUDEP (Tavemor et al, 1996; Nei et al, 2004). Interstitial myocardial fibrosis, 
focal leucocytic infiltration and abnormalities of the cardiac conducting system have been 
found in SUDEP victims at autopsy (Stollberger and Finsterer 2004). Localisation related
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(especially temporal lobe) seizures are commonly associated with tachycardia and 
tachyarrhythmias (Blumhardt et al, 1986; Di Gennaro et al, 2004). Ictal bradycardia has been 
reported by several authors, occurring either as a primary event (Rocamora et al, 2003; 
Devinsky et al, 1997) or in relation to ictal apnoea (Nashef et al, 1996; So et al, 2000). There 
is evidence for deranged regulation of cardiovascular reflexes in patients with temporal lobe 
epilepsy with or without hippocampal sclerosis (Ansakorpi et al, 2004; Mayer et al, 2004). 
Reduced heart rate variability has been reported in patients with temporal lobe epilepsy and 
could be a marker of disturbed autonomic control (Tomson et al, 1998; Ansakorpi et al,
2002; Ferri et al, 2002). Seizure associated apnoea is another important potential mechanism 
of SUDEP. Cases of SUDEP occurring in patients undergoing video EEG monitoring suggest 
that respiratory compromise rather than cardiac causes maybe the mechanism underlying 
SUDEP (Bird et al, 1996; So et al, 2000). Central respiratory depression owing to ictal 
activity, post ictal hypotonia of the muscles of respiration and reduction in tidal volume in 
the prone position can all cause respiratory compromise.
1.5.5. Antiepileptic drugs and risk of SUDEP
Some reports suggest an increased risk of SUDEP in patients taking carbamazepine 
(Timmings et al, 1993), but other investigators have not found such an association (Leestma 
et al, 1997; Nilsson et al, 1999). The possible effect of AEDs such as phenytoin and 
carbamazepine on cardiac conduction is also important in this regard (Walczak, 2003). There 
is conflicting data regarding AED serum levels and SUDEP risk. Some studies have found 
low serum and hair levels in SUDEP cases (Terrence et al, 1975; Leestma et al, 1989; George 
and Davies 1998), and poor adherence to prescription is considered a risk factor for SUDEP. 
It has been suggested that abrupt withdrawal of AEDs can increase the autonomic 
dysfunction causing cardiac arrhythmias (Kenneback et al, 1997, Hennessey et al, 2001). 
Other studies, however, have failed to find an association between lower serum levels and
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SUDEP (Opeskin et al, 1999; Walczak et al, 2001). Nilsson and colleagues reported 
polytherapy, frequent dose changes and high carbamazepine concentrations to be more 
common in patients dying of SUDEP than controls (Nilsson et al, 2001). This could however 
merely be indicative of the severity of the epilepsy than a causative role for AEDs in 
SUDEP. To date there is no clear evidence to implicate any specific AED in SUDEP.
1.6. Summary
While patients diagnosed with epilepsy clearly have a higher mortality risk compared to the 
general population, this is not uniform in all patients. Several demographic factors as well as 
the type, underlying aetiology and severity of epilepsy all affect the prognosis for life.
SUDEP is the most frequent epilepsy related cause of death. Individuals with uncontrolled 
epilepsy are at highest risk of SUDEP, especially those with co existing intellectual deficits 
and those who have failed evaluation for epilepsy surgery. Population based longitudinal 
studies can provide the most realistic picture of risks in the epilepsy patients living in the 
community. Such data are important from the public health perspective and can inform health 
service planning. Cohort studies in representative patient group will provide the most 
accurate assessment of risks to help counsel patients with epilepsy.
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2. Comparison of mortality in adults with newly diagnosed and chronic epilepsy
2.1. Prognosis for life
It is generally accepted that patients with epilepsy are at higher risk of premature death 
compared to the general population. Whether mortality risks should be discussed with 
patients routinely, however, is a matter of debate (Beran et al, 2004). Physicians have a 
responsibility to discuss fully and frankly the material risks associated with any medical 
condition and /or treatment. Material risk in this context is considered one that the doctor 
knows, or should know, that the individual patient willl rate as significant (Beran et al, 2004). 
While it is clear that the risk of premature death, especially SUDEP, is increased manifold in 
certain subgroups of patients with epilepsy, the overall! risk for patients with epilepsy in the 
community probably remains small (Part IV, section L5.4). Routinely discussing mortality 
issues with patients at the time of the first specialist consultation could cause undue alarm 
and impede the return to independent and productive life, which is the goal of treatment for 
most patients with epilepsy. Clinicians have to balance this consideration against the need for 
patients and their relatives to be provided information on risks. Studies that help to quantify 
risks in specific groups of patients and identify clinical! and demographic characteristics of 
those at particularly high risk of premature death could help in this process.
Data from community-based studies is of limited use to clinicians in counselling patients in 
specific settings. Cohort studies in representative patient groups provide more relevant data 
to help assess risks in individual patients. High death rates are seen in the early years after 
diagnosis of epilepsy, most of which is attributable to tlhe underlying condition causing 
epilepsy. Much of the late mortality in epilepsy is seen in patients who do not achieve seizure 
control with AED treatment (Part IV section 1.4.5). Thus, different factors operate in 
determining the prognosis for life in patients with newly diagnosed and chronic epilepsy.
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Several studies have shown that the prognosis for seizure control is considerably worse in 
patients failing their first AED compared to treatment naive patients (Part II, section 1.4). 
Therefore, any discussion of mortality risks with patients should take the prognosis for 
seizure control into consideration. For this reason, patients with newly diagnosed and chronic 
epilepsy need to be treated separately in studies of mortality. We analysed mortality data in 
cohorts of patients with newly diagnosed and chronic epilepsy attending the Epilepsy Unit, 
Western Infirmary, Glasgow, Scotland to quantify the risk of premature death in the two 
patient groups.
2.2. Methods
2.2.1. Newly diagnosed cohort
This group consisted of 890 patients diagnosed with epilepsy after presenting with seizures 
between August 1981 and May 2001 (Part II, Section 1.2.3). There were 465 (52%) males 
and 425 females (Table 27). The median age at onset of seizures was 29 (range 1 to 93) years 
and at diagnosis of epilepsy was 31 years (range 9 to 93). Epilepsy was classified as 
localisation related in 625 (70%) patients of which 268 (30%) had identifiable cerebral 
lesions on imaging investigations and were categorised as symptomatic epilepsy. Of the 
remaining patients 117 (13%) had idiopathic generalised epilepsy and in 148 (17%), epilepsy 
could not be classified. Learning disabilities were present in 30 patients, 25 of whom was 
classified as mild. The mean follow up period of survivors was 92 months and the total 
follow up for the cohort was 6480 person years.
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2.2.2. Chronic epilepsy cohort
This cohort consisted of patients previously diagnosed with epilepsy and treated with AEDs 
who were referred to the Epilepsy Clinic because of inadequate control of seizures. A total of 
2689 patients who had been treated unsuccessfully with between one and nine AEDs were 
seen over the study period. This included 1276 (47%) males and 1413 females with a median 
age of 33 years (range 11 to 90) at the first clinic visit (Table 27). The median age at onset of 
epilepsy was 17 years (range 0 to 87 years). Epilepsy was classified as localisation related in 
1683 (63%) and idiopathic generalised in 218 (8%) patients. In 785 (29%) patients epilepsy 
was unclassified. Underlying structural abnormalities could be identified in 723 (27%) 
patients with localisation related epilepsy who were designated as symptomatic epilepsy. 
Survivors in this cohort had a mean follow up of 108 months, with a total follow up of 22931 
person years for the whole cohort.
2.2.3. Data collection
The study was granted approval by the West Ethics Committee of the Greater Glasgow 
Health Board. Clinical details and demographic information of all patients attending the 
Epilepsy Unit are maintained on an electronic database. The patient list was matched against 
the death database at the General Register Office for Scotland, Edinburgh. Death certificate 
copies were obtained for patients whose demographic information matched. Deaths were also 
reported by patients’ General Practitioners (GP) and carers. In these cases, cause of death 
was ascertained from the GP or the health authority (Greater Glasgow Health Board) records. 
Both cohorts were followed up until death or censored on 1st of October 2003.
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2.3. Analysis
2.3.1. Survival
Comparison was made with an age and sex matched cohort constructed from the UK 
Government Actuary Departments’ Interim Life Tables (http://www.gad.gov.uk/Life_Tables/ 
Historical_Interim_life_tables.htm) to reflect the expected mortality in the Scottish 
population over the study period. Kaplan-Meier survival curves were plotted separately for 
each of the epilepsy cohorts and controls. Patients were categorised into 10 year age bands 
from 20 and under to 70 and over. The number of expected deaths was calculated by 
summing individual expected mortality over study period. Observed and expected deaths 
were compared using a %2 statistic on 1 degree of freedom. Standardised Mortality Ratios 
(SMRs) were calculated as the ratio of observed to expected deaths, for all patients and 
separately for each age category and epilepsy type. Confidence intervals (95% Cl) for SMR 
were derived from the confidence interval for the binomial proportion of observed deaths, 
regarding the expected deaths as a known constant.
2.3.2. Cause of death
Causes of death were categorised as malignant neoplasia, ischaemic heart disease, 
cerebrovascular disease, respiratory diseases, accidents, intentional self-harm and ‘other 
causes’, to calculate proportional mortality rates. Expected proportion of deaths from each 
cause was calculated for males and females separately in each age band based on the General 
Registrar Office for Scotland mortality statistics (GROS Vital Events Reference Tables, 
Table 6.2. Death rates by sex, age and cause, 2001). Observed and expected deaths were 
compared using a x2 statistic on 1 degree of freedom. Cause-specific SMRs and 95% Cl s 
were calculated as described in section 2.3.1.
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2.3.3. Cox proportional hazards model
Cox proportional hazards models of time to death were constructed to analyse the effect of 
age, sex and type of epilepsy on survival in both the newly diagnosed and chronic epilepsy 
cohorts. Age was used as a categorical variable in 5-year bands. Univariate and multivariate 
models were analysed.
2.4. Results
2.4.1. Survival of patients
There were 93 deaths (56 male, 37 female) in the cohort of 890 patients with newly 
diagnosed epilepsy (crude death rate 10.4%). This was significantly higher than the 66 deaths 
expected based on the mortality data for age and sex matched Scottish population (x2=10.5; 
p=0.0007). The overall ratio of observed to expected number of deaths was 1.41 (95% Cl
1.15 -  1.74). The Kaplan Meier survival curves for patients and age and sex matched 
controls (Figure 19) shows that the excess mortality is largely in the early years after 
diagnosis of epilepsy.
In the cohort of patients with chronic epilepsy (n= 2689) there were 316 deaths (193 male, 
123 female) during the study period resulting in a crude death rate of 11.8%. The expected 
number of deaths based on the age and sex matched controls cohort was 155, which was 
significantly lower than the observed number of deaths (Xz=167; pO.OOOl). The overall ratio 
of observed to expected number of deaths for this cohort was 2.04 (95% Cl 1.82-2.27). 
Kaplan-Meier survival curve for patients with chronic epilepsy and age and sex matched 
controls are shown in Figure 20.
201
Pr
op
or
tio
n 
su
rv
iv
in
g
cx
_G
_ O
—  00
— vo .si
_ <N
0
1T3
£o
co
cd
d)
o » n o « n oo O n 0 0 o o
© © © ©
CXJJ
•au
T3
d>
C/3Oa
.2
£
G
-G
G
.2
3
cx
.G
>
'E !
aIfH
o
.o
’E h
t-i
.2‘3
§
On
d>
t-i
Gbp
Eh
20
2

2.4.2. Mortality by type of epilepsy
In the newly diagnosed cohort, Kaplan Meier analysis by type of epilepsy shows 
significantly reduced survival for patients with symptomatic epilepsy compared to those with 
other types of epilepsy (pO.OOl; Figure 21). Comparison with expected number of deaths 
revealed SMR of 3.14 (95% Cl 0.86-7.81; p=0.016) for idiopathic generalised epilepsy, 1.12 
(95% Cl 0.68-1.56; p=0.60) for cryptogenic epilepsy, 1.96 (95% Cl 1.15-3.32; p=0.018) for 
unclassified epilepsy and 1.44 (95% Cl 1.10-1.78; p=0.007) for symptomatic epilepsy 
(Figure 22).
In the chronic epilepsy cohort, Kaplan Meier analysis showed a significantly decreased 
survival for patients with cryptogenic, symptomatic and unclassified epilepsy, but not for 
those with idiopathic generalised epilepsy (pO.OOl; Figure 23). SMR for idiopathic
It
j generalised epilepsy was 1.21 (95% Cl 0.25-3.48; p=0.74), for cryptogenic epilepsy was 2.25
(95% Cl 1.85-2.66; p<0.0001), for unclassified epilepsy was 2.23 (95% Cl 1.87-2.58, 
pO.OOOl) and for symptomatic epilepsy was 1.67 (95% Cl 1.32-2.21 p<0.0001; Figure 24).
There were important differences in the age of onset of the different types of epilepsy which 
would contribute to differences in survival. In both cohorts, patients with symptomatic 
epilepsy were older at diagnosis that those with cryptogenic or unclassified epilepsy who in 
turn were older than those with idiopathic generalised epilepsy (Table 28 and 29). Thus 
patients with symptomatic epilepsy could be expected to have reduced survival on account of 
being older. In the chronic epilepsy cohort, however, there was a significant difference in 
mortality only for idiopathic generalised epilepsy, with all other types showing higher 
mortality rates.
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Table 28. Age at diagnosis by type of epilepsy in patients with newly diagnosed epilepsy
n (%) Male (%) Mean age (SD) Range
Idiopathic Generalised 117(13%) 55 (47%) 21 (9.2) 9.2 to 71.2
Cryptogenic 357 (40%) 156 (44%) 35 (17.2) 11.2 to 82.8
Symptomatic 268 (30%) 169 (63%) 48 (21.1) 13.2 to 93.0
Unclassified 148 (17%) 85 (57%) 32(15.5) 12.3 to 80.0
Total 890 465 (52%) 36(19.4) 9.2 to 93.0
Table 29. Age at diagnosis by type of epilepsy in patients with chronic epilepsy
n (% ) Male (%) Mean age (SD) Range
Idiopathic Generalised 218 (8%) 85 (39%) 24 (9.9) 12 to 73
Cryptogenic 963 (36%) 408 (42%) 35 (14.7) 11 to 85
Symptomatic 723 (27%) 382 (53%) 41 (16.5) 11 to 90
Unclassified 785(29%) 401 (29%) 36 (14.7) 12 to 88
Total 2689 1276 (47%) 36(15.5) 11 to 90
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2.4.3. Mortality by sex and age at diagnosis
There were 56 deaths among the 465 males with newly diagnosed epilepsy (expected 42.2, 
SMR 1.33; 95% Cl 1.00-1.65). The female cohort (n=425) had 37 deaths (expected 23.3; 
SMR 1.59; 95% Cl 1.10— 2.07). Thus, there was no significant difference in mortality 
between the sexes (%2 2.64, p=0.104) and gender did not appear to have a significant 
influence on survival in this cohort of patients (see Cox model, Part 4, section 2.4.7). In the 
newly diagnosed cohort, the highest excess mortality was seen in patients in the 31 to 40 year 
age group (Figure 25). Mortality risks in younger patients were generally higher in 
comparison to the control population, whereas patients aged over 60 years at diagnosis did 
not appear to have a significant excess mortality risk.
In the chronic epilepsy cohort, there were 193 deaths among the 1276 males (expected 91, 
SMR 2.11, 95% Cl 2.11-2.39, p<0.0001). Among the 1413 female patients in this cohort, 
there were 123 deaths (expected 63, SMR 1.95, 95% Cl 1.62-2.28, p<0.0001). Thus, there 
was a significant excess mortality in both sexes, but this was more pronounced in males 
(X2=26.6, p<0.0001) and gender had a significant effect on survival in patients with chronic 
epilepsy (See Part IV, section 2.4.7). The highest excess mortality risk was seen for youngest 
patients (Figure 26). SMR fell with rising age and those over the age of 60 had no elevated 
mortality risk compared to age and sex matched controls.
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2.4.4. Mortality by age and type of epilepsy
SMRs were calculated for cryptogenic, unclassified and symptomatic epilepsies based on age 
at diagnosis. Idiopathic epilepsy was not subject to this analysis as very few patients in either 
cohort were diagnosed after the 3rd decade of life. The highest excess mortality was seen for 
patients diagnosed with symptomatic epilepsy below the age of 40 years, and those with 
unclassified epilepsy diagnosed under the age of 50 (Table 30). In the chronic epilepsy 
cohort the youngest age categories had the highest SMRs across all epilepsy types (Table 
31).
2.4.5. Mortality risks and response to treatment
Patients with newly diagnosed epilepsy were evaluated for mortality risks based on response 
to treatment. Of the 890 patients in this group 462 achieved seizure freedom and 318 failed to 
do so. Response to treatment was not known for the remaining 110. Amongst those who 
failed to respond to treatment (n=318), there were 42 deaths while only 16.5 deaths could be 
expected based on population statistics (SMR 2.54, 95% Cl 1.84 -3.44). Among patients 
entering remission with AED treatment (n=462), there were 41 deaths with 43.1 expected 
(SMR 0.95, 95% Cl 0.68 - 1.29). Among patients whose response to treatment was not 
known (n=l 10) there were 5.9 deaths expected and 10 observed (SMR 1.69, 95% Cl 0.81 - 
3.12). Thus, almost all of the excess mortality was observed in patients who did not achieve 
seizure freedom on treatment. Furthermore, the excess mortality in this group of patients was 
similar to that seen in the chronic epilepsy cohort, suggesting that only patients who fail to 
respond to treatment are subject to higher risks.
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2.4.6. Cause of death
The proportion of deaths from each cause in the newly diagnosed population is shown in 
Figure 27. Cause specific SMR was particularly high for respiratory disorders, with 18 deaths 
occurring where only 7 could be expected based on population mortality statistics (Figure 
28). Of these, 14 patients died of pneumonia. There were no extra deaths from cardiovascular 
and cerebrovascular disorders when the two groups were analysed separately, but when 
combined as deaths from vascular disease, there were significantly more deaths than 
expected. The proportion of deaths from malignancies were lower than expected, but not 
significantly so (13 deaths observed, 17.3 expected, p=0.24). Deaths from accidents and 
intentional self-harm were also higher than expected, but as the expected numbers of deaths 
were less than 5 in each case, the two categories were combined for x2 analysis. Statistical 
significance was maintained in the combined analysis. There were 7 cases of probable 
SUDEP in this cohort, resulting in an incidence of 1.08 per 1000 patient years (1 per 926 
patient years). The median age of patients dying of SUDEP was 28 (range 18-31) years. 
SUDEP occurred after a median of 73 months (range 10 to 146) after diagnosis of epilepsy. 
There were 2 males and 5 females in this group, one had idiopathic generalised epilepsy, and 
2 patients each had post traumatic, cryptogenic and unclassified epilepsy.
Proportion of deaths from each cause in the chronic epilepsy cohort is shown in Figure 29 
SMRs were elevated for all causes of death although this did not reach statistical significance 
for deaths from cancer and ischaemic heart disease (Figure 30). The greatest excess 
mortality was from respiratory disorders, cerebrovascular disease and accidents and deaths 
from other causes. There were 55 cases of probable SUDEP and a further 18 cases of deaths 
from status epilepticus in this cohort. The incidence of SUDEP was significantly higher 
among patients with chronic epilepsy than those with newly diagnosed epilepsy (x2 13.02,
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pO.OOOl). In this cohort of patients the incidence was 2.4 per 1000 patient years (1 per 417 
patient years). The median age at SUDEP was 35 years (range 17-81). SUDEP occurred after 
a median of 255 months (range 5 to 738) after diagnosis of epilepsy. Of the patients dying of 
SUDEP, 33 (60%) were male. Only 1 patient had idiopathic generalised epilepsy; 8 had 
symptomatic, 18 cryptogenic and 28 unclassified epilepsy.
Respiratory disorders are not generally classed among seizure related causes of death. 
However, aspiration pneumonia is a frequent cause of death in institutionalised patients, 
especially those with co existing intellectual impairment (White et al, 1972; Zielinski et al, 
1974; Iivaninen and Lehtinen, 1979; Klenerman et al, 1993). The high PMR for deaths from 
respiratory disorders seen in both newly diagnosed and chronic epilepsy cohort would 
suggest that this is an important cause of death in patients in the community as well. Deaths 
from SUDEP, SE, accidents, suicide and treatment related deaths are conventionally classed 
as epilepsy related in epidemiological studies. Treatment related deaths in this regard 
includes deaths directly attributable to adverse effects of AEDs (eg: Steven Johnsons 
syndrome), those caused by deleterious drug interactions (eg: Carbamazepine and Warfarin) 
and those occurring as a direct consequence of surgical treatments for epilepsy (temporal 
lobectomy, implantation of VNS). Epilepsy related causes of deaths were significantly more 
common in patients with chronic epilepsy than in those with newly diagnosed epilepsy {yl =
11.7; p=0.0001). Similarly deaths due to SUDEP were also more common in the chronic 
epilepsy cohort (/2=7.2; p=0.006).
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2.4.7. Cause of death by age
Expected and observed numbers of deaths from each cause was analysed separately for 
patients aged less than and over the age of 60, using the %2 test. In the newly diagnosed 
cohort overall numbers of deaths were significantly higher than expected in patients aged less 
than 60 years at diagnosis but not in older patients (Table 32). Important differences were 
observed in the incidence of cancer related deaths with significant excess mortality in 
patients over the age of 60, but not in younger patients. Deaths from intentional self-harm 
and accidents were higher in the younger age group but not in patients over the age of 60, 
although this result should be interpreted with caution as the numbers were small. Similarly, 
deaths from cerebrovascular disease and ischaemic heart disease showed significant excess in 
the younger age group when analysed as a combined group of deaths from vascular disease.
In the chronic epilepsy cohort, as in the newly diagnosed cohort, overall numbers of deaths 
were significantly more than expected only in the younger age group, not in those aged over 
60 years at diagnosis. Patients aged less than 60 years had excess mortality in all categories, 
but in older patients only deaths from respiratory disorders and cerebrovascular disease were 
in excess of the expected number of deaths. Deaths from ‘other’ causes was higher in the 
older age group, most of which were from cancer (n=31) respiratory infections (n=24) 
ischaemic heart disease (n=19) and cerebrovascular disease (n=18).
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Table 32. Cause o f death by age in newly diagnosed epilepsy
< 60 years old > 60 years old
Obs Exp X2 p-value Obs Exp X2 p-value
Cancer 8 5.48 0.28 5 13.02 0.026
IHD 8 2.79
0.0058
12 10.82 0.72
CVD 1 0.90 10 5.84 0.086
Respiratory 4 1.03 0.0035 14 6.03 0.0012
Accidents 8 1.11
<0.0001
1 0.71
0.82ISH 3 1.04 0 0.09
Other 16 5.49 <0.0001 3 11.16 0.015
Total 48 17.85 <0.0001 45 47.69 0.70
Table 33. Cause of death by age in chronic epilepsy
< 60 years old > 60 years old
Obs Exp X2 p-value Obs Exp X2 p-value
Cancer 42 22.14 <0.0001 24 24.92 0.85
IHD 25 10.80 <0.0001 14 18.74 0.27
CVD 20 3.52 <0.0001 18 9.41 0.0051
Respiratory 24 3.85 <0.0001 24 9.80 <0.0001
Accidents 13 4.08 <0.0001 1 1.23 0.71
ISH 9 4.11 0.016 0 0.23
Other 94 22.40 <0.0001 8 19.28 0.010
Total 227 70.90 <0.0001 89 83.6 0.55
Obs -  Observed Exp - Expected
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2.4.8. Factors affecting survival after diagnosis of epilepsy
Cox proportional hazards models of time to death were constructed to analyse the effect of 
age at diagnosis, sex and type of epilepsy on survival. Increasing age at diagnosis and 
symptomatic epilepsy was associated with reduced survival in the univariate analysis, while 
patients’ gender showed no effect on survival. However, in the multivariate model, only 
increasing age at diagnosis remained independently predictive of reduced survival (Table 
34).
In patients with chronic epilepsy cohort, increasing age was significantly showed significant 
univariate association with reduced survival, while female sex and idiopathic generalised 
were associated with improved survival. These factors remained independently predictive in 
the multivariate model (Table 35). Unlike with the newly diagnosed cohort, symptomatic 
epilepsy was not associated with reduced survival in this cohort. This probably indicates the 
differences in the underlying aetiology in patients with symptomatic epilepsy among patients 
with newly diagnosed and chronic epilepsy.
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2.5. Discussion
Examining mortality of epilepsy separately in patients with newly diagnosed and chronic 
epilepsy provides instructive insights into the risks in these two disparate groups of patients 
with very different outlooks in terms of seizure control and prognosis. Such data enable risks 
in individual patients to be placed in perspective and aid counselling during specialist 
consultation. This study analysed mortality risks in patients with newly diagnosed epilepsy 
and those referred following unsuccessful trial of at least one antiepileptic drug at a single 
centre.
Overall mortality shows an increase of approximately 40% in the newly diagnosed epilepsy 
patients compared to an age and sex matched Scottish cohort. When 10-year age bands were 
examined separately, the highest mortality was seen for younger patients, rising to a peak 
SMR of 8.0 in the 31-40 year age group. Analysis based on type of epilepsy showed 
significantly higher number of deaths than expected among patients with symptomatic and 
unclassified epilepsy, but not among those with idiopathic or cryptogenic epilepsy. The most 
marked excess mortality was seen for patients diagnosed with symptomatic epilepsy under 
the age of 40 (SMR 8.64). Overall, there were 54 deaths among patients with newly 
diagnosed symptomatic epilepsy, where only 38 were expected. The leading causes of death 
in this group of patients were malignancy including brain tumours (n=9), cerebrovascular 
disease (n=8) and ischaemic heart disease (n=7). In this cohort, 73 patients had epilepsy due 
to cerebrovascular disease, and it is therefore not surprising from vascular disorders such as 
strokes and myocardial infarctions were a leading cause of death in this group. This death 
rate was significantly higher than expected only in younger patients, who would generally 
not be expected to develop vascular disease. There was no excess mortality from this cause in
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patients aged over 60 at diagnosis. Thus the mortality of newly diagnosed epilepsy largely 
reflects the natural history of the underlying condition causing seizures.
Survival was worse in the chronic epilepsy cohort with over double the expected number of 
deaths occurring as could be expected. The highest SMR were seen for the youngest patients 
with no excess mortality in those aged over 60. Significantly reduced survival was seen for 
symptomatic, cryptogenic and unclassified epilepsy but not for those with idiopathic 
generalised epilepsy. This is possibly due to the better prognosis for seizure control in this 
type of epilepsy with appropriate AED treatment. Many patients with idiopathic generalised 
epilepsy remain uncontrolled because of treatment with inappropriate antiepileptic drugs 
(Benbadis et al, 2003). Once they come to specialist attention and drug therapy is 
rationalised, seizure control can be achieved relatively easily.
When cause of death was analysed for newly diagnosed patients, greatest number of excess 
deaths were seen for respiratory disorders (including inhalation pneumonia), accidents, 
intentional self-harm and deaths from vascular disease (cerebrovascular and ischaemic heart 
disease). These effects were seen equally for males and females. The majority of excess 
mortality was seen in patients aged less than 60 years at diagnosis. There was no significant 
increase in mortality risk for older patients. In patients with chronic epilepsy, the cause 
specific SMRs were elevated for all causes of death, chiefly in patients age less than 60 years 
at diagnosis.
Of the 316 deaths in this cohort, 55 were considered to be due to SUDEP, and a further 17 
occurred in relation to status epilepticus. The incidence of SUDEP was significantly more 
likely in patients with chronic epilepsy compared to those with newly diagnosed epilepsy.
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The overall incidence of SUDEP in this analysis was 1.08 per 1000 patient years in the newly 
diagnosed patients. As discussed in part IV, section 1.5.2. the incidence of SUDEP in the 
Rochester study was 0.35 per 1000 patient years, while a prospective study in newly 
diagnosed patients reported SUDEP incidence of 1.2 per 1000 patient years (Ficker et al, 
1998; Walczak et al, 2001). The NGPSE reported its first case of SUDEP after 8000 patient 
years of follow up, suggesting that SUDEP was a rare event in newly diagnosed patients 
(Lhatoo et al, 1999). In patients with chronic epilepsy, however, SUDEP rate was 2.4 per 
1000 patient years. SUDEP rates ranging from 3 to 10 per 1000 patient years have been 
reported in institutionalised patients, those attending specialist clinics with uncontrolled 
epilepsy, and those in surgical programmes (See part IV, section 1.5.2.) The population with 
chronic epilepsy in this study had a mixture of varying severity of epilepsy, intellectual 
impairment and other risk factors. The rate of SUDEP is significantly higher in this 
population than in the newly diagnosed cohort.
Cox model analysis showed patients with symptomatic epilepsy and those with increasing 
age at diagnosis had significantly shortened survival compared to those with other types of 
epilepsy. In patients with chronic epilepsy, increasing age at diagnosis was associated with 
shortened survival, while female sex and idiopathic generalised epilepsy were associated 
with improved survival. Increased mortality in males with epilepsy has been reported by 
other authors (Rafnsson et al, 2001). A clear explanation for this observation is not 
forthcoming, but is possibly related more to lifestyle factors than biological ones. Most of the 
deaths in newly diagnosed epilepsy occurs in the early years after diagnosis and reflects the 
natural course of the underlying cerebral pathology. The association of symptomatic epilepsy 
with reduced survival observed in newly diagnosed patients but not in those with chronic
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epilepsy probably reflects the variations in underlying aetiology of epilepsy in the two 
groups, and the differences in their natural course and outlook.
2.6. Conclusions
There is an approximately 40% increase of mortality in patients with newly diagnosed 
epilepsy, most of which is seen in younger patients with symptomatic epilepsy. No 
significant excess mortality was seen in patients with other types of epilepsy or those aged 
over 60 years at diagnosis. However, in those who fail treatment with at least one AED, 
mortality risks are significantly higher. This is most marked in younger patients and for all 
epilepsy types except idiopathic generalised epilepsy. The data confirms that SUDEP is a 
rare event in patients with newly diagnosed epilepsy. However, in patients who fail to 
achieve seizure control, this is significantly more likely. These factors should be taken into 
consideration while counselling patients with epilepsy.
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General discussion
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Being diagnosed with epilepsy can be a devastating event for patients. It not only has 
significant health consequences, but social and economic implications too. For the majority 
of adults, the onset of epilepsy leads to several lifestyle restrictions (Gilliam et al, 1997). The 
unpredictable and uncontrollable nature of epileptic seizures engenders a sense of loss of 
control in the sufferer. Certain elements of seizures such as incontinence can also be a source 
of embarrassment, which often leads to restricted social activity and isolation. Loss of 
driving privileges is probably the most frequent cause for concern for adult patients and can 
have a significant impact of quality of life for patients in the developed world. Furthermore, 
for those employed in potentially hazardous occupations, such as operating machinery or 
working at heights, being diagnosed with epilepsy results in loss of employment and 
livelihood. Regaining these requires the complete and sustained control of seizures. Hence, 
for a patient diagnosed with epilepsy, the most important question is “how likely are the 
seizures to stop?” Knowing the likely outcome of treatment also helps patients cope with the 
emotional strain of being diagnosed with a chronic disorder. It could be said that as far as the 
patient is concerned, the prognosis is probably more important than the diagnosis in this 
situation. Prognosis for seizure control should therefore be an integral part of the discussion 
between clinician and patient at the time of making the diagnosis of epilepsy.
Epilepsies are a heterogeneous group of disorders with varying underlying pathology, much 
of which is not clearly understood (Part I, section 1). An ever-increasing number of epilepsy 
syndromes are being recognised, thanks to progress in molecular biology and cerebral 
imaging technology. Our understanding of the natural history of these syndromes however 
has lagged behind the insights gained into their underlying pathophysiology. A discussion of 
the prognosis of epilepsy syndromes requires knowledge of the natural history of the 
condition. Epidemiological studies examining the course of the disorder over an extended
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period of time are required to fully appreciate the long-term behaviour of any chronic 
condition. In addition to demographic and clinical factors, genetic variations among 
individuals could also play an important part in determining outcome of antiepileptic drug 
(AED) treatment, and should also be taken into consideration in any study of prognosis. The 
overall objective of this thesis was to utilise an existing database of epilepsy patients to study 
the natural history of treated epilepsy in adult and adolescent patients, both in terms of 
seizure control and of survival. It is hoped that the observations from these studies will 
inform and guide clinicians in discussing the prognosis of epilepsy with patients.
Patterns of response to treatment
The clinical studies in newly diagnosed epilepsies reveal some interesting aspects of the 
course of treated epilepsy. Response to treatment was usually obvious in the first few years 
after starting treatment. The majority of patients responding to treatment did so immediately, 
with 50% of all patients entering remission doing so by the end of the first year on treatment. 
These immediate responders constituted one third of all patients. Those who failed to enter 
remission within 3 years of starting treatment had very little chance of achieving remission. 
Over 90% of responders were taking their first or second AED regime. Of those failing two 
well-tolerated regimes, less than 10% achieved seizure freedom with further 
pharmacotherapy. The dose of AEDs resulting in treatment response was modest in most 
cases. Combination treatment with two or more AEDs resulted in seizure freedom only in a 
small number of patients. The majority of patients responding to treatment remained seizure 
free till the end of follow up and were considered to be in remission, while approximately 
10% relapsed and developed uncontrolled epilepsy.
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Thus, we observed four major categories of response to AED treatment (Figure 31). The 
first category, constituting approximately one third of patients, responded rapidly and 
completely to treatment with the first AED. A smaller proportion entered remission with 
the subsequent treatment attempts, including combination treatment. Approximately 10% 
of responders later developed uncontrolled epilepsy and were classified as relapse. The 
remaining one third of patients never gained complete control of seizures is spite of 
several changes to AED regime. In the majority of cases, these groups can be reliably 
identified in the first few years of treatment of epilepsy. This allows management 
strategies to be formulated appropriately and also enables specialist services to be better 
targeted.
Identifying drug resistant epilepsy
In patients failing the first AED, prognosis for subsequent control varied with the reason 
for failure of initial treatment. Those failing because of adverse effects had a remission 
rate similar to treatment naive patients, while those who received the initial AED at target 
doses and failed to achieve seizure control had significantly lower chances of entering 
remission with further pharmacotherapy. However, the overall responder rates with 
subsequent treatments were significantly lower than that with the first drug. The 
prognosis for seizure control therefore declined with each failed AED regime, with only 
8% of those failing 2 well tolerated AED regimes achieving seizure control and with 
further pharmacotherapy; this figure falling to 3% after failure of 3 such regimes. This 
pattern was observed for both idiopathic generalised and localisation related epilepsy. 
Thus, patients failing 2 well-tolerated AED regimes remain uncontrolled in over 90% of 
cases and are likely to have drug resistant epilepsy. These patients should ideally be 
referred to a regional epilepsy programme, as they require confirmation of the diagnosis
235
and classification of epilepsy, rationalisation of pharmacotherapy and evaluation for 
possible epilepsy surgery.
Is epilepsy a progressive condition?
The phenomenon of relapse that we observed in approximately 10% of responders does 
suggest that in some cases, seizure disorders do progress. This has been documented in 
patients undergoing epilepsy surgery evaluation, a substantial proportion had had periods 
of perfect seizure control, but has hitherto not been quantified in newly diagnosed 
epilepsy (Berg et al, 2003). This is because many epidemiological studies adopt a 
simplistic approach to evaluating outcomes, whereby patients are considered in remission 
or not. The real life outcomes in patients are more complex and many patients can have 
periods of remission followed by relapse. There is some evidence from animal studies as 
well as serial imaging studies in human epilepsy that some seizure disorder may be 
associated with progressive structural changes in the brain (Briellmann et al, 2002; Liu et 
al, 2002; Fuerst et al, 2003). The proposed underlying mechanisms for worsening of 
seizure disorders over time include a progressive primary aetiology, an initial 
precipitating injury followed by a slowly evolving cellular events, development of 
pharmacological tolerance, seizure induced plasticity and kindling with the progressive 
structural and functional alterations induced thereby and genetic factors (Sutula, 2004). 
Identification of patients who exhibits a progressive deterioration of seizure control could 
help test these hypotheses in the clinical setting.
Outcomes in symptomatic epilepsy syndromes
No significant differences in outcomes were observed among patients with various 
localisation-related epilepsy syndromes. Even patients with Mesial Temporal Lobe
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Epilepsy with Hippocampal Sclerosis and Cortical Dysplasia, syndromes commonly 
believed to respond poorly to AED treatment, showed immediate response to treatment in 
a sizeable proportion of cases (Part II, section 2.4). Thus the response to treatment in 
these syndromes is better than that reported from previous studies carried out in selected 
populations (Semah et al, 1998, Stephen et al, 2001). This also implies that clinical 
outcomes cannot be reliably predicted from the clinical characteristics of the epilepsy 
alone. The data suggest the existence of unidentified factors that determine response to 
treatment, which could include genetic and environmental background and also gene- 
gene and gene-environment interactions.
Role of pharmacogenomics in predicting treatment outcomes
Clinical characteristics of seizure disorder alone are therefore insufficient to predict the 
likelihood of response to treatment. Genetic influences that determine response to 
treatment are important in this regard. Single nucleotide polymorphisms (SNPs) in genes 
that encode proteins involved in the pharmacokinetic and pharmacodynamics of AEDs 
could play a role in determining response to drug treatment in epilepsy, especially if they 
alter the amino acid sequence of the protein (Part III, section 1.3.). Voltage gated sodium 
channels, which are primarily responsible for the generation of action potential in 
nervous tissue, are also the chief molecular target for a number of commonly used 
antiepileptic drugs. The a subunit confers the essential properties of the voltage-gated 
sodium channel and bears the binding site for the antiepileptic drugs that act thereon 
(Ragsdale et al, 1996). Studies of expression patterns of the sodium channel a subunit 
subtypes have shown that Nav1.2, encoded on SCN2A is the most widely expressed 
isoform in the seizure prone areas of the human brain (Whittaker et al, 2000). We 
conducted a case control association study to examine the prevalence of a specific coding
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SNP (.R19K) on the SCN2A gene in responders and non-responders AED treatment. The 
prevalence of the K-\ariant allele was significantly higher in non-responders compared to 
responders, defined as those remaining seizure free for at least 6 months after starting on 
treatment. This result, if replicated, would indicate that the polymorphic variant of 
SCN2A is linked to the molecular basis of drug resistant epilepsy, at least in some 
patients. The predictive value of the polymorphism in identifying non-responders 
however was limited, with a test efficiency of only 48%. Response to drug treatment is 
governed by a multitude of genetic and environmental factors, and the low predictive 
value of one SNP in such a multifactorial outcome is not surprising. The discipline of 
pharmacogenomics is at present in its infancy. Screening for a large number of SNPs in 
several candidate genes using high throughput genotyping techniques and the use of more 
sophisticated bioinformatics paradigms for analysing the relationship with response to 
treatment promise to allow better predictability of response to AED treatment.
Outcomes in elderly patients
In this analysis, the best outcomes with treatment were seen in the elderly population 
with 85% achieving remission with AED treatment. Good prognosis for epilepsy with 
onset after the age of 60 has also been reported by other authors (Ramsay et al, 2004). 
Thus, old age is the commonest time to develop epilepsy as well as the age group with 
the best response to AED treatment. One possible explanation that links these two 
phenomena is that relatively trivial processes, which would normally not cause seizures 
in younger subjects, bring about recurrent seizures in older patients. These would be 
controlled relatively easily by AEDs. Another possibility is that the aging brain is 
incapable of undergoing the structural changes required to develop pharmacoresistant 
epilepsy owing to reduced neuronal plasticity. These hypotheses, however, are
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speculative and would be difficult to test. Even if proven correct, these would not impact 
on the current approach to management of seizures in the elderly. An alternative 
explanation is that many of the seizures observed in this age group are acute symptomatic 
events resulting strokes that do not cause clinically obvious neurological deficits. Roberts 
and colleagues studied 132 patients with late onset epilepsy using CT scanning and found 
that 21% of patients aged over 60 had clinically silent cerebral infarction (Roberts et al, 
1988). Early seizures occur in up to 33% patients with ischaemic strokes, but only 2-4% 
of patients develop post-stroke epilepsy (Camilo and Goldstein, 2004). Thus acute 
symptomatic seizures accompanying strokes would have low risk of recurrence and 
would not normally require treatment with AEDs. If shown to be correct, this would 
mean that many older patients presenting with seizures might not be at as high a risk of 
recurrence as commonly believed, and a more conservative approach may be safely 
adopted in deciding the need for AED treatment. This is especially important as AEDs 
often cause cognitive adverse effects and problems with drug interactions in this group of 
patients. Moreover, persons aged over 65 years constitute the fastest growing segment of 
the population of most developed countries and seizures in the elderly is likely to assume 
greater public health importance. This hypothesis however needs to be tested 
prospectively using specialised cerebral imaging techniques designed to identify acute 
infarcts in non-eloquent cortex in older patients presenting with seizures.
The mortality of epilepsy- what to tell the patient?
It is now widely accepted that epilepsy is associated with an increased mortality. 
However, clinicians remain uncertain as to whether mortality risks should be discussed 
routinely with patients. There is a potential for causing harm by imparting information 
that the patient does not actively seek as it can produce undue alarm and impede the
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return to a productive life. As patients are relatives have a ‘right to know’ about the risks 
associated with their condition, it can also be argued that they have a ‘right not to know’, 
especially if the knowledge would not alter the management of the condition (Beran et al, 
2004). However, material risks (those that the patient is likely to consider significant) 
need to be discussed. Cohort studies in representative patient groups provide the most 
useful data to help assess risks in individual patients.
We found a 40% increased mortality in patients with newly diagnosed epilepsy compared 
to age and sex matched controls whereas the chronic epilepsy cohort had a 110% increase 
in mortality risk. In newly diagnosed patients, highest excess mortality was seen for 
younger patients especially those with symptomatic epilepsy. Mortality risk was highest 
in the 30-40 year age group. When types of epilepsy were analysed separately, patients 
with symptomatic and unclassified epilepsy had higher SMR with no significant excess 
death rates seen for patients with cryptogenic and idiopathic epilepsy. Analysis of SMR 
based on age and type of epilepsy showed SMR of 8.64 for patients diagnosed with 
symptomatic epilepsy below the age of 40. These results suggest that the excess mortality 
of newly diagnosed epilepsy is largely seen in younger patients with symptomatic 
epilepsy, and most likely represents the natural history of the underlying condition 
causing seizures in these patients.
For patients failing to achieve seizures control with their first AED, the chances of 
seizure control with further pharmacotherapy is significantly lower than for treatment- 
naive patients (Part II, section 1.5). These patients are at high risk of developing 
pharmacoresistant epilepsy. Studies to date suggest that mortality risks in patients with 
drug resistant epilepsy are likely to be higher than those in patients with well-controlled
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epilepsy (Part IV, section 1.4.5). In the present analysis, patients with chronic epilepsy, 
defined as those failing treatment with at least one AED, were over twice as likely to die 
as their age and sex matched controls. The excess risk was observed for all epilepsy types 
except idiopathic generalised epilepsy. Youngest age groups had the highest excess 
mortality, which was equally high for patients with symptomatic, cryptogenic and 
unclassified epilepsy. Analysis of cause of death showed significantly more deaths than 
expected from all causes, but this excess was restricted to patients aged less than 60 
years. Thus, as with newly diagnosed epilepsy, younger patients with chronic epilepsy 
are at higher risk of premature death.
High profile cases of SUDEP in otherwise healthy young people have been reported in 
the lay press and the efforts of patient organisations and charities have raised the profile 
of epilepsy as a potentially life threatening condition in the public consciousness 
(National sentinel audit on epilepsy death, Report 2002). In the present analysis, the 
incidence of SUDEP in newly diagnosed patients was approximately 1 per 1000 patient 
years, and in the chronic epilepsy this was 2.4 per 1000 patient years. Thus, SUDEP is a 
rare event, but significantly more likely in those with uncontrolled epilepsy than in those 
with new onset epilepsy. These facts need to be borne in mind while counselling patients 
regarding risks associated with epilepsy.
Future studies - Predicting outcomes in individual patients
Clinical prediction models are intended to reduce the uncertainty in clinical practice and 
to guide decision-making. The methodological standards in developing prediction models 
have been well established (Wasson et al, 1985; Braitman and Davidoff, 1996; Laupacis 
et al, 1997). The data collected will be analysed further with a view to constructing a
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prediction model to identify patients likely to develop drug resistant epilepsy early. 
Factors influencing the likelihood of response to each AED regime will be assessed in a 
multivariate model. Time to event analysis using the Kaplan Meier method is envisaged, 
with Cox proportional hazards method to study the effect of risk factors on prognosis for 
achieving remission. The findings from this analysis would then be tested prospectively 
in other populations of adult and adolescent patients with new onset epilepsy. This could 
enable stratification of the risk of drug resistant epilepsy at the time of diagnosis and can 
help target specialist services. More detailed descriptive studies of various subgroups of 
patients with specific epilepsy syndromes will also be undertaken. Immediate responders 
to treatment and those remaining uncontrolled probably represent the two ends of the 
spectrum of response to treatment. A comparative analysis of the two subgroups of 
patients will also be performed.
Conclusion
The clinical studies presented have identified the common patterns of response to 
treatment in newly diagnosed epilepsy and shed light on the long-term behaviour of 
several well-defined epilepsy syndromes. Pharmacogenomic data in conjunction with the 
clinical characteristics of patients has the potential to help predict the response to 
treatment. The risk of premature death is not uniform in patients with epilepsy, but varies 
depending on the type and severity of the epilepsy and the underlying condition. These 
data will help clinicians to discuss prognosis with patients at the time of making the 
diagnosis of epilepsy.
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Appendix 1. International classification o f epileptic seizures
I. Partial (focal) seizures (seizures beginning locally)
A. Simple (consciousness not impaired)
1. With motor symptoms
2. With somatosensory or special sensory symptoms
3. With autonomic symptoms
4. With psychic symptoms
B. Complex (with impairment of consciousness)
1. Beginning as simple partial seizure (progressing to complex seizure)
2. Impairment of consciousness at onset
a. Impairment of consciousness only
b. With automatisms
C. Partial seizures becoming secondarily generalised
II. Generalised seizures
A. Absence seizures
1. Typical
2. Atypical
B. Myoclonic seizures
C. Clonic seizures
D. Tonic seizures
E. Tonic-clonic seizures
F. Atonic seizures
III. Unclassified seizures
Adapted from Commission 1981
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Appendix 2. International classification o f epilepsies and epileptic syndromes
1. Localisation related (Partial, Focal)
1.1. Idiopathic (age related onset)
■ Benign epilepsy with centrotemporal spikes
■ Benign epilepsy with occipital paroxysms
■ Primary reading epilepsy
1.2. Symptomatic (defined by location and aetiology)
■ Chronic epilepsia partialis continua of childhood
■ Seizures with specific modes or precipitation
■ Temporal lobe epilepsies
■ Frontal lobe epilepsies
■ Parietal lobe epilepsies
■ Occipital lobe epilepsies
1.3. Cryptogenic
2. Generalised
2.1. Idiopathic (with age related onset)
■ Benign neonatal familial convulsions
■ Benign neonatal convulsions
■ Benign myoclonic epilepsy in infancy
■ Childhood absence epilepsy
■ Juvenile absence epilepsy
■ Juvenile myoclonic epilepsy
■ Epilepsy with GTCS on awakening
■ Others
2.2. Cryptogenic
■ West syndrome
■ Lennox-Gastaut syndrome
■ Epilepsy with myoclonic-astatic seizures
■ Epilepsy with myoclonic absences
2.3. Symptomatic
■ Non specific
o Early myoclonic encephalopathy 
o Early infantile epileptic encephalopathy with burst 
suppression 
o Others
■ Specific syndromes
o Epilepsies in other disease states
3. Undetermined whether focal or generalised
■ Neonatal seizures
■ Severe myoclonic epilepsy of infancy
■ Epilepsy with continuous spike-and-waves during slow-wave sleep
■ Acquired epileptic aphasia (Landau-Kleffner syndrome)
■ Other
4. Special syndromes
■ Situation related seizures
Adapted from Commission 1989
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Appendix 3. Epilepsy syndromes and related conditions
Benign familial neonatal seizures 
Early myoclonic encephalopathy 
Ohtahara syndrome 
f  Migrating partial seizures of infancy 
West syndrome
Benign myoclonic epilepsy in infancy
Benign familial infantile seizures
Dravet’s syndrome
jMyoclonic status in nonprogressive
encephalopathies
BECTS
Early-onset benign childhood occipital 
epilepsy (Panayiotopoulos type) 
Late-onset childhood occipital epilepsy 
(Gastaut type)
Epilepsy with myoclonic absences 
Epilepsy with myoclonic-astatic seizures 
Lennox-Gastaut syndrome 
Landau-Kleffner syndrome (LKS) 
Epilepsy with continuous spike-and- 
waves during slow-wave sleep 
Childhood absence epilepsy 
Progressive myoclonus epilepsies 
Idiopathic generalized epilepsies with 
variable phenotypes
Juvenile absence epilepsy 
Juvenile myoclonic epilepsy 
Epilepsy with generalized tonic- 
clonic seizures only 
Adapted from Commission, 2001
Reflex epilepsies
Idiopathic photosensitive 
occipital lobe epilepsy 
Other visual sensitive epilepsies 
Primary reading epilepsy 
Startle epilepsy 
ADNFLE
Familial temporal lobe epilepsies 
f  Generalized epilepsies with febrile 
seizures plus
tFamilial focal epilepsy with variable 
foci
Symptomatic (or probably 
symptomatic) focal epilepsies
Limbic epilepsies
Mesial temporal lobe epilepsy 
with hippocampal sclerosis 
Mesial temporal lobe epilepsy 
defined by specific aetiologies 
Other types defined by location and 
etiology 
Neocortical epilepsies
Rasmussen syndrome 
Other types defined by location 
and etiology
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